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Vascular endothelial growth factor (VEGF A) plays a central role in the maintenance 
of  vascular  reactivity  and  its  aberrant  control/function  is  implicated  in  the 
development of varicose veins (VVs).  However, it is unclear where the problem is; 
with the vessels ability to produce VEGF A or indeed an inability to mediate an 
appropriate  response/control  to  VEGF A  when  produced.  Here,  the  patterns  of 
activation of VEGF, its receptors and the adherens junction component, β catenin 
were investigated in primary VV.   
Samples  of  varicose  or  control  greater  saphenous  vein  (GSV)  were  divided  into 
segments  by  anatomical  position,  descending  from  the  sapheno femoral  junction 
(SFJ).  SFJ and segmental competence were determined from duplex scan.  For each 
segment, patterns of gene transcription (VEGF, VEGF receptors, β catenin, c myc and 
cyclin D1) and β catenin protein were examined in relation to the underlying venous 
incompetence.    Separately,  release  of  soluble  VEGFR1  (s.flt 1,  fms  like  tyrosine 
kinase receptor 1) was investigated following an induced venous hypertension/stasis.  
In VVs overall, transcription of all genes were elevated (p<0.001) and in VVs with 
SFJ incompetence (p<0.001).  In competent VV segments (no reflux), transcription of 
VEGF A121 (p<0.02), VEGF A165 (p<0.006) and VEGFR2 (p<0.007) were elevated.  
Gene  transcription  was  unaffected  by  segmental  position.    When  the  SFJ  was 
functional β catenin protein was elevated in VVs overall (p<0.06), and increased with 
descending position from the SFJ (p<0.01); transcription was unaltered.  Plasma s.flt 
1 was markedly elevated in VVs (p<0.001), while cuff application induced a rapid 
(10 minutes, p<0.015) elevation in s.flt 1 in control (54.2%) which was not observed 
in VVs (5.5%, p>0.1). 
SFJ  incompetence  was  associated  with  an  elevated  in  transcription  of  all  genes 
examined  reflecting  perhaps,  a  later  stage  of  disease  development.    In  contrast, 
elevated transcription of VEGF receptors in segments of competent VV may be an 
earlier event.  Disturbed β catenin activity (possible due to VEGF) precedes vessel 
wall  compromise  in  VVs,  with  elevated  β catenin  protein  potentially  providing  a 
mechanism for vessel wall remodelling.  Loss of release of s.flt 1 may be important 
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1.1  PRIMARY VARICOSE VEINS 
1.1.1  Definition of varicose veins  
Peripheral vascular disease of the lower limb, broadly speaking can be separated into 
two categories caused either by blockage of the vein from a blood clot (thrombosis) 
or  through  inadequate  venous  drainage  (venous  insufficiency)  (Nicolaides  2000; 
Beckman  2002).    Chronic  venous  insufficiency  (CVI)  is  a  broad  term  describing 
incompetence of the deep, superficial and/or perforating veins (Ricotta et al., 1997) 
and as such is further subdivided according to  the anatomical location  where the 
complication  presents,  as  either  deep  or  superficial  disease  (Beckman  2002).  
Superficial CVI describes incompetence of the superficial venous system of the lower 
limb and is referred to clinically as varicose veins (VVs) (Nicolaides 2000; Beckman 
2002).  Functional characteristics associated with VVs including disturbed blood flow 
(reflux/stasis), venous hypertension and dilatation (Browse et al., 1999;  Labropoulos 
et  al.,  1999;  Nicolaides  2000;  Ruckley  et  al.,  2002)  contribute  to  further 
complications  including  lipodermatosclerosis,  haemorrhage  and  ulceration  in  a 
proportion of patients (Shami et al., 1992; Lees et al., 1993; Evans et al., 1999; 
London et al., 2000).  Classically, VVs arising as a result of an identified problem 
such as deep vein thrombosis are referred to  as secondary  VVs (Golledge et al., 
2003).    However  in  the  majority  of  cases  there  is  no  identifiable  cause  for  the 
development of VVs which are then classified as primary VVs (Nicolaides 2000).     
 
Within this setting, to define varicosity has proved difficult due in part to the complex 
multimodal  venous  pathophysiology  presented  by  CVI  (Ricotta  et  al.,  1997).  
Furthermore, a lack of consistency in the diagnostic evaluation of CVI and VVs has 
led to conflicting reports, both in studies of the clinical management of VVs as well 23 
as data obtained from epidemiology studies.  Originally VVs were defined by the 
WHO as “a saccular dilatation of the veins which are often tortuous”; a definition 
however,  which  excludes  intradermal  subcutaneous  veins  (venectasis)  and  any 
tortuous dilated vein secondary to previous thrombophebitis or ateriovenous fistula 
(Browse et al., 1999).  The definition was amended to include any subcutaneous vein 
that  had  permanently  lost  its  valvular  efficiency  and  become  elongated,  tortuous, 
pouched  and thickened  (Dodd et al., 1956).   In 1978 the Basle study introduced 
criteria for the classification of VVs based on their location and graded according to 
severity (Widmer 1978) and being the most comprehensive, was widely used (Allan 
et al., 2000). 
 
It  is  only  recently  that  a  comprehensive  classification  system,  developed  for  the 
evaluation  of  severity  of  functional  venous  disease  (venous  reflux)  by  Duplex 
ultrasonography,  has  been  agreed  by  an  international  committee  of  the  American 
Venous Forum (Porter et al., 1995).  The committee produced a consensus document 
for the classification and grading of chronic venous disease on the basis of clinical 
manifestation  (C),  aetiology  (E),  anatomical  distribution  of  involvement  (A),  and 
underlying pathophysiological findings (P), termed the C.E.A.P. classification (Table 
1.1).    Accordingly,  VVs  as  defined  by  C.E.A.P  are  “palpable  subcutaneous, 
permanently dilated veins equal to or more than 4mm in diameter in the upright 
position”  a  definition  which  includes  all  refluxing  tubular  veins  including  truncal 
varicosities, tributaries and non saphenous veins (Porter et al., 1995; Allegra et al., 
2003).  More recently, the Venous Severity Scoring system was introduced to modify 
the  C.E.A.P.  assessment  and  account  for  the  dynamic  changes  in  outcome  with 
therapeutic management (Rutherford et al., 2000).    24 
 
CEAP    Classification  Description 
Clinical   C0  no visible disease   
  C1  telangiectase or 
reticular veins  
(intradermal venules < 1mm)   
(subdermal veins to 4mm) 
  C2  varicose veins    (subcutaneous, palpable veins >4mm) 
  C3  oedema   
  C4  skin changes without ulceration   
  C5  skin changes with healed ulceration   
  C6  skin changes with active ulceration   
Aetiology  EC  congenital disease   
  EP  primary disease  (undetermined cause) 
  ES  secondary disease  (known pathological) 
Anatomy  AS  superficial veins  1.   telangiectase or reticular veins 
2.   greater saphenous – above knee   
3.   greater saphenous – below knee 
4.   lesser (short) saphenous vein 
5.   nonsaphenous veins 
  Ad  deep veins  1.   inferior vena cava 
2.   common iliac 
3.   internal iliac   
4.   external iliac 
5.   Pelvic: gonadal, broad ligament,  
6.   common femoral 
7.   deep femoral 
8.   superficial femoral 
9.   popliteal 
10. crural – anterior/posterior tibial  
11. muscular – gastronemial, soleal 
  AP  perforating veins  1.   thigh 
2.   calf 
Pathology  PR  reflux   
  PO  obstruction   
  PR<O  reflux and obstruction   
 
 
Table 1.1  C.E.A.P. classification of venous insufficiency (Porter et al., 1995).  
The classification was devised to standardize the diagnosis of venous insufficency 
when  considering  both  anatomic  location  and  pathological  features  of  disease 
presentation. 
 25 
1.1.2  Epidemiology of varicose veins 
1.1.2.1  Prevalence  
VVs  are  estimated  to  affect  approximately  a  quarter  (10  –  40  %)  of  the  adult 
population (30 – 70 years) in Westernised societies (Callam 1994; Bradbury et al., 
1999; Evans et al., 1999).  Approximately 20 percent of patients who present with 
primary VVs will go on to develop further complications including superficial or 
deep thrombosis, lipodermatosclerosis, haemorrhage from a superficial varicosity or 
ulceration (Shami et al., 1992; Lees et al., 1993; Evans et al., 1999; London 2000).  
Consequently  primary  VVs  and  their  complications  are  a  cause  of  considerable 
morbidity  ranking  seventh  out  of  the  twenty  eight  chronic  diseases  listed  (Green 
1995) and treatment of CVD consumes an estimated 2% of UK’s national healthcare 
resources (Liang 1992). 
 
1.1.2.2  Risk factors  
The suggested risk factors for VVs include amongst others gender, age, pregnancy, 
family history, race, occupation, obesity and diet (Callam 1994; Browse et al., 1999; 
Evans  et  al.,  1999;  Allen  et  al.,  2000;  Fowkes  et  al.,  2001;  Lee  et  al.,  2003).  
However, epidemiological data suggests that only family history, age and gender are 
risk factors associated with an increased incidence of VVs. (Widmer 1978; Abramson 
et al., 1981; Callam 1994; Fowkes et al., 2001).  Most studies suggest women have a 
higher incidence of VVs (26 38%) than men (10 20%) (Coleridge Smith 1999; Allen 
et al., 2000) typically presenting with a male to female ratio of 1:3 (1:1.5 to 1:4.4) in 












National Health Survey   3.5   0.8  1:4.4  US Dept of Health 
1935 36, 1951 61 
1 
UK Survey of Sickness 1950  3.7   2.2  1:1.7  Logan et al., 1957 
1 




25.9   12.9  1:2.0  Coon et al., 1973 
Basle Study Switzerland  3.2   5.2  1:0.6  Widmer 1978 
Western Jerusalem  29.5   10.4  1:2.8  Abramson et al., 1981 
New Zealand Maori 
Community 
40   21.5  1:1.9  Beaglehole 1986 
Framingham Study  2.6   1.9  1:1.4  Brand F et al.,1988 
Aachen District  29   14.5  1:2.0  Liepnitz et al., 1989 
2 
Edinburgh Vein Study  32   40  1:0.8  Evans et al., 1999 
Edinburgh Vein Study 
 (superficial system) 
15   9  1:1.7  Allan et al., 2000 
 
 
Table  1.2  Prevalence  of  varicose  veins  in  the  general  population. 
Most studies observed an increased incidence of primary VVs in females compared 
with males with only two studies contradicting the gender bias (in bold).  This was 
attributed to a higher prevalence of mild (Grade 1) trunk varices in men (Edinburgh 
Vein Study) and a suggested age bias in the Basle study, due in part to a smaller 
number of younger women in the study  (
1Browse et al., 1999; 
2 Evans et al., 1999). 27 
The importance of other risk factors in the development of varicosity is more difficult 
to  determine,  due  in  part  to  the  different  methodologies  used  in  the  various 
epidemiological studies.  More recently the Edinburgh Vein Study concluded that no 
strong and consistent lifestyle risk factor could be associated with the development of 
VVs. (Fowkes et al., 2001; Lee et al., 2003)  
 
1.1.3  Pathology of varicose veins 
1.1.3.1  Anatomy of the lower limb 
The venous anatomy of the lower limb consists of the superficial and deep (below the 
muscular  facia)  venous  systems  which  are  connected  by  the  perforating  veins 
(communicating  system)  (Green  1995).    Primary  VVs  are  the  most  common 
manifestation of CVI and tend to affect the superficial venous system predominately 
(Beckman 2002).  The primary collecting veins of the superficial system are the short 
saphenous vein (SSV), the greater saphenous vein (GSV) and their tributaries which 
serve as a conduit passing blood centrally and eventually to the popliteal and femoral 
veins of the deep system respectively (Figure 1.1) (Beebe Dimer et al., 2005).  The 
SSV originates in the lateral foot and passes posteriorly lateral to the Achilles tendon 
in the lower calf, usually lying directly above the deep fascia in the midline as it 
reaches the upper calf.  Here it perforates the deep fascia in the lower part of the 
popliteal fossa and joins the popliteal vein of the deep system (Gray 1918).  The GSV 
originates in the medial foot and passes upward anterior to medial malleolus crossing 
the medial tibia in a posterior direction to ascend in the medial line across the knee.  
Above the knee it continues anteromedially above the deep fascia to the thigh, where 
it passes through the foramen ovale and joins the common femoral vein at the groin 













































Figure 1.1  The venous anatomy of the lower limb.  
Blood from the superficial system (dark) empties into the deep system (light) and is 
returned to the inferior vena cava via the femoral vein.  
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The correct venous drainage is from the superficial to the deep systems (Green 1995).  
Venous blood is pumped out of the deep system of the lower extremities through the 
action of the plantar venous plexus (foot pump) and the soleal sinuses (calf muscle 
pump) back to the right atrium of the heart (Araki et al., 1994; Marieb 1998).  Blood 
flow  is  maintained  in  a  distal  to  proximal  direction  in  the  superficial,  deep  and 
perforating  veins  by  bicuspid  valves,  located  along  the  length  of  the  vein  and  at 
positions where the superficial system joins the deep system (Figure 1.2; Ricotta et 
al., 1997; Marieb 1998).  The valves prevent retrograde flow of blood from the deep 
system back into the superficial system and maintain the pressure differential between 
the deep system (high pressure) and the superficial systems (low pressure) (Ricotta et 
al., 1997; Marieb 1998; Beebe Dimmer et al., 2005).   
 
Historically  varicosity  was  thought  to  start  at  points  of  primary  valvular 
incompetence  where  the  superficial  veins  communicate  with  the  deep  veins, 
particularly  at  the  SFJ,  saphenopopliteal  junction  (SPJ)  and  perforating  veins 
(Nicolaides 2000; Golledge et al., 2003).  Valvular incompetence allows retrograde 
flow from the deep system back to the superficial system transferring the normal high 
pressure of the deep system to the superficial venous system with associated venous 
hypertension  (Green  1995;  Nicolaides  2000).    Venous  hypertension  and  dilation 
initiates incompetence of adjacent valves leading to the clinical manifestations of 
venous  reflux  and  morphological  changes  of  the  vessel  wall  seen  with  VVs 




































Figure 1.2  Compartmentalisation of the deep and superficial veins in the limb. 
Blood from the superficial system (low pressure 20 80mmHg) drains to the deep 
system (high pressure ~80+ mmHg), the direction of blood flow being maintained in 
part  by  competent  perforators  and  venous  valves  (A).    Perforator  incompetence 
facilitates  the  retrograde  flow  of  blood  from  the  deep  to  superficial  system, 
facilitating  the  transfer  of  pressure  and  blood  reflux  implicated  with  vessel  wall 
remodelling in the development of primary VVs (B). 31 
1.1.4  Theories on the development of varicose veins  
Varicosity  is  a  complex  pathology  characterised  by  venous  hypertension,  blood 
turbulence  (stagnation  and/or  reflux),  vascular  dilatation  and  aberrant  vessel  wall 
remodelling (Browse et al., 1999; Badier Commander et al., 2000; Golledge et al., 
2003).    Several  theories  describing  the  development  of  primary  VVs  have  been 
proposed,  although  the  precise  aetiology  remains  undefined.    Generally  however, 
valvular  incompetence  following  vessel  wall  dilation  is  considered  the  principal 
determinant  of  varicosity  (Browse  et  al.,  1999),  due  to  either  increased  venous 
pressure and/or structural changes to the vessel wall (Golledge et al., 2003; Beebe 
Dimer et al., 2005). 
Venous pressure and descending valvular incompetence:  Trendelenburg introduced 
the  concept  of  descending  valvular  incompetence  as  the  primary  cause  of  VVs 
(referenced in Browse et al., 1999).  He suggested that venous valves protect the 
vessel wall below the valve from the pressure in the vein above it.  Failure of the SFJ 
permitted  reflux  into  the  GSV  which  resulted  in  descending  sequential  valvular 
incompetence due to the increased pressure on these sites (Golledge et al., 2003).  
However,  studies  of  venous  valves  have  demonstrated  that  the  valve  can  tolerate 
higher pressure than that of the vein wall itself and that the vessel wall would most 
probably  dilate  before  the  valve  became  incompetent  (Browse  et  al.,  1999).  
Furthermore a primary defect in the valve cannot explain the histological evidence of 
apparently  normal  vein  segments  in  continuity  with  varicose  segments  (Badier 
Commander et al., 2001) when the whole vein wall is subjected to the same increased 
pressure (Browse et al., 1999).  Finally, more recently the identification of isolated 
valvular incompetence and reflux at sites distal to a competent SFJ has all contributed 32 
to the evidence contradicting this theory (Abu Owen et al., 1994; Labropoulos et al., 
1999; Labropoulos et al., 2000; Hollingsworth et al., 2001B).  
Perforator incompetence:  In contrast, incompetence of one or more perforator veins 
in the lower leg results in retrograde blood flow and elevated pressure from deep to 
superficial veins during muscular contraction (Figure 1.2) (Nicolaides 2000).  Over 
time, the superficial veins become chronically  dilated preventing their  apposition, 
which reverses blood flow.  As other perforator valves become incompetent, reflux 
occurs at additional sites along the GSV eventually initiating incompetence at the SFJ 
(Nicolaides 2000).  This theory can explain why varicosities are often found below 
competent  valves,  but  not  why  veins  used  as  arterial  bypass  conduits  (at  arterial 
pressures) become hypertrophic rather than dilated or grossly varicose (Rose et al., 
1986; Canham et al., 1997).  Furthermore, although trauma induced arteriovenous 
fistulas cause veins to dilate aberrantly, this returns to normal when the fistulas are 
repaired,  providing  further  evidence  that  VVs  may  not  necessarily  be  caused  by 
elevated pressures unless the walls are inherently weak (Nicolaides 2000). 
Structural weakness/dysfunction of the vessel wall:  An inherent weakness in the vein 
wall, due to structural problems in the vessel wall itself, has been proposed to lead to 
incompetence  of  the  valves  when  the  vessel  dilates  which  results  in  reflux  and 
development of varicosity (Golledge et al., 2003).  Evidence for this theory has come 
from numerous studies which demonstrate that VVs have a number of abnormalities 
in their structural components when compared to normal veins.  VVs have abnormal 
collagen and elastin content (increased as well as decreased) (Travers et al., 1992; 
Gandhi et al., 1993; Venturi et al., 1996), aberrant intimal and medial smooth muscle 33 
 cell  content  (Thulesius  et  al.,  1974;  Travers  et  al.,  1992)  and  different  ratios  of 
matrix degrading enzymes when compared to normal veins (Badier Commander et 
al., 2000).  Furthermore histological analysis of VVs has determined that structural 
changes in the wall are not distributed uniformly along the vein and segments of 
gross  varicosity  are  interspersed  by  seemly  normal  or  atrophic  segments  (Badier 
Commander et al., 2001). A congenital weakness of the wall may be a factor, as more 
than half of patients affected have a positive family history of VVs (Travers et al., 
1996).  Primary wall weakness may explain why varicosities are often found below 
competent valves, but the lack of consistent results from different studies has failed to 
present a cohesive mechanism for this theory.  This may relate to the fact that many 
of the findings reported are describing final stages of disease and are potentially the 
result of varicosity and not necessarily the cause (Golledge et al., 2003).   
Deregulated venous tone:  A further theory is that dilatation results from an inability 
of the vein to contract adequately, as a result of smooth muscle cell or endothelial 
dysfunction (Schuller Petrovic et al., 1997; Brunner et al., 2001; Lowell et al., 1992).  
Support  for  this  theory  has  come  from  numerous  investigations  that  demonstrate 
abnormal  responses  of  VVs  and  their  components  to  substances  including 
phenylephrine (Brunner et al., 2001), cyclic GMP (NO) and release of prostacyclin 
(Schuller Petrovic  et  al.,  1997)  and  noradrenalin  (Crotty  2003)  implicated  in  the 
regulation of vascular homeostasis.  Notably, these studies suggest a spectrum of 
disease  may  exist  with  dysfunction  of  the  vessel  wall  being  potentially  both 
progressive and associating with more severe disease (Schuller Petrovic et al., 1997; 
Brunner et al., 2001). 34 
1.1.5  Structure of the vein wall 
The vein wall, like that of the artery is composed of three distinct layers, the tunica 
intima, tunica media and tunica adventitia which surround the vessel lumen (Figure 
1.3) (Browse et al., 1999).  The muscle layers of the vein, however tend to be thinner 
and the lumen proportionately larger than those of arteries of a similar size (Marieb 
1998).  Vein also contains a smaller proportion of elastic tissue in their wall, which 
allows  veins  to  distend  rapidly  when  filling  with  blood  with  minimal  change  in 
pressure (Marieb 1998;  Ricotta et al., 1997).   Indeed, besides being a  conduit to 
return blood to the heart, veins function as blood reservoirs (capacitance vessels) 
capable of accommodating up to 65% of the blood supply of the body at any given 
time  (Marieb  1998;  Green  1995).    It  is  now  well  established  that  the  cellular 
components of the vessel wall actively participate in the maintenance of normal blood 
flow and the regulation of vascular homeostasis (Davies et al., 1993; Gocke et al., 
1998; Browse et al., 1999). 
 
1.1.5.1  Tunica intima 
The  tunica  intima  is  comprised  of  the  vascular  endothelium  and  subendothelium 
layer,  which  consists  of  connective  tissue  and  smooth  muscle  cells  (SMC).    The 
endothelium is a confluent monolayer of simple, squamous endothelium that lines the 
luminal surface of all blood vessels (Davies et al., 1993; Marieb 1998).  Positioned at 
the interface between the circulating blood and the body’s tissue, the endothelium 
forms  a  semi permeable  surface  that  limits  passive  transfer  of  cellular  and  fluid 
elements between the circulating blood and the tissue (Makrides et al., 1998; Dejana 
et al., 2004).   35 
 
 




Figure 1.3  Transverse section of the saphenous vein wall (elastic van Gieson stain). 
The vein wall is composed of three distinct layers, the tunica adventitia (A), tunica 
media (M) and tunica intima (I) containing the endothelial cell lining surrounding the 
vessel lumen (L).  The majority of the smooth muscle responsible for passive tone is 
contained in two concentric layers in the tunica media (Woodside et al., 2003).  The 
tunica adventitia, a loosely bound matrix of fibroblasts, smooth muscle cells and extra 
cellular  matrix  supports  the  nerves  supplying  the  sympathetic  innervation  of  the 
media layer, as well as the vessel’s blood supply via the vasa vasorum (Marieb 1998). 
In addition to bicuspid valves, vein differs to artery by having less muscle and a 
proportionately  larger  lumen  than  artery  of  a  similar  size  (Browse  et  al.,  1999) 
(Section  published  with  permission,  courtesy  Dr  M  Dashwood,  Dashwood  et.  al. 
2009).  36 
This strategic location of the endothelium allows it to “sense” changes in circulating 
blood  factors  and  haemodynamic  forces,  to  which  it  responds  by  producing  and 
releasing vasoactive substances (Table 1.3) (Cohen 1998).  These agents participate 
in  multiple  physiological  processes  in  the  vessel  wall  including  the  regulation  of 
vascular tone (Cohen 1998; Verma et al., 2002) and blood pressure (Davies et al., 
1993), activation of platelets (Gokce et al., 1998), influence blood thrombogenicity 
and coagulation (Gertler et al., 1992), regulate leukocyte adherence (Gokce et al., 
1998)  and  over  the  longer  term  participate  in  cellular  proliferation  and  matrix 
degradation typical of vessel wall remodelling. (Quyyumi 1998).  Among the more 
important functions of the endothelium is the integration of the numerous paracine 
and auotocrine signalling pathways required to regulate vascular homeostasis (Davies 
et  al.,  1993;  Verma  et  al.,  2002).    Consequently,  the  vascular  endothelium 
participates in the metabolism and transport of a multitude of blood borne substances 
to the sub endothelial tissue (Davies et al., 1993; Makrides et al., 1998; Gokce et al., 
1998).  In addition, the normal activity of the endothelium maintains a frictionless, 
anti thrombotic surface of the lumen by favouring factors that inhibit coagulation and 
activate fibrinolysis over those that promote thrombosis and endothelial activation 
(Davies et al., 1993; Keaney 2000; Verma et al., 2002). 
 
Endothelial cells in larger vessels are attached to the surface of the vessel through 
interaction with the underlying sub endothelium, a highly organised matrix including 
collagen,  elastin,  fibronectin,  laminin  thrombospondin  and  glycosoaminoglycans 
(Davies et al., 1993; Browse et al., 1999). The sub endothelium provides structural 
integrity, mechanical strength and elasticity to the vessel wall (Davies et al., 1993).  
Although endothelial cells secrete a variety of proteases including metalloproteases,  37 
Function  Role  Mediated by 
vasomotor tone  dilation  nitric oxide,  
prostacyclin (PGI2) 
bradykinin 
endothelial derived hyperpolarising factor 
  constriction  endothelin, prostaglandin H2 (PGH2) 
endothelium derived constricting factor 
angiotensin II, platelet derived growth factors 
reactive oxygen species (superoxide)  
adenosine triphosphate (ATP) 
thromboxane A2 
fibrinolysis  anti fibrinolytic  plasminogen activator inhibitor 1 (PAI 1) 
  pro fibrinolytic  tissue plasminogen activator (t PA) 
urokinase type plasminogen activator (u PA) 
thrombosis  anti coagulants  heparan sulphate 
dermatan sulphate 
thrombomodulin 
  pro coagulants  tissue factor 
von Willebrand factor 
  platelet inhibitors  nitric oxide,  
prostacyclin (PGI2) 
cell growth  inhibition  nitric oxide 
heparan sulphate 
prostacyclin (PGI2) 
  promotion 
platelet derived growth factor (PDGF) 
fibroblast growth factor (bFGF) 
vascular endothelial growth factor  
angiotensin II 
endothelin 
matrix degradation  inhibition  tissue inhibitor of metalloproteases (TIMP 1) 
  promotion  matrix metalloproteases (MMP 1, 2, 9, 12) 
inflammation  anti inflammatory  nitric oxide 
  pro inflammatory  E selectin 
intercellular adhesion molecule (ICAM 1) 
vascular cell adhesion molecule (VCAM 1) 
monocyte chemotactic protein (MCP 1) 
interleukin  8 (IL 8) 
 
Table 1.3  Role of the vascular endothelium in the regulation of homeostasis. 
(from Gokce et al., 1998) 38 
collagenases,  elastases  and  gelatinases  the  turnover  of  the  subendothelium  in  a 
normal vessel is usually low, being balanced in part by the secretion of inhibitors of 
the  above  mentioned  proteases  (Davies  et  al.,  1993;  Browse  et  al.,  1999).  
Modulation  of  the  connective  tissue  matrix  by  synthesis  and  degradation  of  its 
components allows the endothelium to control the activity of the smooth muscle cells 
and the structure of the vessel wall (Davies et al., 1993; Quyyumi 1998).   
 
1.1.5.2  Tunica media 
The tunica media contains the bulk of the smooth muscle of the vein, arranged both 
circumferentially and longitudinally in the vessel wall interspersed with bundles of 
connective tissue including collagen and elastic lamina (Marieb 1998; Browse et al., 
1999).  The size of the tunica media varies considerably in different veins from no 
smooth muscle cells (small venules, inferior and superior vena carva) to thick layers 
of smooth muscle fibres interspersed with elastic fibres and collagen (GSV) (Browse 
et al., 1999).   
 
The  media  of  the  GSV  is  composed  of  two  distinct  concentric  muscle  layers  as 
determined by histology (Badier Commander et al., 2001).  The inner layer appears 
as thin, clustered longitudinal muscle bundles, while the large outer layer contains 
circular bundles of SMC arranged in concentric lamellae surrounded by connective 
tissue (Badier Commander et al., 2001; Woodside et al., 2003).  When examined by 
electron  microscopy,  the  SMC’s  appear  as  spindle  shaped  cells    suggestive  of  a 
contractile phenotype (Pappas et al., 1998) and lie in close proximity to each other in 
parallel arrays surrounded by bundles of regularly arranged collagen fibres (Rose 39 
1986).  The elastic network consists of a thin and continuous internal elastic lamina 
and regular longitudinal medial elastic fibres (Badier Commander et al., 2001).   
 
The active and variable tone of the vein is regulated by the smooth muscle in the 
media.  The passive tone is provided by the elastic properties of the vein wall which 
in the resting state is the major source of venous tone (Browse et al., 1999).  Changes 
in tone are mediated through the sympathetic nervous system (adrenergic innervation 
through  nerve  endings  that  terminate  in  the  media)  (Browse  et  al.,  1999),  local 
metabolites and circulating or endothelial derived vasoactive substances (Table 1.3; 
Davies et al., 1993). 
 
1.1.5.3  Tunica adventitia 
The tunica adventitia of the GSV is composed of extracellular matrix (collagen and 
elastin fibres, Elsharawy, et al., 2007) fibroblasts (Satore et al., 2001), and a loosely 
organized  outer  longitudinal  layer  of  smooth  muscle  cells  (Canham  et  al.,  1997, 
Pappas et al., 1998).  Historically, the tunica adventitia (and surrounding perivascular 
tissue) was considered to be merely a supportive layer, thought to protect and anchor 
the  vessel  to  the  surrounding  tissue  structure  (Rose  et  al.,  1986).    The  nerves 
responsible for the sympathetic innervation of the tunica media are localised here 
(Crotty, 2003), as well as the vasa vasorum (or vasa venarum in the vein) which 
supply  the  outer  muscle  layers  with  oxygen  and  nutrition  (Crotty,  2003;  Marieb 
1998). 
 
It is now realised that the tunica adventitia is much more than an inert support and the 
interaction  between  the  tunica  adventitia  and  underlying  tunica  media  and  intima 40 
layers is integral to both the survival and proper functioning of the vessel (Crotty, 
2003, Dashwood et al., 2004; Siow et al., 2007.).  The GSV has an extensive network 
of  vasa  venarum  which  extend  deep  into  the  tunica  media  and  in  certain  cases 
penetrate the tunica intima (Dashwood et al., 2004; Scotland et al., 2000).  Large vasa 
venarum  have  a  significant  SMC  content  in  the  vessel  wall,  while  smaller  vasa 
venarum like those typically observe in the tunica media have none (Dashwood et al.,  
2004) and tend to be thin walled endothelial cell channels (Dashwood et al., 2004).   
 
While the presence of smooth muscle cells suggests the vasa venarum regulate their 
own  tone  (Crotty,  2003),  they  are  themselves  thought  to  be  actively  involved  in 
influencing the tone of the GSV (Dashwood et al., 2004; Scotland et al., 2000).  The 
vasa venarum are sensitive to a large number of mediators of vascular tone (Scotland 
et al., 2000) and a considerable portion of the saphenous vessels endothelial (and 
neuronal) NO is suggested to originate from here (Dashwood et al., 2009).   
 
More direct evidence for the important role of the adventitia is demonstrated from the 
results of studies into the improved patency of GSV vein grafts (Dashwood et al., 
2009).  Comparisons of patency rates for vein harvested by conventional techniques, 
to that of a “no touch” technique (Souza et al., 2009) (which reduces vessel trauma 
and preserves the structures of the adventitia), highlight the important contribution 
the  adventitia  and  vascular  structures  like  the  vasa  venarum  have  in  maintaining 
saphenous vessel wall reactivity (Souza et al., 2006; Souza et al., 2009). 41 
1.1.6  Morphology of varicose saphenous vein 
Histological and ultrastructural studies have highlighted significant differences in the 
composition and organisation of cellular and matrix constituents of varicose vessels 
compared to normal GSV.  Observations from these studies suggest that an overriding 
feature  of  varicosity  is  a  loss  of  organisational  structure  in  the  vessel  wall  as 
evidenced  by  the  disruption  of  medial  SMC  bundles  (circular  and  longitudinal) 
(Travers et al., 1996), changes in SMC phenotype, fragmentation of elastic lamallae, 
and inappropriate deposits of extra cellular matrix components (ECM) like collagen, 
in  different  layers  of  the  vessel  wall  (Rose  1986;  Venturi  et  al.,  1996;  Badier 
Commader et al., 2001; Woodside et al., 2003).  
 
Varicose GSV generally demonstrate an increase in diameter of the vessel lumen and 
either a gain or loss, in cross sectional area of intima, media and whole wall (Travers 
et al., 1996; Jones et al., 1999; Badier Commader et al., 2001; Wali et al., 2002A).  
This is suggested to occur due to increased transmural pressure and altered vessel 
wall  remodelling  (Travers  et  al.,  1996).    A  large,  diffuse  thickened  intima  with 
intimal hypertrophy and/or hyperplasia and deposits of extra cellular fibrous tissue is 
frequently  observed  (Badier Commader  et  al.,  2001;  Wali  et  al.,  2002A).    With 
intimal hyperplasia, medial SMC transform from a contractile (spindle shape) to a 
migratory/secretory phenotype (elliptical morphology with numerous vacuoles in the 
cytoplasm) and migrate from the media to the intima (Pappas et al., 1998; Aguilera et 
al., 2003).  These medial derived SMC release ECM degrading enzymes (Badier 
Commader  et  al.,  2000;  Woodside  et  al.,  2003;  Aguilera  et  al.,  2003)  which 
contribute in part to the degeneration of the basement membrane and fragmentation 42 
of the elastic lamina seen in VVs (Badier Commader et al., 2000; Woodside et al., 
2003; Aguilera et al., 2003). 
 
The  media  of  varicose  GSV  exhibits  large  heterogeneity  in  its  thickness  due  to 
alternating segments of atrophic and hypertrophic segments (Badier Commader et al., 
2001).  Atrophic segments tend to have diminished quantities of SMC and ECM, 
while  hypertrophic  segments  have  relatively  more,  but  more  importantly  the 
organisation of the media layer is radically disturbed (Badier Commader et al., 2001; 
Wali et al., 2002B).  The medial SMC bundles are generally disorganised having lost 
the parallel array structure inherent with circular or longitudinal orientation (Pappas 
et al., 1998; Badier Commader et al., 2001).  The structure of the medial SMC layer 
tends to be interspersed with accumulated fibrous tissue and collagen deposits which 
totally disrupt the regular pattern of smooth muscle cell bundles (Rose 1986; Venturi 
et al., 1996).  In both atrophic and hypotrophic varicose segments the medial elastic 
network is highly disorganised and fragmented (Badier Commader et al., 2001; Wali 
et al., 2002B). 
 
The pattern of appearance of VVs suggests a progressive disease (Jones et al., 1999; 
Brunner et al., 2000; Labropoulos et al., 2005) associated with extensive vessel wall 
remodelling  (Gandhi  et  al.,  1993;  Venturi  et  al.,  1996;  Badier Commader  et  al., 
2000) which over time results in the dilated, elongated and tortuous veins observed 
(Travers et al., 1996; Woodside et al., 2003).  The structural abnormalities described 
above, together with their irregular distribution along the vessel (Badier Commader et 
al., 2001) and presence of localised dilatation in segments of the vein wall in VVs  43 
(Labropoulos et al., 1999) may suggest that a localised fault (possibly blood borne) 
potentially could be implicated in the development of VVs.   
 
Here, clear candidates for an early or initiating problem may be with the endothelial 
cell and/or the smooth muscle cell of the vessel wall (Davies et al., 1993; Gokce et 
al., 1998; Bundy et al., 2000) where dysfunction of the endothelium may result in 
reduced  smooth  muscle  action  (Lowell  et  al.,  1992).    As  many  of  the  changes 
observed in the varicose vessel wall appear to be secondary to the action of the same 
cytokines required for the regulation of normal vascular homeostasis (Gale et al., 
1999;  Yancopoulos  et  al.,  2000;  Badier Commader  et  al.,  2001),  an  imbalance 
between these mediators may be involved (Schuller Petrovic et al., 1997, Brunner et 
al., 2001).  
 
Vascular  endothelial  growth  factor  (VEGF)  plays  a  central  role  in  maintaining 
vascular integrity and reactivity by (in concert with nitric oxide) (Dulak et al., 2003) 
mediating vaso permeability and dilatory responses (Ferrara et al., 2003).  Previously 
however, patients with primary VVs, in contrast to normal controls demonstrated a 
loss of the release of VEGF following a mild, experimentally induced venous stasis 
(Hollingsworth  et  al.,  2001A).    Furthermore,  plasma  nitric  oxide  was  reduced 
significantly  suggesting  perhaps  that  a  fault  in  VEGF  maintenance  of  vascular 
reactivity might be involved (Hollingsworth et al., 2001A).   44 
1.2  VASCULAR ENDOTHELIAL GROWTH FACTOR 
In 1983 Senger et al. described the partial purification of a novel protein from tumour 
ascites fluid that induced vascular leakage in the skin of guinea pigs.  The protein was 
named  vascular  permeability  factor  (VPF)  and  was  considered  to  be  a  specific 
regulator of tumour blood vessel permeability (Senger et al., 1983).  In 1989 two 
groups independently reported the purification and partial amino acid sequence of an 
endothelial specific mitogen, purified from pituitary folliculostellate and ATt20 cells 
respectively,  which  they  named  vascular  endothelial  growth  factor  (VEGF)  and 
vasculotropin  respectively  (Ferrara  et  al.,  1989;  Ploüet  et  al.,  1989).    Molecular 
cDNA cloning and characterisation of protein by sequencing demonstrated that VPF 
and  VEGF  were  encoded  by  the  same  gene  and  were  indeed  the  same  molecule 
(Leung et al., 1989; Keck et al., 1989, Senger et al., 1990).  Furthermore, it was 
demonstrated that VEGF was a potent and specific mitogen for vascular endothelial 
cells and that several VEGF isoforms are produced from this gene by alternative 
splicing to form active disulphide linked homodimers (Ferrara et al., 1989; Leung et 
al., 1989; Tischer et al., 1991; Keck et al., 1989).  More importantly, this was the first 
demonstration that VEGF could have multiple regulatory functions on blood vessel 
physiology, including the stimulation of endothelial proliferation and migration, as 
well as the regulation of endothelial monolayer permeability (Senger et al., 1983; 
Ferrara et al., 1989; Ploüet et al., 1989; Keck et al., 1989). 
 
Several additional members of the VEGF family have been identified based on their 
structural homology to the original VEGF (VEGF A).  They include four genes for 
VEGF (VEGF B E) and a related growth factor, placenta growth factor (PIGF), all of 
which  contain  eight  conserved  cysteine  residues  required  for  dimerisation  and 45 
binding  of  the  ligand  to  the  respective  VEGF  receptors  (Klagsbrun  et  al.,  1996).  
VEGF A  shares  approximately  20%  amino  acid  homology  with  platelet  derived 
growth factor (PDGF), while PIGF shares 53% amino acid sequence homology to the 
PDGF like region of VEGF A (Keck et al., 1989; Maglione et al., 1991).  PIGF 
expression  is  restricted  to  the  placenta  where  alternative  splicing  generates  three 
distinct isoforms (Maglione et al., 1991).  VEGF A/PIGF heterodimers exist in vivo 
but have weaker mitogenic activity than VEGF A homodimers and might represent a 
mechanism for modulating VEGF A bioactivity (Cao et al., 1996).  VEGF B has 
43%  homology  to  VEGF A165  and  is  expressed  in  a  variety  of  tissues  but  is 
particularly abundant in the heart and skeletal muscle (Olofsson et al., 1996).  VEGF 
B  can  form  heterodimers  with  VEGF A  which,  when  expressed  in  the  same  cell 
remain  associated  with  the  cell  surface  and  perhaps  indirectly  control  VEGF A 
release and bioavailability (Olofsson et al., 1996).  The 23kDa VEGF C is a potent 
mitogen  for  endothelial  cells  in  vitro  (Joukov  et  al.,  1996).    VEGF C  has  30% 
homology  to  VEGF A165,  but  is  more  closely  related  to  VEGF D  (Joukov  et  al., 
1996).    VEGF C  is  thought  to  participate  in  the  development  of  both  embryonic 
vascular and lymphatic tissue, but in adult tissue probably acts as a paracine regulator 
of  lymphanogenesis  and  maintenance  of  lymphatic  vessels  (Jeltsch  et  al.,  1997; 
Joukov et al., 1997; Kukk et al., 1996).  Less is known of VEGF D (c fos induced 
growth  factor),  but  expression  patterns  in  mice  suggest  an  important  role  in  the 
development of lung tissue (Farnebo et al., 1999).  All of these polypeptides are 
endogenously expressed in mammals, except for VEGF E which is encoded by a 
double stranded DNA parapoxvirus, orf and can induce microvascular proliferation 
and dilation (Meyer et al., 1999; Wise et al., 1999).   46 
Following the discovery of VEGF, the specific receptors for VEGF A were identified 
through binding studies and the genes encoding the tyrosine kinase receptors were 
isolated (Vaisman N et al., 1990; Devries et al., 1992; Terman et al., 1992; Millauer 
et al., 1993).  It is now realised that VEGF family of homodimeric glycoproteins 
mediate  their  effect  through  interaction  with  three  signalling  tyrosine kinase 
receptors:  VEGFR1  (flt 1,  fms  like  kinase  1)  including  a  soluble  truncated  form, 
soluble flt 1 (s.flt 1), VEGFR2 (KDR, kinase domain receptor, flk1) and VEGFR3 
(flt 4) in addition to an accessory receptor (neuropilin) (Ferrara et al., 2003).  The 
various members of the VEGF family have overlapping affinities to the receptors 
with VEGFR2 binding VEGF A, C and D, whereas VEGFR1 binds VEGF A & B 
and PIGF specifically, while VEGFR3 binds VEGF C and VEGF D only (Neufeld et 
al., 1999; Ferrara 1999; Yancopoulos et al., 2000; Figure 1.4). 
 
VEGFR1 and VEGFR2 confer the endothelial specificity of VEGF A as they are 
expressed predominantly in endothelial cells (Millauer et al., 1993; Yamaguchi et al., 
1993; Quinn et al., 1993; Fong et al., 1995).  A few additional cell types express one 
or  both  of  these  receptors,  as  VEGFR1  expression  has  been  demonstrated  in 
trophoblast cells, monocytes (Clauss et al., 1996; Barleon et al., 1996) and renal 
mesangial  cells,  while  VEGFR2  is  also  expressed  in  haematopoietic  stem  cells, 
megakaryocytes and retinal progenitor cells (Neufeld et al., 1999).  The expression of 
VEGFR3  becomes  restricted  mainly  to  the  lymphatic  endothelium  of  adult  tissue 
(Pajusola  et  al.,  1992)  where  it  is  suggested  to  have  a  role  in  the  regulation  of 
lymphangiogenesis  (Kukk  et  al.,  1996;  Jeltsch  et  al.,  1997).    The  co receptor 
neuropilin, demonstrated to play a role in axon guidance is implicated in VEGF A165 

























Figure 1.4  Interaction of VEGF protein family with VEGF receptors.   
Arrows  indicate  the  documented  interaction  of  VEGF  family  members  with  each 
specific receptor.  VEGFR1 selectively binds PIGF, VEGF A and VEGF B, while 
VEGFR2  binds  VEGF A,  C  and  D.    VEGFR3  is  thought  to  be  involved  in 
lymphangiogenesis  and  is  a  selective  receptor  for  VEGF C  and  D  specifically.  
Neuropilin binds VEGF A165 only (adapted from Yancopoulos et al., 2000). 48 
1.2.1  Molecular characteristics of VEGF A 
The VEGF A gene is localised on chromosome 6p21, spans approximately 14kb, and 
is comprised of eight exons separated by seven introns (Tischer et al., 1989).  To date 
five isoforms of VEGF A have been identified all the result of alternative splicing 
(exons 6 and 7) of the mature 3.2kb message RNA (Tischer et al., 1989; Houck et al., 
1991; Poltorak et al., 1997).  The resulting proteins range in length from 121 to 206 
amino acids (VEGF A121 VEGF A145 VEGF A165 VEGF A189 VEGF A 206) and are 
all capable of inducing EC proliferation, albeit with different efficiency (Figure 1.5) 
(Keyt et al., 1996A).  VEGF A121  and lacks the amino acids encoded by both exons 6 
and 7, whereas VEGF A145 lacks exon 7 but is distinguished by the presence of only 
the first 21 amino acid residues of exon 6 (Tischer et al., 1991; Poltorak et al., 1997).  
VEGF A165 lacks the 41 amino acid residues encoded by exon 6, while VEGF A189 
lacks 17 amino acids encoded by exon 6 (Tischer et al., 1991).  VEGF A206 is the 
only  isoform  to  contain  all  8  coding  exons  (Tischer  et  al.,  1991).    The  varied 
properties of different VEGF A protein isoforms are dependant in part to the specific 
exons  that  are  spliced,  which  affect  the  heparin  binding  capability,  secretory 
characteristics,  affinity  to  VEGF  receptors  and  mitogenic  potency  of  the  isoform 
(Park et al., 1993; Keyt et al., 1996B). 
 
Although transcripts encoding VEGF A121 VEGF A165 and VEGF A189 are detected 
in most cell types that express VEGF A, VEGF A165 is the predominant molecular 
species produced by a variety of normal and transformed cells (Houck et al., 1991).  
In contrast the expression of VEGF A206 and VEGF A145 is rare (Houck et al., 1991).  



















































Figure 1.5  Molecular structure of the VEGF A gene. 
The  various  protein  isoforms  are  derived  from  alternative  splicing  of  the  mature 
VEGF A message.  The mRNA sequence that code for protein domains required for 
VEGF  homodimerisation  and  binding  VEGF  receptors  and  heparin  are  annotated 
(adapted from Bates et al., 2002). 50 
45 kDa.  VEGF A165 is a basic heparin binding protein due to the presence of 15 basic 
amino acids within the 44 residues encoded by exon 7 (Ferrara et al., 1989; Ploüet et 
al., 1989; Houck et al., 1992).  In contrast VEGF A121 which lacks both this region 
and  exon  6  is  weakly  acidic  and  does  not  bind  heparin  (Houck  et  al.,  1992).  
Consequently  VEGF A121  is  freely  secreted  from  VEGF A  producing  cells,  while 
VEGF A165  is  released,  although  a  significant  quantity  remains  bound  to  the  cell 
surface  and  ECM  (Park  et  al.,  1993).    As  VEGF A189  and  VEGF A206  contain 
additional sequences in exon 6 that mediate heparin binding and bind heparin with 
great affinity, they tend to be sequestered in the ECM (Houck et al., 1992; Park et al., 
1993).   
 
VEGF A189 and VEGF A206 can be release from ECM by heparin, plasmin (following 
cleavage of the COOH terminus) and urokinase type plasminogen activator (uPA) 
(Houck  et  al.,  1992;  Park  et  al.,  1993;  Ploüet  et  al.,  1997).    Indeed,  proteolytic 
cleavage  of  recombinant  VEGF A189  and  VEGF A206  is  required  to  exert  their 
mitogenic  effect  and  uPA VEGF A  fragments  have  equivalent  endothelial  cell 
mitogenicity  to  that  of  VEGF A165  (Houck  et  al.,  1992;  Ploüet  et  al.,  1997).  
Although  not  all  VEGF A  isoforms  contain  a  site  for  uPA  cleavage  they  all  are 
cleaved by plasmin in exon 5 (Figure 1.5).  However, the plasmin VEGF A fragment 
(VEGF A110) elicits a 50 fold reduced mitogenic effect on endothelial cells (similar to 
that observed for VEGF A121) compared to VEGF A165 and uPA VEGF A189 (Keyt et 
al., 1996B; Ploüet et al., 1997).  This suggests that the domains encoded by exon 6 
and 7 not only regulate the availability of VEGF A through heparin sulphate binding 
but also modulate the activity and mitogenic potency of VEGF A (Houck et al., 1992; 
Klagsbrun et al., 1996; Ploüet et al., 1997).   51 
All VEGF A protein isoforms are secreted as covalently linked homodimers which 
associate initially through hydrophobic interactions before being stabilised by Cys
51 
to  Cys
61  inter chain  disulphide  bonds  (Potgens  et  al.,  1994).    The  signal  peptide 
comprising  exon  1  and  four  residues  of  exon  2,  contains  an  amphipathic  α helix 
required for dimerisation which is cleaved off during secretion (Keck et al., 1989; 




67) in exon 3 required for binding of VEGF A to VEGFR1 




86) essential for binding to VEGFR2 (Keyt et al., 1996A).  Three 
highly  flexible  loops  are  clustered  at  each  pole  of  the  dimer  interface.    Loop  II 
contains the VEGFR1 binding determinants and lies close to loop III of the opposing 
monomer, which binds to VEGFR2 (Keyt et al., 1996A).  The positioning of these 
receptor binding interfaces at each pole of the VEGF A seems to facilitate receptor 
dimerisation, which is essential for transphosphorylation  and signalling as mutant 
dimers that have only one receptor binding site antagonise native VEGF A activity 
(Siemeister et al., 1998). 
 
1.2.2  Regulation of VEGF A expression 
VEGF A  is  produced  by  numerous  cell  types  besides  endothelial  cells,  including 
vascular  smooth  muscle  cells  (Tischer  et  al.,  1991),  pericytes,  fibroblasts, 
keratinocytes,  macrophages,  lymphocytes,  megakaryocytes,  neutrophils,  basophils, 
mast cells, astrocytes and tumour cells (Neufeld et al., 1999; Ferrara 1999).  The 
generation of VEGF A mRNA is regulated both at the transcriptional (Tischer et al., 
1989; Houck et al., 1992) and post transcriptional level (Levy et al., 1996), while post 
translational processing is also implicated in regulating VEGF A protein availability 52 
and activity  (Dulak et  al., 2003;  Lee et al., 2005).  Transcriptional regulation of 
VEGF A synthesis is mediated through the binding of several transcription factors 
including  HIF 1,  AP 1  (activator  protein 1),  AP 2,  SP 1,  CREB  and  STAT3  to 
consensus sequences present in the promoter region of the VEGF A gene (Figure 1.6) 
(Tischer et al., 1989; Pages et al., 2005). 
 
Hypoxia:    Hypoxia  induces  a  rapid  and  potent  increase  in  VEGF A  transcription 
(other VEGF family members are not upregulated by hypoxia) mediated in part by the 
binding  of  HIF 1  (heterodimer  of  HIF 1α  and  HIF 1β,  aryl  hydrocarbon  receptor 
nuclear translocator, ARNT) to the 47bp hypoxia response element (HRE) located at  
985 to  939bp upstream from the transcriptional start in the VEGF A gene promoter 
(Liu et al., 1995; Levy et al., 1995).  In addition, hypoxia increases the half life of 
VEGF A mRNA (which is intrinsically labile under normoxic conditions) between 
three to eight fold (Levy  et al., 1996) through the binding of a hypoxia induced 
stability factor (HuR) to sequences in both the 5’ and 3’ untranslated region (UTR) 
(Shima et al., 1995; Levy  et al., 1996; Levy  et al., 1998).  Furthermore, the 5’ UTR 
contains both an alternative transcription initiation site and internal ribosomal entry 
site (IRES), which facilitates enhanced translation of uncapped VEGF A mRNA via 
the IRES in conditions of stress (like hypoxia) that inhibits cap dependant translation 
(Akiri et al., 1998).  
 
Nitric Oxide:  Nitric oxide (NO) induces VEGF A synthesis in numerous cell types, 
including  vascular  smooth  muscle  cells,  macrophages,  keratinocytes,  and  tumour 
cells (Dulak et al., 2003).  NO influences VEGF A transcription by a mechanism 
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Figure 1.6  Molecular structure of the VEGF A gene promoter. 
The  promoter  region  binding  sites  for  transcription  factors  implicated  in  the 
transcriptional activation of VEGF A (adapted from Pages et al., 2004). 54 
transcription  of  VEGF A  being  dependant  on  MAPK  and  protein  kinase  B  (Akt) 
activation  of  transcription  factors  like  AP 1  and  hypoxia inducible  factor  (HIF 1) 
(Kimura et al., 2000; Kimura et al., 2003).  Furthermore, effects of NO on VEGF A 
production are similarly mediated by heme oxygenase (HO 1), an enzyme generating 
carbon monoxide, iron and biliverdin from its substrate heme, upregulated by hypoxia 
(Dulak et al., 2003).  With respect to NO effects on VEGF A expression therefore, 
NO mimics hypoxia by acting as an intracellular activator of HIF 1α (Kimura et al., 
2000) the classic activator of VEGF A gene transcription, (Sandau et al., 2001; Dulak 
et al., 2003).  
 
Cytokines, growth factors and inflammation:  A large number of factors both elevate 
VEGF A gene transcription and/or induce the release of VEGF A including cytokines 
(IL 1β,  IL 6,  TNF α),  growth  factors  (EGF  PDGF β,  bFGF,  TGF β,  KGF), 
prostaglandins (PGE1, PGE2, PGJ2), cyclic AMP (reviewed in Neufeld et al., 1999; 
Ferrara  et  al.,  2003).    In  addition,  reactive  oxygen  species  (H2O2,  NO)  added 
exogenously  or  derived  from  activated  macrophages,  neutrophils,  vSMC  and 
endothelial cells, upregulate VEGF A gene transcription in various cell and animal 
models (Neufeld et al., 1999; Ferrara et al., 2003). 
 
Transformation and differentiation:  Many tumours secrete high concentrations of 
VEGF A  and  several  specific  cell  transformation  events  including  p53  activating 
mutations  and  oncogenic  mutations  (or  amplification)  of  ras  are  associated  with 
increased VEGF A expression and angiogenesis in developing tumours (Neufeld et 
al., 1999).  The von Hippel Lindau tumour suppressor gene (VHL) is also implicated 
in the regulation of VEGF A expression in von Hippel Lindau disease and sporadic 55 
clear cell renal carcinomas (Ferrerra 1999).  VHL is a negative regulator of hypoxia 
induced  transcription  of  many  genes,  including  the  transcription  of  VEGF A 
(Siemester et al., 1996).  Wild type VHL sequesters protein kinase C isoforms (PKCζ 
and PKCδ) which prevents their translocation from the cell membrane and activation 
of the MAPK signalling pathway leading to the induction of VEGF A transcription 
(Pal et al., 1997).  At the level of transcription, VHL forms a complex with the SP 1 
transcription factor inhibiting the binding of SP 1 to the VEGF A gene promoter, 
which prevents SP 1 mediated VEGF A transcription (Tischer et al., 1991).  Mutation 
of  VHL  therefore  causes  a  loss  of  suppression  of  VEGF A  transcription  in  these 
pathologies (Siemester et al., 1996; Ferrerra 1999). 
 
Post translational regulation of VEGF A availability:  As stated (1.2.1) the domains 
encoded  by  exon  6  and  7  regulate  the  availability  of  VEGF A  through  heparan 
sulphate binding, as well as modulating the potency of the released VEGF A protein 
(Klagsbrun et al., 1996).  As such the binding of VEGF A to components of the ECM 
is thought to be a reservoir for the storage of growth factor, used to mediate both the 
availability  and  activity  of  VEGF A  (Houck  et  al.,  1992;  Ploüet  et  al.,  1997).  
Furthermore, this suggests that VEGF A protein is made available to endothelial cells 
by two different mechanisms, either directly through secretion by VEGF A producing 
cells  or  following  release  by  proteolytic  cleavage  from  the  ECM  (Ferrara  1999).  
Notable, as VEGF A is itself demonstrated to up regulate the expression of proteases 
implicated in matrix degradation (Pepper et al., 1991) in effect it may regulate the 
release of matrix bound VEGF A in a positive feedback mechanism.   56 
1.2.3  Molecular characteristics of VEGF receptors  
In vascular endothelium, VEGF A’s mode of action occurs through the activation of 
either one or both of the homologous high affinity protein tyrosine kinase receptors 
(RTK), the 180kDa VEGFR1 (flt 1, fms like tyrosine kinase receptor) or 230kDa 
VEGFR2 (KDR, kinase insert domain receptor) (Vaisman et al., 1990; Devries et al., 
1992;  Terman  et  al.,  1992;  Millauer  et  al.,  1993).    The  VEGF  receptors  are 
characterised by the presence of seven extra cellular immunoglobulin like loops, a 
trans membrane  region  and  a  conserved  intracellular  tyrosine  kinase  domain 
interrupted by a kinase insert sequence (split tyrosine kinase domain) and represent a 
new family of tyrosine kinase receptors (Figure 1.7) (Shibuya et al., 1990; Terman et 
al.,  1992;  Tanaka  et  al.,  1997;  Shinkai  et  al.,  1998).    More  recently,  a  soluble 
truncated form of VEGFR1 (s.flt 1) comprised of only the first six immunoglobulin 
like  domains  has  been  identified  and  is  proposed  to  function  as  a  specific  high–
affinity antagonist of VEGF A function (Kendall et al., 1993; Kondo et al, 1998; 
Belgore et al., 2000).   
 
Besides the two VEGF receptors, VEGF A165 (exon 7 domain) binds the co receptor 
neuropilin 1 (NRP1) the neuronal receptor of the semaphorin family (Soker et al., 
1996; Soker et al., 1998).  NRP1 has a wide tissue distribution including the vascular 
endothelium, but lacking an intracellular domain is suggested to enhance the binding 
of  VEGF A165  to  VEGFR2  and  play  a  role  in  VEGFR2  dependent  migration  of 
endothelial cells in response to VEGF A165 (Soker et al., 1998). 
 
Binding of VEGF A induces homodimerisation of the VEGF receptors followed by 
autophosphorylation and activation of downstream signalling cascades (Zachary et 57 
al., 2001; Ferrara et al., 2003).  VEGFR1 is reported to have a greater affinity for 
VEGF A165  (Kd  10 30pM,)  than  VEGFR2  (75 125pM),  although  binding  studies 
report a 10 fold increase in the level of expression of VEGFR2 on EC  (Devries et al., 
1992;  Waltenberger  et  al.,  1994).    Indeed  receptor  binding  studies  investigating 
phosphorylation status following stimulation with VEGF A suggest, that VEGFR2 is 
the major mediator of the mitogenic, angiogenic and permeability enhancing effects 
of VEGF A (Terman et al., 1992; Millauer et al., 1993; Waltenberger et al., 1994; 
Ferrara  et  al.,  2003).  Conversely,  VEGFR1  undergoes  weak  tyrosine 
autophosphorylation in response to VEGF A in EC and is proposed to be a decoy 
receptor, negatively regulating the activity of VEGF by both preventing VEGF A 
binding to VEGFR2 and modulating VEGFR2 activity (Devries et al., 1992; Park et 
al., 1994; Waltenberger et al., 1994; Zeng et al., 2001).   
 
Further evidence for this role has come from the identification of a soluble truncated 
form of VEGFR1, s.flt 1 which inhibits the activity of VEGF A by sequestering it 
from VEGFR1 and VEGFR2 (Kendall et al., 1993; Kendall et al., 1996A; Barleon et 
al., 1997B; Ferrara et al., 1998; Barleon et al., 2001).  Furthermore s.flt 1 is proposed 
to directly modulate the action of VEGFR2 by forming nonsignaling dimers, down 
regulating the phosphorylation status of the receptor (Kendall et al., 1993; Kendall et 
al., 1996A; Graubert et al., 2001).  Finally, in mice the absence of VEGFR1 induces 
embryonic death which can be prevented by the presence of the extra cellular IgG 
domains of VEGFR1 which allows normal development (Fong et al., 1995; Hiratsuka 
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Figure 1.7  Molecular structure of the VEGF A receptors. 
Structure of VEGFR1 (membrane and soluble flt 1), VEGFR2 (KDR) and neuropilin 
illustrating  extra cellular  IgG like,  trans membrane  and  intra cellular  split  kinase 
domains.  Proposed domain function, VEGF A binding sites and VEGFR2 major 
tyrosine  phosphorylation  sites  are  annotated  (adapted  from;  Tanaka  et  al.,  1997; 
Shinkai et al., 1998; Ferarra 1999). 
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1.2.4  Regulation of VEGF receptor expression  
The expression of VEGFR1 and VEGFR2 is predominantly restricted to the vascular 
endothelium  (Millauer  et  al.,  1993;  Quinn  et  al.,  1993).    Both  receptors  contain 
control  elements  in  their  promoter  regions  essential  for  endothelial  cell  specific 
transcription  (Morishita  et  al.,  1995;  Patterson  et  al.,  1995).    However,  a  few 
additional  cell  types  do  express  the  VEGF  receptors,  notably  the  expression  of 
VEGFR1  on  monocytes  which  mediates  VEGF A  induced  chemotaxis  and  tissue 
factor production in these cells (Barleon et al., 1996; Clauss et al., 1996; Neufeld et 
al.,  1999).    Generally,  in  EC  the  regulation  of  VEGF  receptor  expression  is 
coordinated with that of VEGF A (Wang et al., 2000) as factors that up regulate 
VEGF A expression tend to induce receptor expression (Shen et al., 1998).  
 
Hypoxia:    VEGFR1  (membrane  and  soluble),  like  VEGF A  contains  a  hypoxia 
response  element  (HRE,  position   976  to   937)  in  its  promoter  and  is  potently 
upregulated by hypoxia in a HIF 1 dependant mechanism (Liu et al., 1995; Gerber et 
al., 1997; Huckle et al., 2004).  In contrast, the promoter for VEGFR2 lacks a HRE 
and  transcription  of  the  receptor  is  not  induced  by  hypoxia  (Gerber  et  al.,  1997; 
Waltenberger et al., 1996).  However the expression of VEGFR2 is increased by 
hypoxia indirectly at the post transcriptional level, by paracine factors released from 
ischaemic tissue and hypoxic dependant increases in VEGF A expression (Brogi et 
al., 1996; Waltenberger et al., 1996; Wang 2000).  
 
Growth  factors:    Numerous  growth  factors  affect  the  expression  of  the  VEGF 
receptors in endothelial cells including VEGF A (Barleon et al., 1997A).  VEGF A 
stimulation of VEGFR2 potently induced both transcription and protein expression  60 
of VEGFR2 in adrenal cortex EC (Shen et al., 1998).  Similarly up regulation of 
VEGF A is associated with elevated VEGFR1 (both membrane and soluble isoforms) 
expression in human EC (Barleon et al., 1997A).  Conversely, down regulation of 
VEGFR2 receptor expression and desensitisation of cellular responsiveness following 
chronic incubation with VEGF A is coupled with up regulation of VEGFR2 gene 
transcription (Wang et al., 2000).  Consistently, an increase in VEGF A expression in 
EC models results in elevated VEGF receptor expression suggesting that VEGF A 
modulates  the  expression  of  its  own  receptors  in  a  positive  feedback  mechanism 
(Shen et al., 1998; Wang et al., 2000). 
 
Heparan sulphate proteoglycans:  VEGF receptor function is further modulated by 
heparin and heparan sulphate proteoglycans (HSPGs) (Fairbrother et al., 1998).  For 
VEGFR2, low concentrations of heparin sulphate (0.1 10 g/ml) strongly potentiate 
the binding of VEGF A165, while conversely higher concentrations inhibit VEGF165 
binding (Gitay Goren et al., 1992).  This effect is heparin specific as depletion of cell 
surface HSPG by heparinase treatment severely reduces binding, which is restored 
with the addition of exogenous heparin (Terman et al., 1994).  As VEGF A121 lacks 
both exons 6 and 7 (heparin binding sites) binding of VEGF A121 to VEGFR2 is 
unaffected  by  heparinase  or  exogenous  heparin  (Gitay Goren  et  al.,  1992).    For 
VEGFR1, even though both VEGF A165 and VEGF A121 binding are inhibited by 
heparin, the presence of HSPG is required for proper functioning as treatment with 
heparinase totally abolishes binding to VEGFR1 (Cohan et al., 1995). 61 
1.2.5  Mechanisms of action and signal transduction  
VEGF A  activates  almost  all  known  endothelial  cell  signalling  pathways  in  vitro 
(Bates et al., 2002) with the identification of over forty specific signalling molecules 
activated in response to VEGF A signalling (Zachary et al., 2001).  As discussed in 
chapter  1.2.1.  receptor  binding  studies  suggest  that  in  vascular  EC,  VEGF A 
signalling is mediated predominantly via VEGFR2 (Vaisman et al., 1990; Millauer et 
al.,  1993;  Waltenberger  et  al.,  1994).    Although  VEGFR1  is  weakly  tyrosine 
phosphorylated in response to VEGF A (Hiratsuka et al., 1998), in EC its activation 
is not associated with the mitogenic, angiogenic and permeability enhancing effects 
of VEGF A (Millauer et al., 1993; Waltenberger et al., 1994).  The discussion below 
therefore, will concentrate primarily on the signalling mechanism(s) of VEGFR2 in 
the vascular endothelium. 
 
VEGFR2 signal transduction follows the consensus scheme for activation of receptor 
tyrosine kinases (RTK) (Schlessinger 2000).  Binding of VEGF A induces receptor 
dimerisation (Potgens et al., 1994; Fuh et al., 1998) resulting in autophosphorylation 
of five specific tyrosine residues within the dimeric complex (Figure 1.8) including 
Tyr
951, Tyr
996 (kinase insert domain); Tyr
1054
, Tyr
1059 (kinase domain) and Tyr
1175 and 
Tyr
1214 (C terminal tail) (Vaisman N et al., 1990; Terman et al., 1992; Millauer et al., 
1993; Kendall et al., 1999; Matsumoto et al., 2001).  Tyr
1054 and Tyr
1059 are located 
in the activation loop of the tyrosine kinase domain and are required for maximal 
activation of the VEGFR2 kinase (Dougher et al., 1999).  Both Tyr
1059 and the COOH 
terminal Tyr
1175 appear to mediate VEGF induced proliferation as mutation of Tyr
1059 
leads to a loss of intracellular Ca
2+ mobilisation and ERK activation (Zeng et al., 
2001) while Tyr
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Figure 1.8  Tyrosine phosphorylation sites of VEGFR1 (flt 1) and VEGFR2 (KDR). 
The  intercellular  domains  of  homodimeric  complexes  of  VEGFR1  and  VEGFR2 
following receptor activation are autophosphorylated at tyrosine residues.  Tyrosine 
residues  are  indicated  by  numbers  next  to  an  encircled  Y,  while  known 
autophosphorylation  sites  (major  in  black,  minor  in  grey)  are  indicated  by  an 
encircled P.  Binding of signal transduction molecules containing an SH2 domain to 




996 are located in the kinase insert domain with Tyr
951 being 
essential for VEGF A induced migration (Zeng et al., 2001).   
 
Tyrosine autophosphorylation of VEGFR2 is crucial for recruitment and activation of 
a variety of signalling complexes required by the cell (Hunter 2000; Schlessinger 
2000; see Figure 1.8).  Most tyrosine autophosphorylation sites are located in non 
catalytic regions of the receptor molecule (Schlessinger 2000) and function as binding 
sites for molecules with Src homology 2 (SH2) (Kroll et al., 1997; Guo et al., 1995) 
or phosphotyrosine binding (PTB) domains (Hunter 2000; Schlessinger 2000).  These 
signalling  molecules  are  themselves  regulated  by  phosphorylation  and  either  bind 
directly to phosphorylated tyrosine domains on the receptor, or to docking/scaffolding 
proteins (via SH2  binding domains) recruited by the activated receptor (Hunter 2000; 
Bogatcheva et al., 2003).  By this mechanism VEGFR2 activates numerous effector 
proteins which mediate the various physiological effects of the growth factor VEGF 
A (Guo et al., 1995; Schlessinger 2000; Bogatcheva et al., 2000; see Figure 1.9)  
 
Proliferation/migration  –  activation  of  MAPK:    For  EC  proliferation,  VEGF A 
activation  of  VEGFR2  stimulates  PLCγ  mediated  generation  of  inositol  1,4,5 
triphosphate  (IP3)  (Wu  et  al.,  2000).    This  induces  protein  kinase  C  (PKC) 
mobilisation of Ca
2+ from intracellular stores (Zachary et al., 2001), and activation of 
the mitogen activated kinase (MAPK) pathway (Kroll et al., 1997).  Notably, VEGF 
A induces EC proliferation by activating the RAF MEK ERK pathway, an unusual 
feature of which is the requirement for PKC instead of Ras (Takahashi et al., 1999; 
see Figure 1.9).Survival and NO – PI3K Akt pathway: Besides proliferation, VEGF 
A  is  a  survival  factor  for  EC  mediated  by  VEGFR2 activation  of  the 64 
phosphatidylinositol 3  kinase     protein  kinase  B  (VEGFR2 PI3K Akt)  pathway 
(Gerber  et  al.,  1998A;  Shiojima  et  al.,  2002;  Figure  1.9).    PI3K Akt  induces 
expression the anti apoptotic proteins Bcl 2 and A1 (Gerber et al., 1998B) which 
inhibit the  activation  of  upstream  caspases  pro apoptotic  proteins  (Zachary  et  al., 
2001).    Furthermore,  VEGFR2  activation  of  PI3K Akt  induces  eNOS  activity 
stimulating production of NO in EC (Ku et al.,1993; Kroll et al., 1998; Fulton et al., 
1999; Dulak et al., 2003) as confirmed by PI3K inhibitors which inhibit VEGF A 
induced increase in NO release from endothelial
 cells (Shiojima et al., 2002).  In 
addition VEGF A effects on Rho family mediated actin rearrangements associated 
with EC migration are PI3K Akt are dependant (Zeng et al., 2001)  
 
Adhesion  status  and  permeability:    The  signalling  activity  of  VEGFR2  is  further 
influenced  by  the  adhesion  status  of  endothelial  cell cell  contacts  (Rahimi  et  al., 
1999; Lampugnani et al., 2003).  Contact inhibited cells like the vascular endothelium 
have a reduced responsiveness to VEGF A induced proliferation and migration when 
confluent (Rahimi et al., 1999; Lampugnani et al., 1997). This is regulated in part by 
vascular endothelial cadherin (VE cadherin), a component of the endothelial adherens 
junction (AJ) (Carmeliet et al., 1999; Venkiteswaran et al., 2002).  VEGF A binding 
to VEGFR2 phosphorylates components of the AJ resulting in a loss of cadherin 
mediated  endothelial  cell cell  adhesion  and  reduced  endothelial  barrier  function 









































































































Figure 1.9  Schematic of VEGFR2 (KDR) signal transduction pathways. 
VEGF A binding induces receptor dimerisation and autophosphorylation of tyrosine 
residues  on  receptors  intracellular  domains.  Tyrosine  phosphorylation  activates 
several  SH2  domain  containing  signalling  molecules,  either  directly  following 
binding (PLCγ) or by indirect mechanism(s) (PI3K, Src) which activate signalling 
pathways  implicated  in  the  regulation  of  endothelial  cell  proliferation,  migration, 
vascular homeostasis and permeability (adapted from Matsumoto et al., 2001). 66 
1.2.6  Role of VEGF A in the vasculature 
The  establishment  and  maintenance  of  a  vascular  supply  is  a  fundamental 
requirement  not  only  for  organ  development  and  differentiation  during 
embryogenesis but also for vascular remodelling, wound healing and reproduction in 
the adult (Ferrara 1999).  The dimeric glycoprotein VEGF A is a potent, specific 
mitogen for vascular endothelial cells (Tischer et al., 1989; Millauer et al., 1993) that 
modulates  a  range  of  endothelial  cell  functions  ranging  from  initial  vascular 
patterning in the developing embryo (Yancopoulos et al., 2000; Jian 2003) to the 
regulation of angiogenesis and multiple components of vascular homeostasis in the 
adult (Ku et al., 1993; Bates et al., 1996; Klagsbrun et al., 1996; Ferrara et al., 2003). 
 
1.2.6.1  VEGF A in the developing embryo  
During embryogenesis, mesoderm derived stem cells (hemangioblasts) form blood 
islands that develop into primitive embryonic endothelial and haematopoietic cells 
(angioblasts) (Shalaby et al., 1995; Jian 2003).  One of the key markers defining the 
angioblast  is  the  expression  of  the  VEGF A  receptor,  VEGFR2  (KDR,  Flk 1) 
(Shalaby et al., 1995; Millauer et al., 1993).  The blood island constitutes the basis 
for the primary vascular plexus which matures through vasculogenesis (the de novo 
formation of blood vessels from angioblasts or stem cells), sprouting angiogenesis 
(formation of new capillaries from existing vessels) and intussusception (the splitting 
of the vessel into two daughter vessels) (Shalaby et al., 1995; Millauer et al., 1993; 
Jian 2003).  VEGF A signalling is an important aspect of this process that not only 
initiates new vessel formation but also regulates a chain of molecular events that 
ultimately leads to the development of a mature vascular network (Yancopoulos et 
al., 2000; Jian 2003).  Indeed, VEGF A is essential to vasculogenesis, with loss of a  67 
single VEGF A allele in mouse models leading to gross developmental abnormalities 
in the forming vasculature and embryonic death between days 11 and 12 (Table 1.4) 
(Carmeliet  et  al.,  1996;  Ferrara  et  al.,  1996).    Furthermore,  mice  lacking  either 
receptor die even earlier between embryonic days 8.5 and 9 (Shalaby et al., 1995; 
Millauer  et  al.,  1993;  Fong  et  al.,  1995).    Targeted  homozygous  inactivation  of 
VEGF A  mimics  that  of  VEGFR2  and  results  in  extensive  endothelial  apoptosis, 
reduced blood island formation and consequently, major tube vessels fail to develop 
(Shalaby et al., 1995; Carmeliet et al., 1996; Ferrara et al., 1996; Gale et al., 1999).  
Conversely,  the  absence  of  VEGFR1  results  in  a  preponderance  of  disorganised 
endothelial cells that fail to form tubules, although mice lacking only the intracellular 
tyrosine kinase domain of VEGFR1 survive with a near normal vasculature (Fong et 
al., 1995). 
 
1.2.6.2  VEGF A in the adult vasculature 
In the adult, VEGF A plays a central role in the maintenance of vascular homeostasis 
by  regulating  multiple  functions  of  blood  vessel  physiology,  including  processes 
involved  with  angiogenesis  (Ferrara  et  al.,  2003),  promotion  of  endothelial  cell 
survival (Gerber et al., 1998A) and regulation of vascular tone (Servos et al., 1999) 
and permeability (Bates et al., 2002).   
 
The principal mechanism for the formation of new vessels in the adult appears to be 
angiogenesis (Carmeliet et al., 1996; Yancopoulos et al., 2000).  Proteases, produced 
by activated EC degrade the basement membrane, thus enabling EC migration into 
the  tissue  to  form  a  capillary  spout  (Jian  2003).    Here,  EC’s  proliferate  and 









   cause of lethality 
VEGF A (+/ )  vasculogenesis/ 
angiogenesis 
E11.5    reduced red blood cell count 
  defective heart & aorta formation 
  defective vessel connectivity 
  defective vessel sprouting 
 
VEGF A ( / )  vasculogenesis  E10.5    absent dorsal aorta 
  defective EC development 
 
VEGFR1 (flt 1)  vasculogenesis  E8.5 9.5    failure of EC organisation  




vasculogenesis  E8.5 9.5    failure of EC differentiation 
  abnormal vessel structures 




Table 1.4  Effects of VEGF gene knockout models. 
The  observed  morphological  characteristics  associated  with  gene  knockouts  of 
VEGF A  and  its  receptors  in  mouse  models  of  vasculogenesis  (from  Gale  et  al., 
1999). 69 
which initiate the deposition of a supporting basement membrane required for vessel 
development (Yancopoulos et al., 2000).  VEGF A has a central role in all these 
processors  processors  (Table  1.5)  as  besides  inducing  endothelial  migration  and 
proliferation  (Ferrara  et  al.,  2003)  VEGF A  induces  EC  expression  of  proteases 
(interstial  collengenase,  urokinase type  and  tissue–type  plasminogen  activators) 
(Pepper  et  al.,  1991),  production  of  cellular  energy  (stimulates  hexose  transport) 
(Pekala et al., 1990), elevated microvascular leakage (Bates et al., 1996) and the 
continued survival of nascient endothelial cells (Gerber et al., 1998A).   
 
Indeed, a fundamental function of VEGF A, both in the development of new and 
maintenance of existing vessel integrity is the promotion of endothelial cell survival 
through  the  inhibition  of  endothelial  apoptosis  (Gerber  et  al.,  1998A).    VEGF A 
effects
 on cell survival have been shown to be mediated by PI3K and Akt (Gerber et 
al., 1998A; Shiojima et al., 2002; see chapter 1.2.5).  The central role of this pathway 
in controlling
 endothelial cell viability is illustrated by the activation of PI3K Akt 
signalling by several other
 endothelial cell stimuli associated with the inhibition of 
apoptosis (Fulton et al., 1999; Shiojima et al., 2002).   
 
In addition, it is well established that VEGF A acts via VEGFR2 to stimulate the 
release of endothelial nitric oxide (NO) (Ku et al., 1993; Kroll et al., 1998), both in a 
Ca
2+ dependant and Ca
2+ independent mechanism(s) mediated by Akt activation of 
endothelial nitric oxide synthase (eNOS) (Gerber et al., 1998A; Fulton et al., 1999).   
Moreover, VEGF A produced by vSMC stimulates the production of NO (via eNOS) 
in the vascular endothelium (Kroll et al., 1998; Dulak et al., 2003).  However, NO 
when released  from the endothelium in turn acts on vSMC to produce VEGF A, 70 
generating  a  positive  feed  back  ‘loop’  mechanism  central  to  regulating  multiple 
functions of vessel physiology (Servos et al., 1999, Bundy et al., 2000; Kimura et al., 
2003).  NO [and prostacyclin (PGI2)] (Murohara et al., 1998) have been implicated in 
mediating diverse effects of VEGF A including the regulation of vascular tone and 
permeability (Ku et al., 1993; Dulak et al., 2003). 
 
Generation  of  new  blood  vessels  by  angiogenesis  is  accompanied  by  increased 
vascular permeability (Bates et al., 2002), the regulation of which is critical to normal 
vascular  function  (Dejana  et  al.,  2001).    Indeed  elevated  expression  of  VEGF A 
associated with pathological angiogenesis (Brown et al., 1993) results in immature 
vessels  with  unregulated  blood  flow  (Dvorak  et  al.,  1999).    Although  the 
mechanism(s)  are  unclear,  VEGF A  is  demonstrated  to  induce  vascular  leakage 
(Dvorak et al., 1999) and endothelial fenestrations in various vascular beds (Roberts 
et al., 1995), increase hydraulic conductivity in a Ca
2+ dependant mechanism (Bates 
et al., 1996) and initiate the rearrangement of the actin cytoskeleton (Shiojima et al., 
2002).  More recently VEGF A acting via VEGFR2 was demonstrated to dismantle 
the  endothelial  adherens  junction  (AJ)  (Esser  et  al.,  1998)  resulting  in  a  loss  of 
cadherin mediated cell cell adhesion (Kevil et al., 1998) and increased endothelial 
permeability (Cohen et al., 1999).  In addition, dismantling of the AJ is suggested to 
regulate the responsiveness of EC to VEGF A signalling, as the loss of cell adhesion 
is required to deregulate contact inhibition required for endothelial cell proliferation 
and migration associated with vessel remodelling and angiogenesis (Rahimi et al., 
1999; Lampugnani et al., 1997; Dejana et al 2000; Dejana et al., 2001).   
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 function  receptor  mediated by  biological effect 
MAPK  
 
•  DNA synthesis 
•  transcription of cmyc, cfos, cyclin D1  
•  cdk4 activation 
•  translocation of PKCα, PKCβ 
PI3K Akt   •  Rho GTPases 







2+ mediated increase in cGMP 





•  phosphorylation of PKCγ, FAK, paxillin 
•  phosphorylation of VE cadherin 
plackoglobulin, p120, PECAM 1  
•  actin filament reorganisation  
•  Rho GTPases 
migration 
VEGFR1    •  tissue factor, uPA, tPA production 
vascular tone  
 









•  NO production, gene expression 
•  NO mediated ERK activation 
 
•  Ca
2+ mediated increase in cGMP 
•  increase in NO production 
•  increase prostacyclin (PGI2) production 
 






raf 1 (ERK) 
 
adherens junction  
 
 
NO & PGI2 
•  PKG mediated increase in permeability 
•  cPLA2 activation 
•  phosphorylation of VE cadherin, β 
catenin plackoglobulin, p120,  
•  elevated permeability 
survival 
 
VEGFR2  PI3K  Akt 
 
•  cell survival (increased Bcl 2) 
•  inhibition of apopotosis (BAD) 
 
 
Table 1.5  Function of VEGF A on adult vascular endothelium. 
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1.3  VEGF A, THE ADHERENS JUNCTION AND Β CATENIN 
1.3.1  The adherens junction, Wnt signalling and β catenin 
The vascular endothelium, a continuous monolayer that lines the lumen of all blood 
vessels forms an semi permeable surface that limits passive transfer of cellular and 
fluid elements between the circulating blood and the vessel wall (Makrides et al., 
1998; Dejana et al., 2004; (see chapter 1.4.1).  The integrity of the endothelium is 
maintained by a number of junctional zipper like structures, including tight junctions 
and the endothelial adherens junction (AJ) (Dejana et al., 2000; Bazzoni et al., 2004), 
that regulate endothelial barrier function and vessel morphogenesis (Gory Faure et 
al., 1999; Carmeliet et al., 1999; Dejana et al., 2001 Bazzoni et al., 2004).  
 
The endothelial AJ is comprised of vascular endothelial cadherin (VE cadherin), a 
cadherin  expressed  exclusively  on  the  vascular  endothelium  (Lampugnani  et  al., 
1992;  Breviario  et  al.,  1995),  which  promotes  calcium  dependant,  extra cellular, 
homophilic  cell–cell  binding  (Lampugnani  et  al.,  1992;  Dejana  2004).    Intra 
cellularly,  the  cadherin  cytoplasmic  domain  interacts  with  three  related  proteins 
belonging to the “armadillo” family of proteins (β catenin, γ catenin/plakoglobin and 
p120)  which  mediate  linkage  to  the  intracellular  actin  cytoskeleton  via  α catenin 
(Lampugnani et al., 1997; Nelson et al., 2004; Figure 1.10).  The structural integrity 
of the AJ is negatively regulated by phosphorylation (Nelson et al., 2004).  Following 
growth factor  activation, tyrosine phosphorylation of β catenin (Tyr
654, Tyr
142) by 
receptor tyrosine kinases or cytoplasmic tyrosine kinases (Wheelock  et al., 2003) 
disrupts the AJ resulting in a loss of cadherin mediated cell cell adhesion (Dejana 
2004) with the release of β catenin, the transcriptional activator of the Wingless (Wnt) 

















































Figure 1.10  Molecular structure of vascular endothelial cadherin. 
Schematic illustrating the Ca
2+ dependent extra cellular domains of VE cadherin (blue 
rectangles) implicated in mediating cell–cell adhesion in the vascular endothelium.  
Intracellularly VE cadherin binds the armadillo family of proteins (p120/ γ catenin, 
plakoglobin, β catenin, α catenin) tethering the AJ to the intracellular cytoskeleton.  
The AJ is negatively regulated by phosphorylation and the stability of the complex is 
maintained by tethered protein tyrosine phosphatases (PTP) which bind to conserved 
protein binding domains (SRC homology 2 domains, SH2) in the intracellular domain 
(A). Activation of tyrosine kinase receptors (like VEGFR2) phosphorylate tyrosine 
residues in the intracellular domain of VE cadherin, destabilising the complex which 
leads to the dismantling of the AJ (B).  74 
In general, mechanisms that activate tyrosine kinase tend to reduce cadherin mediated 
adhesion and elevate levels of cytoplasmic β catenin (Esser et al., 1998; Wright et al., 
2002; Wheelock et al., 2003), while activation of protein tyrosine phosphatases (PTP) 
stabilises the AJ, increasing cadherin mediated adhesion and reducing cytoplasmic β 
catenin (Lampugnani et al., 2003; Nelson et al., 2004).   
 
The  ability  of  β catenin  to  accumulate  in  the  cytoplasm  is  tightly  regulated  by  a 
complex of proteins that control the metabolic stability of β catenin (Moon et al., 
2004).  According to the canonical Wnt pathway, cytoplasmic β catenin is targeted 
for degradation (Aberle et al., 1997) by a complex of serine/threonine kinases [casein 
kinase I (CKI), glycogen synthase 3β (GSK 3β); (Ikeda et al., 1998; Sakanaka et al., 
1999)] in a scaffolding complex of axin (Ikeda et al., 1998; Sakanaka et al., 1998) 
and the adenomatous polyposis coli protein (APC; Rubinfeld et al., 1996; He et al., 
1998;  Figure  1.11).    However,  a  large  family  of  secreted  glycoproteins  (Wnts) 
stabilise  β catenin  by  inhibiting  GSK 3β  (Akiyama  2000;  Moon  et  al.,  2004).  
Binding of a Wnt ligand to Frizzled receptors (Fz), a family of 7 trans membrane 
receptors  (7 TM),  activates  Dishevelled  (Dsh)  in  the  cytoplasm  (Akiyama  2000; 
Goodwin  et  al.,  2002).    Dsh  inhibits  the  GSK 3β  containing  phosphorylation 
complex, promoting the accumulation of β catenin via this, the canonical pathway 
(Ikeda et al., 1998; Sakanaka et al., 1999; see Figure 1.11).   
 
In addition, a second class of Wnts function via a β catenin independent mechanism 
(the Wnt/Ca
2+ pathway), stimulating the release of intracellular calcium and activating 













































Figure 1.11  β catenin and the Wnt signalling pathway.   
In the absence of a Wnt stabalisation signal (OFF), free cytoplasmic β catenin is 
rapidly  phosphorylated  by  GSK 3β,  and  marked  for  degradation  via  ubiquitin 
mediated proteolysis.  Conversely, the presence of a Wnt signal acting through the 
Frizzled  receptor  (ON)  inactivates  GSK 3β  which  allows  the  accumulation  of  β 
catenin in the cytoplasm.  Free β catenin translocates to the nucleus which results in 
TCF/LEF mediated gene transcription.  Interestingly, Akt, the mediator of VEGF A 
induced  EC  survival  induced  via  VEGFR2  similarly  inhibits  GSK 3β  which  may 
result in the accumulation of β catenin in the cell. 76 
When stabilised, cytoplasmic β catenin translocates to the nucleus (Huber et al. 1996; 
Blankesteijn  et  al.,  2001),  binds  the  T  cell  factor/lymphoid  enhancer  factor 
(TCF/LEF) transcription complexes (Behrens et al., 1996; He et al., 1998; Shtutman 
et al., 1999) and initiates the transcription of numerous genes involved in cellular 
proliferation  and  differentiation  potentially  implicated  with  vascular  remodelling 
including c myc (MYC), cyclin D1 (CND1) and the matrix metalloproteases MMP2, 
and MMP7 (Gumbiner 1995; Behrens et al., 1996; He et al., 1998; Shtutman et al., 
1999).    In  addition  to  regulating  endothelial  barrier  function  therefore,  the  AJ  is 
suggested to regulate the activity of β catenin signalling by maintaining bound β 
catenin  in  the  AJ  and  thus  preventing  its  translocation  to  the  nucleus  for  gene 
transcription (Gottardi et al., 2004; Dejana 2004).  The precise role of β catenin in the 
vasculature is unclear however, although there  is an absolute requirement for the 
protein  as  the  conditional  inactivation  of  the  β catenin  gene  causes  a  defective 
vascular pattern with fragile vessels (Cattelino et al., 2003).   
 
1.3.2  VEGF A, VEGFR2 and the adherens junction  
The mechanism(s) through which VEGF A mediates vascular permeability are not 
clearly understood, although like most other mediators of permeability including NO, 
thrombin and histamine (Andriopoulou et al.,  1999; Bates et al., 2002; Dejana et al., 
2001), VEGF A increases paracellular permeability of the vascular endothelium by 
disrupting the endothelial AJ (Kevil et al., 1998).  VEGF A binding to VEGFR2 
tyrosine phosphorylates components of the AJ (Esser et al., 1998; Cohen et al., 1999) 
resulting in a loss of cadherin mediated endothelial cell cell adhesion and reduced 
endothelial barrier function (Cohen et al., 1999).  Dismantling of the AJ therefore 
results in increased endothelial paracellular permeability (Kevil et al., 1998, Dejana  77 
et al., 1997) and the release of β catenin into the cytoplasm (Cohen et al., 1999; 
Figure 1.12).  Furthermore, dismantling of the AJ regulates the responsiveness of EC 
to VEGF A signalling, as the loss of cell adhesion is required to deregulate contact 
inhibition  required  for  endothelial  cell  proliferation,  migration  and  permeability 
associated  with  vessel  remodelling  and  angiogenesis  (Rahimi  et  al.,  1999; 
Lampugnani et al., 1997; Dejana et al 2000; Dejana et al., 2001).   
 
Following VEGF A activation, VEGFR2 associates with VE cadherin (Rahimi et al., 
1999; Wright et al., 2002; Zanetti et al., 2002) forming a complex that localises to the 
intracellular junction (Carmeliet et al., 1999; Rahimi et al., 1999; Lampugnani et al., 
2003).  The formation of VE cadherin VEGFR2 complex is dependant on the β 
catenin binding domain of VE cadherin (amino acids 703 784; Carmeliet et al., 1999) 
as demonstrated by the failure of truncated VE cadherin to form the complex which 
inhibits  phosphorylation  of  VEGFR2  and  VEGF A  mediated  survival  via  PI3K 
(Carmeliet et al., 1999; Lampugnani et al., 2003). 
 
As protein tyrosine phosphatases (PTP) are tethered at intracellular junctions (Young 
et al., 2003; Nawroth et al., 2002), VE cadherin is suggested to act as a platform 
facilitating interaction between VEGFR2 and PTP found in the AJ (Zanetti et al., 
2002;  Lampugnani  et  al.,  2003).    This  close  proximity  to  PTP  in  the  AJ  is 
demonstrated to modulate the activity of VEGFR2 signalling (Rahimi et al., 1999; 
Zanetti  et  al.,  2002)  by  directing  VEGFR2  signalling  to  specific  pathways 
(Lampugnani et al., 2003).  The pathway selected is determined by recruitment of 
adapter  proteins  (see  chapter  1.2.5)  to  phosphorylated  tyrosine  residues  on  the 
intracellular  VEGFR2  domain  (Carmeliet  et  al.,  1999;  Lampugnani  et  al.,  2003).  78 
Consequently, VEGF A activation induces VEGFR2 mediated EC survival via Akt 
(Carmeliet et al., 1999; Gerber et al., 1998A), while simultaneously inhibiting PLCγ 
mediated proliferation (Lampugnani et al., 2003) in confluent EC.  Furthermore, the 
association of PTP with the VE cadherin VEGFR2 complex can dephosphorylate 
active tyrosine motifs on intracellular domains of VEGFR2, essentially deactivating 


































Figure 1.12  Dismantling of endothelial AJ by VEGF A signalling. 
Confluent endothelial cells present a semi permeable surface to the vessel lumen (A). 
VEGFR2  mediated  signalling  tyrosine  phosphorylates  components  of  the  AJ  (red 
dots) (B) leading to the dismantling of the AJ (C).   Dismantling of the AJ increases 
endothelial paracellular permeability (D) and releases β catenin from the cadherin 
/catenin complex (blue dots).  β catenin, if not degraded translocates to the nucleus 
and activates numerous genes involved with proliferation and vessel wall remodelling 
via  the  TCF/LEF  transcription  complex  (E).  Deactivation  of  VEGFR2  and 
dephosporylation  of  the  catenin/cadherin  components  by  protein  tyrosine 
phosphatases (PTP) co localised here is thought to initiate the restabilisation of the at 
the cadherin / catenin complex complex which reforms the AJ (F). 80 
1.4  VEGF AND PRIMARY VARICOSE VEINS 
The  underlying  clinical  abnormality  associated  with  primary  VVs  is  venous 
incompetence, principally in the greater saphenous system (Labropoulos et al., 1999; 
Ruckley et al., 2002) which results in venous hypertension, perturbed blood flow 
(turbulence, stagnation and reflux), dilatation and abnormal vein wall remodelling 
(Browse et al., 1999; Labropoulos et al., 1999; Nicolaides 2000; Badier Commander 
et al., 2000; Ruckley et al., 2002).  Historically the initiation of varicosity is thought 
to  occur  following  a  “mechanical”  problem  such  as  descending  valvular 
incompetence (Golledge et al., 2003; see chapter 1.1.4).  Clear evidence, however 
refuting  Trendelenburg’s  model  of  ‘descending  valvular  incompetence’  as  the 
primary cause of varicosity, is published extensively in the literature (Abu owen et 
al., 1994; Labropoulos et al., 2000; Hollingsworth et al., 2001B).   
 
The introduction of colour flow duplex ultrasound examination in the diagnosis of 
venous incompetence, has further challenged this assumption and contributed to our 
understanding of the presentation of disease in relation to functional characteristics of 
the varicosity like the underlying venous incompetence (Labropoulos et al., 1997; 
Allen et al., 2000; Ruckley et al., 2002; Cooper et al., 2003).  Observations from 
these studies suggest that the development of varicosity may occur by a process of 
progressive “spreading incompetence” potentially originating and spreading from a 
local focal point(s) (Jones et al., 1999; Labropoulos et al., 1999; Cooper et al., 2003).  
This is substantiated by observations that varicosity is often patchy and irregular, with 
varicose  segments  of  vessel  wall  interspersed  with  apparently  normal  segments 
(Badier Commader et al., 2001; Wali et al., 2001B).   81 
At  the  cellular  level,  histological  analysis  of  the  morphology  and  composition  of 
cellular and matrix components of the vein wall confirms the heterogeneity nature of 
the varicose vessel wall when compared to that of a normal vein (see chapter 1.1.6).  
These distinct patterns of morphological and structural alterations are considered to 
be the result of aberrant vessel wall remodelling (Gandhi et al., 1993; Venturi et al., 
1996; Badier Commader et al., 2000).  Furthermore, it has been demonstrated that the 
processors  involved  are  influenced  by  the  same  growth  factors  implicated  in  the 
regulation  of  normal  vascular  homeostasis  (Yancopoulos  et  al.,  2000;  Badier 
Commader et al., 2001).  This suggests that an aberrant molecular control of, or 
perhaps an inappropriate response to mediators of normal vascular homeostasis like 
VEGF A may potentially pre dispose to the development of primary VVs. 
 
VEGF A, acting in concert with nitric oxide (NO; Servos et al., 1999) plays a central 
role in the maintenance of vascular homeostasis by regulating multiple functions of 
blood vessel physiology including vascular dilatation and permeability (Ku et al., 
1993; Bates et al., 1996; Klagsbrun  et al., 1996; Ferrara  et al., 2003).  Previous 
studies demonstrated that patients with primary VVs had a loss of release of VEGF A 
following  a  mild  experimentally  induced  stasis  (Hollingsworth  et  al.,  2001A).  
Furthermore  plasma  NO  was  reduced  significantly  suggesting  perhaps  a  fault  in 
VEGF maintenance of vascular reactivity (Hollingsworth et al., 2001A).  The loss of 
release of VEGF A in response to a stimuli like disturbed blood flow or elevated intra 
luminal pressure, may suggest a fault in the VEGF system in VVs.  Although VVs 
have  the  ability,  albeit  a  reduced  ability,  to  respond  (contract  or  dilate)  to 
exogenously added mediators of vascular tone in vitro (Schuller Petrovic et al., 1997; 
Brunner et al., 2001), fewer investigations into the ability of the vein wall itself to 82 
produce  mediators  of  vascular  homeostasis  like  VEGF A,  have  as  of  yet,  been 
undertaken.    Moreover,  as  the  control  of  molecules  like  VEGF A,  involved  in 
maintaining  vascular  reactivity  is  fundamental  in  the  regulation  of  homeostasis, 
examination of the activity of such molecules in association to the pattern of disease 
presentation, may help to elucidate the mechanism(s) underlying varicogenesis. 
 
1.5  HYPOTHESIS 
Valve reflux is considered a principal cause of primary VVs, although there is no 
consensus as to whether valve incompetence is the primary initiating event in the 
pathogenesis of varicose disease or may merely occur secondary to vein wall dilation 
(Beebe Dimer et al., 2005).  The proposal here, is that potentially the initiation and 
development  of  primary  VVs  may  arise  following  a  loss  of  regulation/control  of 
VEGF A  locally  by  cells  in  the  vessel  wall,  a  molecule  intimately  implicated  in 
maintaining vascular reactivity.   
 
Functional characteristics like disturbed blood flow within the ‘pre varicose’ vein 
may lead to a temporary hypertensive intra luminal state (Pearson et al., 1998) due 
either to an anatomical abnormality or simply reduced return blood flow due to a lack 
of physical movement (Michiels et al., 1997).  The appropriate homeostatic response 
for  increased  pressure  however,  should  be  to  relieve  ‘symptoms’  by  mediating 
dilatation  (and/or  an  increase  in  vessel  wall  permeability)  to  prevent  venous 
reflux/stasis (Luscher 1991; Browse et al., 1999; Recek 2004) and as such the release 
of dilatory mediators like VEGF A and NO would be expected (Michiels et al., 1997; 
Servos  et  al.,  1999;  Hollingsworth  et  al.,  2001A).    If  not  resolved,  a  localised 83 
abundance of VEGF A combined with a continuous chronic stimulation to dilate may 
result in an altered sensitivity by components of the vein wall to available VEGF A.   
 
Overtime local homeostatic mechanism(s) may become unregulated (Sho et al., 2003) 
which together with other factors associated with CVI, like hypoxia may drive further 
production  of  VEGF A  (Pearson  et  al.,  1998;  Michiels  et  al.,  1996).    The  vein, 
potentially  having  lost  the  ability  to  mediate  an  appropriate  molecular 
response/control to VEGF A may start to respond aberrantly, ultimately resulting in 
the vessel wall remodelling and histological changes seen in VVs. 
 
1.5.1  Aims: 
To investigate this hypothesis, the first requirement is to demonstrate that varicose 
vessels have the capability to produce both VEGF A and its receptors.  As described 
in  chapter  1.2.2  VEGF A  is  regulated  on  multiple  levels,  but  is  transcriptionally 
upregulated in vascular SMC in response to a number of factors including elevated 
venous pressure, disturbed blood flow and hypoxia (Pearson et al., 1998, Shay Salit 
et al., 2002, Sho et al., 2003).   
 
Aim 1: To investigate the pattern of transcription of VEGF A and its receptors in 
relation  to  the  underlying  venous  incompetence:    Here,  the  patterns  of  gene 
transcription of VEGF A and its receptors VEGFR2, VEGFR1, s.flt 1 were examined 
in VVs in relation to the underlying venous incompetence (from duplex scan), to 
investigate  potential  associations  between  a  functional  characteristic  of  varicose 
disease like disturbed blood flow (Browse et al., 1999;  Ruckley et al., 2002) with 
alterations in gene activity.  84 
If  the  vein  can  produce  VEGF A  and  its  receptors,  then  dysfunction  of  venous 
reactivity and vascular remodelling observed in VVs may be due to an inability of the 
vessel wall to respond appropriately to available VEGF A.  As described in chapter 
1.2.5  VEGF A  mediates  vascular  reactivity  and  homeostasis  via  a  number  of 
intracellular signalling pathways.  If as suggested, the action of VEGF A is disturbed 
with the development of primary VVs, then alterations to the proper functioning of 
VEGF A should affect its normal role in homeostasis i.e. the regulation of dilatation 
and permeability.   
 
Aim 2. To examine the pattern of activity of β catenin gene transcription and protein 
expression in relation to the underlying venous incompetence in VVs and control vein 
samples.  Although the mechanisms by which VEGF A induces vascular permeability 
are not clearly understood, VEGF A binding results in the dismantling of the AJ 
resulting  in  a  loss  of  endothelial  cell  adhesion,  with  increased  paracellular 
permeability and the release of β catenin to the cytoplasm (see chapters 1.2.6 and 
1.3.2).  If VEGF A signalling is disturbed with the onset of varicose disease, which 
does indeed occur by a process of progressive “spreading incompetence” (Jones et 
al., 1999; Cooper et al., 2003), then alterations to the pattern of expression of β 
catenin  may  similarly  associate  to  the  patterns  of  disease  presentation  observed.  
Notably,  β catenin  if  not  degraded  may  translocate  to  the  nucleus  and  activate 
numerous genes involved in proliferation and cellular differentiation associated with 
vascular remodelling (see chapter 1.3.1).  So in addition, c myc and cyclin D1 gene 
transcription was similarly examined to investigate possible associations between β 
catenin and the transcriptional activation of its target genes in relation to the patterns 
of disease presentation.   85 
Aim 3:  To examine baseline levels of plasma s.flt 1 in the GSV and its release 
following a mild experimentally induced venous hypertension and whether release is 
affected by varicosity.  Finally in controlling vascular reactivity the endothelium must 
be  able  to  switch  off  cellular  response(s)  to  VEGF A.    A  lack  of  attenuation  of 
VEGF A  signalling  by  mechanisms  modulating  either  VEGF A  availability,  or 
interaction with the VEGF receptors may potentially facilitate continued VEGF A 
signal activation.  The soluble form of VEGFR1, s.flt 1 is proposed to modulate the 
activity of VEGFR2 (Kendall et al., 1996A; Graubert et al., 2001) and so attenuates 
the action of VEGF A signalling (Kendall et al., 1993; Belgore et al., 2000).  Here, 
the release of s.flt in response to elevated venous pressure was examined to determine 
if  a  mechanism  implicated  in  the  modulation  of  VEGF A  action  was  intact  in 














2.  MATERIALS AND METHODS 
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2.1  SAMPLE COLLECTION AND PROCESSING 
2.1.1  Ethics approval and patient selection 
Approval was obtained from the Joint UCL/UCLH Committee on Ethics of Human 
Research prior to commencement of the study for the collection and use of all human 
tissue used in this investigation (see Appendix 1).  The diagnosis of primary VVs was 
made  by  the  referring  surgeon,  and  confirmed  by  the  vascular  technologist  using 
venous  Duplex  ultrasound  scans  as  clinically  evident  VVs,  C.E.A.P.  Grade  II  or 
above  (Porter  et  al.,  1995).    Patients  who  had  either  previous  surgery  for  VVs, 
evidence of current or previous DVT or elected not to consent to the use of blood or 
tissue were excluded from the study. 
 
2.1.2  Sample collection 
Greater Saphenous vein:  Samples of VVs were collected at operation for sapheno 
femoral ligation and stripping of GSV as treatment for primary VVs.  Examination of 
reflux at the sapheno femoral junction (SFJ) and GSV was investigated with patients 
standing and reported as incompetent only when the duration of reflux exceeded 0.5s 
(Porter et al., 1995). The position of incompetent venous segments was cross checked 
against the duplex scan report following removal of the vein.  Prior to operation, a 
record  was  made  from  the  duplex  scan  of  patterns  of  venous  incompetence  and 
distribution  of  varicosities.  Samples  of  control  vein  were  obtained  from  patients 
undergoing  cardiac  bypass  procedures  and  who  had  no  symptoms  or  clinically 
evident signs of varicose disease in either limb; veins were confirmed to be normal by 
a pre operative duplex scan, showing that the vessel was disease free and without 
valvular incompetence in any segment. 
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Following removal, the GSV sample was immediately placed in cold (4°C) Soltran 
kidney  perfusate  solution  (Baxter  Ltd  UK,  appendix  3)  and  transported  to  the 
laboratory for processing.  Varicose GSV sample was dissected into five anatomical 
segments starting from the sapheno femoral junction, as proximal (P), proximal to 
mid (P M), mid (M), mid to distal (M D) and distal (D) (Figure 2.1).  The final 
number of segments harvested from each vein was dependant on the length of the 
vein  that  was  stripped,  with  only  those  stripped  to  below  knee  providing  five 
segments (average length of vein section was between 5 to 10 cm, depending in part 
on  the  extent  of  tortuosity  present  within  the  segment).  With  this  procedure  the 
competency of the segment (reflux as determined by colour flow Doppler) could be 
correlated to the specific anatomical position of the segment along the length of the 
vein.  The author thanks Mr David Cooper for the analysis and alignments of vessel 
segment competencies to that determined by duplex scan and for the collection of 
vein samples. 
 
Between  100  to  300mg  approximately  5  cmsontrol  or  varicose  GSV  tissue  was 
transferred to 2 ml cryovials (Nalgene, UK) and flash frozen in liquid nitrogen (LN2, 
BOC Ltd, UK).  The vein segments were stored under vapour phase of liquid nitrogen 
until subsequent processing for RNA and protein.   
 
Venous stasis and collection of blood plasma:  All individuals enrolled in this study 
were non smokers receiving no medication.  Individuals (control subjects or patients 
with primary VVs) were rested supine for 15 minutes.  A foot vein was cannulated 
using a G23 butterfly and once positioned, was flushed through with 5ml of saline for 
injection.  Individuals were then rested supine for a further 10 minutes before 5ml of 89 
peripheral  blood  was  collected  (into  EDTA;  Vacutainer®)  from  the  foot  vein 
(followed by a further 5ml flush of saline for injection).  A control blood sample was 
removed  from  the  arm  immediately  afterwards.    Whilst  remaining  supine,  a 
sphygmomanometer  cuff  was  placed  directly  below  the  knee  and  inflated  to  90 
95mmHg to prompt a mild induced venous stasis (Hollingsworth et al., 2001A).  Ten 
minutes  following  application  of  the  cuff,  a  further  5ml  of  peripheral  blood  was 
obtained from the foot vein as before.  The author thanks Mr Tang for the collection 
of bloods as described. 
 
Samples  of  peripheral  blood  were  then  separated  through  Ficoll®  (Sigma Aldrich 
Ltd, UK) at 400g for 25 minutes at room temperature.  The plasma was transferred to 





































Figure 2.1  Position of vein segments obtained for analysis.   
Position from the SFJ (position); section number (section) and extent of stripping of 
the  GSV  undertaken  at  operation,  with  corresponding  numbering  of  sections  and 
respective segmental position from the SFJ (stripped GSV).  Section numbering and 
position were performed to match anatomical positions of sections taken for analysis, 
and to enable cross reference to duplex scans to determine competency (reflux or not) 
of the section at the position taken. 
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2.2  EXTRACTION OF RNA AND PROTEIN FROM VEINS  
2.2.1  Background 
Although numerous techniques exist for the isolation of RNA and protein from tissue, 
they all essentially share the following common attributes: i) membrane disruption 
and  cell  lysis,  ii)  inhibition  of  endogenous  ribonuclease  (RNAse)  and  protease 
activity, iii) the separation of cellular constituents and contaminants, iv) recovery of 
intact, uncontaminated RNA or protein.  The first two steps tend to present the most 
problems as all tissues contain endogenous RNAse and proteases sequestered within 
cellular  compartments.    Disruption  of  cell  membranes  during  cell  lysis  releases 
RNAse  and  proteases,  which  if  not  inactivated  immediately  can  cause  the  rapid 
degradation of cellular RNA and protein (Chomczynski 1993).   
 
Most current methods of RNA isolation therefore are based on disrupting the tissue in 
the  presence  of  strong  denaturing  or  chaotropic  chemicals.    High  molarity 
guanidinium solutions of thiocyanate or chloride salts are among the most effective 
protein denaturants and consequently inhibitors of RNAse activity available and have 
found  application  in  most  current  protocols  for  RNA  purification  procedures 
(Chomczynski  et  al.,  1987).    Furthermore,  tissue  homogenates  in  guanidinium 
thiocyanate can be manipulated at room temperature and the hazard of inadvertently 
introducing  exogenous  RNAse  during  processing  is  of  little  importance  (Ambion 
product insert).  Although techniques for the isolation of protein are normally tailored 
to the application for which the protein is be utilised, the method described below 
allows  for  the  isolation  of  RNA,  DNA  and  protein  from  the  same  sample 
(Chomczynski 1993).  The protein obtained is suitable for semi quantitative analysis 
by western blot.   92 
Here,  total  RNA  was  extracted  from  crushed  vein  tissue  segments  using  TRI 
Reagent™ (Sigma Aldrich Ltd, UK) according to the method previously described by 
Chomczynski.  TRI Reagent™, a mixture of guanidine thiocyanate and phenol in a 
mono phasic  solution,  effectively  dissolves  RNA,  DNA  and  protein  on 
homogenisation  of  tissue  (Chomczynski  1993).    After  addition  of  chloroform 
followed by differential centrifugation, the mixture separates into three phases: the 
top aqueous phase containing RNA, the interphase containing DNA and an organic 
phase containing cellular protein.  Each component can then be purified following the 
initial separation of the phases. 
 
2.2.2  Protocol:  Extraction of RNA using TRI Reagent™   
A ceramic mortar was cooled to less than  80°C with liquid nitrogen. A frozen vein 
segment  of  known  mass  was  quickly  removed  from  liquid  nitrogen  storage  and 
placed immediately in the mortar filled with liquid nitrogen.  The tissue was crushed 
to a fine powder, using a pre chilled ( 80°C) pestle, topping up the mixture with 
liquid nitrogen as required to ensure the tissue/powder did not thaw.  After complete 
homogenisation, 1 ml of TRI Reagent™ (Sigma Aldrich Ltd, UK) was added per 50 
100 mg of tissue.  The tissue powder/TRI Reagent™ mixture was frozen with liquid 
nitrogen, transferred to 50 ml Bluemax tubes (Sterilin, UK) and defrosted on the 
bench.  The defrosted tissue/ TRI Reagent™ homogenate was mixed thoroughly and 
incubated for 10 minutes at room temperature to facilitate complete dissociation of 
nucleoprotein complexes.  Insoluble cell debris was collected by centrifugation at 
2000g for 10 minutes at room temperature.  1 ml of the homogenate supernatant was 
transferred  to  1.5  ml  sterile  eppendorf  tubes  (1  ml  per  tube)  containing  0.2  ml 
chloroform  (BDH  Biosciences,  UK).    The  sample  was  mixed  thoroughly  for  15 93 
seconds and incubated on the bench for 10 minutes at room temperature.  The phases 
were separated by centrifugation at 12 000g for 15 minutes at 4°C.  The aqueous 
phase containing total RNA was transferred to a sterile 1.5 ml eppendorf tube without 
disturbing the interphase (containing DNA) to minimise possible DNA contamination 
of the RNA.  The interphase and organic phase were stored at  20°C for subsequent 
isolation  of  cellular  protein.    Total RNA  was  precipitated  from  solution  with  the 
addition  of  0.5  ml  isopropanol  (BDH  biosciences,  UK)  and  collected  by 
centrifugation at 12000 g for 10 minutes at 4°C.  The supernatant was discarded and 
the pellet washed with 1 ml of 75% v/v ethanol by centrifugation at 7500 g for 5 
minutes at 4°C.  The ethanol wash was discarded and the RNA pellet was air dried 
for 3 minutes at room temperature, taking care to prevent complete desiccation of the 
RNA pellet.  The pellet was suspended in 30 50  l in DNAse and RNAse free water 
(Qiagen Ltd. UK) by repeated pipetting with a micropipette and stored at  20°C for 
24 hours.  The RNA solution was defrosted and the concentration of isolated RNA 
was determined by spectrophotometric analysis according to the Beer Lambert Law 
relating concentration of a solution to its absorbance. 
 
Concentration ( g/ l)  =  A260  x   ε  x  Df 
 
where  A260  =  absorbance at 280nm  
  ε  =  extinction coefficient for RNA (M
 1 cm
 1) 
  Df  =  dilution factor (1:50) 
 
The  RNA  was  reverse  transcribed  to  complimentary  DNA  or  stored  at   20°C. 
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2.2.3  Protocol:  Extraction of total protein 
DNA contained in the interphase was precipitated with the addition of 0.3 ml 100% 
ethanol  and  collected  by  centrifugation  at  2000  g  for  5  minutes  at  4°C.    The 
supernatant  (containing  total  protein)  was  transferred  to  a  clean  15  ml  Bluemax 
(Marathon Labs Ltd, UK) and stored on ice.  Total protein was precipitated from the 
phenol ethanol supernatant with 1.5 ml cold 100 % isopropanol.  The sample was 
mixed thoroughly by inversion and incubated on ice for a minimum of 20 minutes.  
Precipitated proteins were collected by centrifugation at 12000 g for 10 minutes at 
4°C.  The supernatant was discarded and the protein pellet washed with 1.5 ml 0.3M 
guanidine hydrochloride/95% ethanol solution.  During each wash the protein pellet 
was incubated for a minimum of 20 minutes at room temperature, then collected by 
centrifugation at 7500 g for 5 minutes at 4°C.  After three washes the protein pellet 
was washed with 2 ml 100% ethanol, vortexed and incubated at room temperature for 
20  minutes.    The  protein  pellet  was  collected  by  centrifugation  at  7500  g  for  5 
minutes at 4°C, the ethanol wash was discarded and the protein pellet dried on the 
bench.  The dried pellet was crushed with a metal rod and total protein was extracted 
with 100  l 1% sodium dodecyl sulphate per 100 mg tissue (SDS, Sigma Aldrich 
Ltd,  UK).    The  extract  was  incubated  at  50°C  for  30  minutes  followed  by 
centrifugation at 10 000 g for 10minutes at 4°C to remove insoluble debris.  The 
cleared supernatant containing total protein was transferred to a clean 1.5 ml sterile 
eppendorf  tube  and  stored  on  ice.    Protein  concentration  was  determined  by  the 
method of Bradford and protein aliquots stored at  20°C (Bradford 1976).  95 
2.3  ANALYSIS OF GENE TRANSCRIPTION  
2.3.1  Reverse Transcription  
Reverse  transcription  (RT),  the  process  of  copying  RNA  to  complimentary  DNA 
(cDNA) is essentially an in vitro adaptation of the mechanism by which RNA viruses 
replicate following transduction in vivo (Lewin 1990).  In the RT reaction, RNA is 
used as template to reverse transcribe a complimentary strand of DNA by the action 
of a RNA directed DNA polymerase.  The RNA is initially denatured by heat and 
then cooled rapidly in the presence of a nucleotide primer.  As the temperature cools 
the primer binds to its target complimentary sequence on the RNA template.  The 
addition  of  a  mixture  of  deoxyribonucleotides  (dNTP)  and  a  DNA  polymerase 
enzyme in an appropriate buffer initiates the polymerisation reaction resulting in the 
production of a complimentary DNA strand. 
 
Enzymes used in RT:  The two RNA dependant DNA polymerase enzymes routinely 
used for RT are derived from the avian myoblastosis virus (AMV) or the moloney 
murine  leukaemia  virus  (MMLV)  (Biosource  Primer).    Here  we  have  utilised 
MMLV RT,  a  DNA  polymerase  that  reverse  transcribes  single  stranded  RNA 
following  priming  with  an  oligonucleotide  primer.    MMLV RT  can  tolerate 
temperatures  up  to  a  maximum  of  42°C  and  like  all  DNA  polymerases,  has  an 
absolute requirement for magnesium ions (Mg
2+) to function (reaction buffer contains 
15mM MgCl2).  The recombinant enzyme is isolated from E.coli expressing a portion 
of the pol gene of MMLV RT on a plasmid (Sigma Aldrich product sheet). 
 
Primers used in RT:  Nucleotide primers confer the specificity of the technique by 
binding to their complimentary target sequence on the RNA template.  Bound primer 96 
serves as a binding site for RT polymerases which then initiate strand synthesis by 
incorporating nucleotides into the growing chain in a 5’ to 3’ direction.  RT primers 
generally fall into one of three categories depending on the application. 
 
Oligo  dT  primers:    Primers  comprising  repeated  thymine  nucleotides  being 
complimentary to the polyadenylation signal on the 3’ end of mammalian message 
RNA  (mRNA)  are  used  to  reverse  transcribe  mRNA.    As  oligo(dT)’s  bind 
specifically  to  mRNA  species  only,  reverse  transcription  using  these  primers 
selectively enriches for genes that have been transcribed and has wide application in 
analysis of gene expression.  Although Oligo(dT)’s often produce a full length cDNA 
product, transcribing the message from the ‘tail end’ can sometimes be problematic, 
for example if the mRNA sequence is either very long or have significant secondary 
structure  
 
Random primers:  Random primers, short random repeats of six to ten nucleotides, 
bind complimentary sequences on all RNA species and therefore reverse transcribe 
total cellular RNA (mRNA as well as ribosomal and transfer RNA species).  As 
random primers bind to the template at multiple sites they are not as constrained by 
long  mRNA  sequences  (or  secondary  structure)  and  therefore  produce  a  higher 
proportion of the 5’ region of the RNA sequence (Bioscience Primer).  However 
random primers only produce cDNA’s of partial length. 
 
Gene specific primers:  Finally gene specific primers can be used to reverse transcribe 
a segment of the mRNA for a specific gene only.  Gene specific primers tend to be 97 
used for the detection of low copy number genes but have the disadvantage in that 
only that one gene sequence can be investigated with the cDNA produced. 
 
2.3.2  Protocol: Reverse Transcription 
Reverse transcription was performed as described in the product sheet for MMLV RT 
supplied with slight modifications (Table 2.1).  Total RNA (4  g) was aliquoted in a 
0.5 ml Eppendorf tube in the presence of 2  l random primers (125 ng/ l) and made 
up to a total volume of 24 l with deionised RNAse free water.  The tube was place in 
a Progene thermal cycler (Techne Ltd, UK) and the sample was heat denatured at 
70°C for 10 minutes.  The sample was removed and cooled on ice for 4 minutes to 
allow the primers to anneal to the RNA template.  A mastermix containing 8  l 5x 
first strand buffer (250 mM Tris HCl, 375 mM KCl, 15 mM MgCl2), 4  l of the 
reducing  agent  DTT  (100  mM)  and  2   l  dNTP  mix  (10  mM  of  each 
deoxyribonucleotide:  adenine,  thymine,  cytosine  and  guanine)  was  added,  the 
solution  was  mixed  and  incubated  at  42°C  for  2  minutes.    2   l  of  recombinant 
MMLV RT, 200 u/ l, Sigma Aldrich Ltd) was added and cDNA was synthesised 
during the following 50 minute incubated at 42°C.  The heat sensitive MMLV RT 
was deactivated with heat at 75°C for 15 minutes, and the newly synthesised cDNA 




Reagent  Concentration / Quantity  Volume ( l)  Total 
Total RNA    4  g  X   
Random primers  125 ng/ l  2   
dd H2O    Y   24  l 
     Heat to 70°C for 10 minutes 
     Chill on ice for 5 minutes, then add 14  l of mastermix 
Mastermix       
First strand buffer  5x  8   
DTT  100 mM  4   
dNTP mix  10 mM each of dATP, dTTP, 
dGTP, dCTP 
2  14  l 
     Incubate at 42°C for 2 minutes, then add 
MMLV RT  200 u/ l  2   
     incubate at 42°C for 50 minutes 
     denature MMLV RT with heat at 75°C for 10 minutes 
Total volume      40  l 
 
 
Table 2.1 Protocol for reverse transcription reaction.  
(5x first strand buffer, see Appendix 4)  99 
2.3.3  Polymerase Chain Reaction  
The polymerase chain reaction (PCR) is an invaluable technique for the analysis of 
gene expression and has revolutionised the field of molecular biology since it was 
first described (Mullis et al., 1986).  PCR, like reverse transcription is an in vitro 
method for the enzymatic synthesis of DNA.  However, unlike reverse transcription 
which  produces  only  one  faithful  copy  of  RNA,  PCR  amplifies  the  target  DNA 
sequence  exponentially,  producing  millions  of  copies  of  the  DNA  sequence  of 
interest  (Bosher  2000).    PCR  is  essentially  a  cycling  reaction  which  utilises  a 
combination  of  alternating  primer  hybridisation  and  DNA  replication  reactions  to 
amplify a sequence of DNA (Figure 2.2).  Each cycle is composed of three individual 
steps, a denaturation step, an annealing step and the strand elongation step.  In the 
denaturing step, the cDNA template is denatured (with heat) to separate the DNA 
double  helix  into  its  two  component  strands,  thereby  exposing  the  purine  and 
pyrimidine base structure contained in the genetic code.  The reaction is then cooled 
during  the  annealing  step  to  a  temperature  which  promotes  optimal  binding  of 
primers  to  their  complimentary  DNA  sequence.    The  bound  primers  serve  as  an 
initiation  site  for  the  binding  of  a  heat  stable  DNA  polymerase.    In  the  strand 
elongation step, the temperature is raise to the optimum for the DNA polymerase 
which synthesizes a new DNA strand in a 5’ 3’ direction using the existing strand as 
the  template.    The  DNA  duplex  consisting  of  the  original  template  and  newly 
synthesised DNA strand are then denatured again and a new cycle of amplification is 
initiated.  Exponential amplification of the DNA sequence of interest results, as with 
each successive cycle both the original template as well as the newly synthesized 






































































Figure 2.2  Schematic of the polymerase chain reaction (PCR).   
In  cycle  1,  a  double  stranded  DNA  template  is  denatured  in  the  presence  of 
complementary primers to facilitate binding at specific binding sites.  The annealed 
primer  serves  as  an  attachment  site  for  a  DNA  dependant  polymerase  which 
synthesises a new DNA strand.  As the newly synthesised strands from cycle 1 can 
now act as template in cycle 2, cycle 2 starts with four templates.  This selective 
amplification of the target sequence yields millions of copies, all of the same size as 
determined by the target sequence determined by the primer pair. 101 
In  a standard PCR reaction, each cycle is repeated thirty to forty times which is 
sufficient to increase the number of copies of the sequence being examined a million 
fold (Bosher 2000).  Amplification by PCR is particularly useful therefore when a 
limiting amount of RNA is available for analysis.  Conversely, in situations when a 
quantitative analysis is to be undertaken, variation in the amounts of starting RNA 
(cDNA)  can  have  a  substantial  effect  on  the  amount  of  final  product  produced 
(Kendall et al., 1996B).  Furthermore, the kinetics of the PCR reaction has a narrow 
linear range, being in dependent in part on the amount of template used at the start of 
the reaction (Higuchi et al., 1993).  These problems need to be addressed when using 
PCR to determine the level of gene transcription in a cell i.e. to control for differing 
amounts of RNA (cDNA) in the samples and the kinetics of the PCR reaction itself.   
 
Two  strategies  are  routinely  used  to  make  an  analysis  of  the  level  of  gene 
transcription.  The  first  makes  use  of  a  known  quantity  of  an  engineered  DNA 
sequence that contains the same primer binding sites as the sequence of interest but 
yields a different size product (Cross 1995).  Both DNA standard and experimental 
sample  are  amplified  in  the  same  reaction  tube  and  the  amount  of  experimental 
product produced is determined from the amount of internal standard used initially to 
give a quantitative result (Heid et al., 1996).  Alternatively, a “house keeping” gene, a 
gene  constituently  expressed  in  the  cell,  is  used  as  an  “internal  standard” 
(Vandesompele et al., 2002).  Here the amount of experimental product is determined 
as a ratio to the amount of “house keeping” gene product produced, to yield a semi 
quantitative result of the level of gene transcription in the sample (Cross 1995).   The 
use  of  primers  to  a  control  transcript,  in  our  case  glyceraldehyde 3 phosphate 
dehydrogenase  (GAPDH),  shows  that  each  sample  investigated  has  undergone 102 
equivalent reverse transcription to cDNA and that the cDNA is amplifiable during 
PCR.  Since the control sequence is not used to define absolute levels of mRNA, 
differences  in  primer  efficiencies  between  the  control  and  test  primers  are  not 
important (Dallman et al., 2005).  Furthermore, this approach can be readily applied 
to the analysis of transcription of multiple genes from the same sample using the 
same “internal standard”.    
 
A  typical  PCR  reaction  requires  the  following  components:  target  DNA, 
oligonucleotide primers, deoxynucleotide triphosphates (dNTP), a thermostable DNA 
polymerase, and magnesium in a suitable reaction buffer.  As the stringency of the 
reaction  is  affected  by  many  of  the  above  parameters  the  reagent  concentrations 
required  for  optimal  amplification  were  determined  empirically  for  each  set  of 
primers, in combination with the initial amount of starting template used.  Important 
points to note in the optimisation of PCR are discussed. 
 
Primer design:  Successful PCR depends more on the design of appropriate primers 
than any other component in the reaction.  The specificity and sensitivity of PCR is 
achieved by exploiting the stringent bonding characteristics of purine pyrimidine base 
pairing in DNA by using sequence specific primer pairs.  The PCR primer therefore 
not only dictates the specific DNA sequence to be amplified, but also defines other 
characteristics of the reaction including size of product and annealing temperature 
used.  Poorly designed primers can both increase the amplification of spurious gene 
products by non specific binding and decrease the product yield by encouraging the 
formation of primer dimers. A few parameters to consider when designing primers 
are discussed below: 103 
Primer Length:  Primers of between 18 to 30 nucleotides in length provide good 
specificity to detect an unique target sequence, while minimising the probability of 
primer dimmer formation (Dallman et al., 2005).  Both primers of the pair should 
ideally contain similar numbers of each nucleotide, while the GC content should be 
between 40 60% (Dallman et al., 2005). 
Primer sequence: The sequence of the primer should be complimentary to a unique 
region of the gene being investigated.  To minimize the probability of non specific 
binding, the primer should not target DNA sequences that contain polypurine (A, G) 
or  polypyrimidine  (T,  C)  sequence  strings,  GC  rich  regions  or  repetitive  DNA 
sequences (Alu elements).  For optimal amplification the binding of the 3’ end of the 
primer is critical as polymerisation occurs in a 5’ 3’ direction.  There should be no 
mismatch between the primer and target sequence within the last 3 6 nucleotides of 
the 3’ end.  Further, stipulating the terminal 3’ nucleotide is a guanine or cytosine 
(GC clamp) improves the efficiency of primer binding due to the stability of the 3’ 
bond  (3  hydrogen  bonds).    Finally  there  should  be  minimal  self complimentary 
within  each  primer  (3’  intra homology)  as  well  as  between  the  two  primer  pairs 
(inter homology) to reduce the formation of artefacts and primer dimers. 
Primer melting temperature: The melting temperature (Tm) of the primer is defined 
as the temperature at which 50% of a primer in solution is hybridised to the target 
sequence (Bosher, 2000).  The specificity of the hybrid formation between primer and 
target  is  influenced  by  both  the  geometry  of  the  bases  responsible  for  hydrogen 
bonding (adenine and thymine, 2 bonds: guanine and cytosine, 3 bonds), as well as 
the electrostatic interaction of the phosphate  groups which tend to destabilise the 
double stranded molecule (Lewin 1990).  The Tm of a PCR primer is dependant on 
the number of GC bases in the primer sequence and the salt concentration of the 104 
buffer  solution.    Consequently,  the  Tm  is  a  good  estimate  of  the  annealing 
temperature used for PCR, as it reflects the temperature required to break half the 
hydrogen bonds between template and primer.  Of the numerous methods used to 
determine the Tm in the PCR the most accurate is a thermodynamic calculation based 
on entropy, enthalpy, free energy and temperature, “the nearest neighbour” formula 
(Bosher 2000). 
Tm = H[S + R ln (C/4)] – 273.15 +16.6log10[K+] 
 
  where  H = enthalpy 
    S = entropy for helix formation 
    R = molar gas constant 
    C = concentration of primer 
 
For simplicity, the Tm for nucleotides of up to 18 nucleotides in length can be 
estimated with the following formula as described by Wallace. 
 
Tm = [(number of G + C) x 4] + [(number of A + T) x 2 ] – 4 
 
 
Template  sequence:  As  mentioned,  each  primer  of  the  pair  should  recognise  a 
segment of the template sequence that is unique.  To reduce the amplification of 
genomic DNA, the primer pair is designed to either anneal to target sequence located 
on an intron exon boundary in the mRNA, or in two different exons (separated by an 
intron).    Consequently,  amplification  of  contaminating  genomic  DNA  will  give  a 
different sized product to the target mRNA.  In practice, with the development of new 
algorithms most primers are routinely chosen with primer picking software.   
 
All primers used in this study, unless stated otherwise, were selected with Primer 3, a 
software  package  from  the  Whitehead  Institute,  available  free  of  charge  on  the 
internet (http://www.genome.wi.mit.edu/cgi bin/primer/primer3).  The homology of 105 
the  selected  primers  were  analysed  against  all  published  sequences  in  the  human 
genome using the Basic Alignment Sequence Homology Tool (BLAST) available 
from NCBI on the internet (http://www.ncbi.nih.gov).  Table 2.2 lists the molecules 
investigated, their chromosomal location and the NCBI reference sequences used to 
select the primers as detailed in this study.  A complete list of the primer sequences, 
including parameters like the targeted exon/intron, Tm and product size are listed in 
Table 2.3 while additional characteristics are presented for VEGF A (Figure 2.3), sflt 
1 (Figure 2.4) and all genes (Appendix 3).   
Annealing  temperature:    The  specificity  of  binding  of  the  primer  to  the  template 
target sequence is determined by the annealing temperature of the PCR reaction.  The 
annealing temperature, as discussed above is determined by the Tm of the primers.  
As the annealing temperature approaches the Tm, the stringency of the reaction is 
increased.  This reduces the possibility of primers binding to non specific sequence 
on the template DNA.  The annealing temperature is generally kept 2 4°C below the 
lowest Tm of the primer pair used in the reaction.  The length of time allowed for 
annealing  is  also  important  and  is  usually  between  30 60  seconds.    Since  DNA 
polymerase  do  have  some  activity  at  lower  temperatures,  a  long  annealing  time 
increases the probability of amplification of non specific products.  In this study, the 
annealing time was set to 30 seconds as standard. 
Elongation:  The efficiency of Taq polymerase is approximately 1000bp per minute at 
72°C.  The time allowed during elongation to synthesize the new DNA strand is 
calculated from the expected size of the product, as defined by the primer pair.  As all 
the primers used in the study were designed to produce products of less than 500bp 






  Gene    symbol  chromosome    ref sequence  size (base pair) 
  GAP  3    GAPDH  12p13    NM_002046.2  1315 
  VEGF A    VEGF  6p12    NM_003376  784 
  β catenin    CTNNB1  3p21    NM_001904.1  3357 
  c myc    MYC  8q24    NM_002467.2  2168 
  cyclin D1    CCND1  11q13    NM_053056  4288 
  VEGFR2     KDR  4q11 4q12    NM_002253  5832 
  VEGFR1     FLT 1  13q12    NM_002019.1  7090 




Table 2.2  Characteristics of the genes examined in this study. 
(see Appendix 3 ). 
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Table 2.3  Primer pairs used in this study. 
Primers  were  designed  with  Primer  3  (http://www.genome.wi.mit.edu/cgi 
bin/primer/primer3) from reference sequence or taken from the literature [GAP452 
and  c myc  (Zhihua  et  al.,  2003),  cyclin  D1  (Gumbiner  et  al.,  1999)  and  VEGF 
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Figure 2.3  Primer pair for VEGF detects all possible splice variants of VEGF A. 
The 13.4 kB VEGF A gene is coded by eight exons that produce a mature mRNA of 
784 bp.  Although four different isoforms of VEGF A exist in the cell, all produced 
by alternative splicing of the mature mRNA, most cells preferentially express VEGF 
A121 189.  VEGF A189 lacks 51 bp in exon 6, while total loss of exon 6 produces VEGF 
A165  mRNA  and  loss  of  both  exon  6  and  7  produces  VEGF A121.    The  primers 
designed for VEGF A were based on those originally used by Tokunaga et al., 1998 
and detect all VEGF A transcripts produced by the cell.  109 
 
 
extra cellular intra cellular
 
flt 1 1338 amino acids
sflt 1 687 amino acids
splice site at intron 13












flt 1 PCR product 277bp
s.flt 1 PCR product 119bp
extra cellular intra cellular
 
flt 1 1338 amino acids
sflt 1 687 amino acids
splice site at intron 13












flt 1 PCR product 277bp
s.flt 1 PCR product 119bp  
 
 
Figure 2.4  Amplification of s.flt 1 requires a unique intronic primer.  
The large 194.7 kb VEGFR1 gene is coded by 30 exons that produce a mature mRNA 
of 7.090 kb.  Alternative splicing of VEGFR1 results in two mRNA transcripts, one 
gives  rise  to  the  membrane  bound  receptor,  while  a  premature  termination  at  a 
polyadenylation site of intron 13 results in the soluble isoform (s.flt 1) (Kendall et al., 
1993; Kondo et al., 1998).  Consequently, 93 base pairs of s.flt 1 are unique and can 
be used to differentiate the mRNA of the two isoforms.  
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Magnesium chloride:  DNA polymerases have an absolute requirement of magnesium 
ions (Mg
2+) to function properly.  The concentration of Mg
2+ therefore can be utilised 
to  alter  the  stringency  of  the  PCR  reaction  by  modulating  the  activity  of  the 
polymerase.  The Mg
2+ concentration affects the efficiency (rate of synthesis) and 
fidelity (error rate) of the polymerisation reaction.  Low Mg
2+ concentration increases 
the stringency of the PCR reaction.  Reactions at high stringency decrease both non 
specific binding of primer to the template, as well as the fidelity of polymerisation.  
Conversely, an excess of Mg
2+ decreases the stringency of the reaction.  Reactions at 
low  stringency  contribute  to  the  production  of  artefacts  (increased  non specific 
binding  of  the  primer)  and  decrease  the  fidelity  (increased  error  rate)  of  the 
polymerase.    Taq  polymerase,  the  most  widely  utilised  heat  resistant  DNA 
polymerase for PCR, demonstrates optimal activity at 1.2 1.3 mM free Mg
2+.  The 
concentration of free Mg
2+ in PCR however, is affected by the concentration of both 
deoxyribonucleotides  (dNTP)  and  primer  in  the  reaction.    In  solution  there  is 
equimolar binding of free Mg
2+ to dNTP and changes in either the primer or dNTP 
concentration will therefore affect the concentration of available Mg
2+.  All PCR in 
this study used 2 mM MgCl2, 200  M dNTP mix (200  M of each dNTP) and 1  M 
of each primer (see Table 2.4).  The theoretical concentration of free Mg
2+ therefore 
was approximately 1.2 mM, approaching the optimal Mg
2+ concentration required for 
Taq polymerase. 
 
DNA  polymerase:    There  are  a  large  number  of  different  DNA  dependant 
polymerases for PCR, all of which however characteristically synthesise DNA in a 
5’ 3’ direction from the free 3’ hydroxyl group.  For PCR, polymerases can generally 
be grouped according to their “proof reading” capability, as defined by the presence 111 
or absence of a 3’ 5’ exonuclease.  Polymerases, like Taq polymerase that do not 
contain 3’ 5’ exonuclease activity have high efficiency (rate of synthesis) but low 
fidelity (high error rate) and incorporate an incorrect nucleotide with a frequency of 1 
in 10
4 bases.  Conversely, polymerases that do contain 3’ 5’ exonuclease activity 
(Pfu, Pwo) make few errors during polymerisation (high fidelity) and are used in 
applications like cloning where the integrity of the product sequence is important.  As 
mentioned  polymerases  have  activity  at  temperatures  below  their  optimum.    The 
consequences of this enzyme property requires special consideration when setting up 
the  reaction,  as  DNA  template  in  the  absence  of  dNTP  can  be  degraded  by 
“proofreading”  polymerases.    Furthermore  Taq  polymerase  has  5’ 3’  exonuclease 
activity, which in the presence of excess enzyme may increase the production of 
artefact by degrading the DNA template.  To circumvent this problem use is made of 
a “hotstart technique”.  Here the components of the reaction are added together in the 
absence of Taq polymerase.  The PCR reaction is started and the polymerase is only 
added to the reaction prior to the initial elongation step.   
 
As analysis of gene transcription used here was semi quantitative, the fidelity of the 
enzyme was not of primary importance.  REDTaq™ polymerase, a Taq polymerase 
mixed  with  an  inert  red  tracer  dye  was  obtained  from  Sigma Aldrich  at  a 
concentration of 1u/ l.  Here, 0.5 units REDTaq™ polymerase per reaction was used 
for PCR, with one unit defined as the quantity of enzyme required to incorporate 
10nmol  of  total  dNTP  into  acid  precipitable  DNA  for  30  minutes  at 74°C.    The 
enzyme was added as the last component according to the “hotstart” method. 112 
2.3.4  Protocol: Polymerase Chain Reaction 
PCR  was  performed  essentially  as  described  in  the  product  insert  supplied  with 
REDTaq™  Polymerase  from  Sigma  with  slight  modifications,  in  a  total  reaction 
volume of 50  l (Table 2.4).  To minimise pipetting errors all reagents were prepared 
as a mastermix (1).  With the exception of REDTaq™ reagents were all vortexed to 
disperse any salt gradients formed on freezing, before the matermix was prepared.  
On completion, the mastermix was vortexed then aliquoted to individual, autoclaved 
0.5ml Eppendorf tubes, prior to the addition of cDNA template (2).  A positive and 
negative control was included for each primer set.  The positive control (cDNA from 
GSV isolation) had previously been demonstrated to produce a PCR product with the 
reaction conditions used.  The negative control simply substituted template cDNA 
with  ddH2O  to  control  for  possible  contamination.    The  reagents  were  mixed  by 
centrifugation at 2000 g for 1 minute and placed in a Techne thermocycler.  The 
reaction was initiated with a four minute denaturation cycle at 94°C, followed by the 
addition of REDTaq™ mix (3) using a “hotstart” at 65°C.  The PCR was amplified 
for 35 cycles (Table 2.5).  After 35 cycles the products were incubated at 72°C for 10 
minutes and chilled to 4°C.  The amount of gene product produced following PCR 
amplification was determined by agarose gel electrophoresis. 
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mastermix  component  volume ( l)  concentration 
1  ddH2O  32.5 or 33.5
    
  10 mM dNTP mix  1.0  200  M 
  25 mM MgCl2  4.0  2 mM 
  10x reaction buffer  4.3  1x 
  100 pmol Forward Primer  0.5  1  M 




   
43 or 44 
 
2  cDNA (100 ng/ l)  2  or  1  0.1 0.2  g/ l 
       
3  ddH2O  4    
  10x reaction buffer  0.5  1x 
  REDTaq 1u/ l  0.5  0.01u/ l 
total  volume  50   
 
 
Table 2.4  The protocol for PCR reaction. 
 
PCR step  temperature  time (seconds) 
denature  94°C  30 
anneal  56 60°C  30 
elongate  72°C  45 
 
 
Table 2.5  PCR cycling parameters. 114 
2.3.5  Electrophoresis 
Electrophoresis involves the movement of a charge molecule in an applied electric 
field.  Migration of the molecule occurs in a liquid medium (a buffer salt solution of 
known pH and ionic strength) following the application of an external voltage (V).  
The  degree  of  movement  of  the  charged  molecule  in  the  applied  electric  field  is 
termed its electrophoretic mobility ( ).    is a function of the size, net charge and 
structural confirmation of the molecule and is described by the following relationship: 
     Q_   
  = 6πηr  x  V  
 
where  Q  =  net charge on the molecule 
  r   =  radius of the molecule 
  η  =  viscosity of the liquid medium 
  V =  applied voltage   
 
In a medium of constant viscosity and at a constant applied voltage, the movement of 
a charged molecule is governed by its charge to size ratio (Q/r), as the charge to size 
ratio increases (the molecule size decreases) the migration of the molecule increases.  
In practice though, resolution of molecules in solution is poor and use is made of an 
inert  solid  support  matrices  (including  starch,  agarose  and  polyacrylamide)  to 
improve separation.  A support matrix is a three dimensional polymer network which 
forms  pores  of  uniform  size,  with  the  size  of  the  pore  being  determined  by  the 
concentration of the gel polymer used.  The porosity of the gel however, presents a 
different effective viscosity of the medium to each molecule through a “molecular 
sieving” effect (as determined by the size of the individual molecule itself).  Due to 
molecular sieving effect of the gel matrix therefore, gel electrophoresis discriminates 
between molecules by better reflecting differences in molecular size.  For molecules 115 
of  a  similar  shape  electrophoretic  mobility  through  a  gel  matrix  is  inversely 
proportional to the log of the molecular weight (Morris et al., 1971).  
 
DNA agarose gel electrophoresis:  The most common inert supports used in DNA 
electrophoresis  are  agarose  or  polyacrylamide.    Agarose,  (a  linear  polysaccharide 
extract) is used for separation of large molecular weight fragments.  Acrylamide gels 
are used for smaller fragments and can resolve differences in DNA to a single base 
pair.    The  optimal  size  of  DNA  fragment  that  can  be  resolved  using  agarose  is 
determined by the porosity of the gel.  The advantage of an agarose matrix is that the 
porosity of the gel can be controlled simply by changing the percentage of agarose 
used in the mixture.  DNA carries a net negative charge due to the negatively charged 
phosphate  groups  in  the  sugar phosphate  backbone.    Because  of  the  phosphate 
groups, the charge of a DNA fragment is almost directly proportional to its molecular 
weight  during  electrophoresis.    Resolution  of  DNA  fragments  therefore  occurs 
through  the  “molecular  sieving”  effect  of  the  gel  as  defined  by  pore  size.    With 
agarose electrophoresis, DNA fragments are resolved according to size. 
 
The migration of DNA through agarose gels is not linear but inversely proportional to 
the log of the molecular weight of the fragment.  For example the separation between 
a 100bp and a 1000bp fragment is greater than that between 1000bp and 2000bp 
fragment.  The migration of DNA through agarose is dependant not only on size, but 
is also affected by the conformation of the molecule.  In general, the more compact 
the structure the quicker it will migrate, as compact structures can negotiate the pores 
in  the  agarose  better  than  a  linear  molecule  of  equal  size.    However,  the 
electrophoretic  mobility  of  DNA  can  be  used  to  approximate  the  size of  a  DNA 116 
fragment,  if  the  migration  of  the  fragment  is  compared  to  that  of  control  DNA 
fragments of known size.   
 
2.3.6  Protocol: Agarose gel electrophoresis 
Agarose gels were made with RNAse free agarose (Merk, UK) using a Tris Borate 
EDTA buffer (TBE, pH 8). A 2% gel was made by dissolving 3 mg of agarose in 150 
ml of 0.5x TBE ( 5x TBE stock: 54 g Tris base, 27.5 g Boric acid, 20 ml 0.5M EDTA 
per litre) in an Erlenmeyer flask.  The mixture was heating in a microwave at 450W 
for 5 minutes to completely dissolve the agarose.  After cooling the mixture to ±60°C 
(under running tap water) 15  l of ethidium bromide (500 g/ml) was added to the gel 
mix.  Ethidium bromide is a potent mutagen that intercalates between the nucleotide 
bases of DNA and fluoresces following stimulation with ultraviolet light (280nm).  
The fluorescence of ethidium bromide therefore is used as a marker to both visualise 
DNA  in  the  gel,  and  following  capture  with  photographic  film,  to  determine  the 
expression ratio for semi quantitative analysis.  The gel mix was then poured into the 
gel dye and three sixteen sample gel combs were set.  The gel was left to cool and set 
for a minimum of 30 minutes.  The gel was transferred to the gel tank and submerged 
under 0.5x TBE running buffer.  10  l of the PCR product was mixed with 2  l of a 
6x sample loading buffer (30% glycerol, 0.25% bromophenol blue, 0.25% cyanin 
orange in 0.5x TBE) and the whole 12  l was loaded into the well.  The glycerol in 
the loading buffer increased the density of the DNA sample which prevents the DNA 
from “floating” out of the well during loading.  Bromophenol blue (BMB) and cyanin 
orange (CO) are tracking dyes that give an indication of the distance migrated by the 
DNA during electrophoresis.  The samples were loaded in sequence as determined by 
their location in the original vein (proximal to distal), for each individual primer set.  117 
The positive and negative controls as well as a 100bp DNA ladder (Sigma) were run 
simultaneously with each sample set.  The DNA fragments were resolved by applying 
an  electric  field  of  120mV,  60mA  for  35  minutes.    On  completion,  the  gel  was 
viewed  on  an  UltraViolet  transilluminator  (UV  Ltd,  UK).    The  product  size  was 
estimated from the migration of the 100bp ladder and compared to the theoretical size 
of the product.  Analysis of the controls (single band in positive, no band in negative) 
indicated a successful PCR.  Finally a photograph of the gel, with all primer sets was 
taken for scanning densitometry analysis using an exposure of ½ second with the F 
stop set to 5.8. 118 
2.4  ANALYSIS OF PROTEIN EXPRESSION 
2.4.1  Background 
Immunoassays are routinely used to measure protein in complex mixtures due to their 
specificity  and  high  sensitivity.    Here,  two  distinct  assays  have  been  utilised  to 
measure protein, namely enzyme linked immunoassay (ELISA) and polyacrylamide 
gel eletrophoresis (PAGE) with Western Blotting.  Analytic separation of protein is 
commonly investigated using PAGE under conditions that prevent aggregation and 
ensure complete dissociation of protein into individual polypeptide subunits (reducing 
SDS PAGE).  The separated proteins can then either be simply stained in the gel or 
transferred onto a solid support in such a manner that the pattern of the proteins 
electrophoretic separation is maintained.  The proteins on the support are probed with 
antibodies raised against a specific antigenic epitope, to detect the protein of interest 
(Western Blotting).  With ELISA the protein of interest is captured by an antibody 
that itself is immobilised to a solid support (96 well plate).  Contaminating cellular 
constituents  are  then  discarded  and  the  captured  ligand  is  detected  with  another 
antibody conjugated to a reporter system.  ELISA and SDS PAGE/western blotting 
are sensitive analytically techniques which can readily discriminate a specific protein 
from a complex protein mix, for the analysis of protein expression. 
 
2.4.2  Sandwich ELISA 
ELISA assays can be separated into four different varieties dependant on generally 
the manner with which the antigen of interest is presented.  i) Direct ELISA involves 
attachment of the antigen/crude lysate directly to the solid support.  The ligand is then 
detected directly with an enzyme labelled antibody.  Direct ELISA generally makes 
measurement  of  crude  samples  difficult  since  contaminating  proteins  compete  for 119 
plastic binding sites and they are not very sensitive.  ii) Similarly, Indirect ELISA 
also involves attachment of antigen to the solid phase followed by the detection of 
antigen with an antibody.  However the primary antibody itself is not labelled but is 
detected  by  a  second  antibody  (raised  against  the  first)  that  is  conjugated  to  an 
enzyme label.  This format increases the sensitivity of the assay compared to Direct 
ELISA and is generally used for the detection of specific antibodies in sera.  iii) A 
third  type  of  ELISA  is  the  Competition  Assay,  which  involves  the  simultaneous 
addition of ‘competing’ antibodies or proteins. The decrease in signal in samples 
where the second antibody or protein is added gives a highly specific result.  iv) The 
final assay and most popular is the Sandwich ELISA.  Sandwich ELISA involves the 
attachment of a capture antibody to a solid phase support. Samples containing known 
or unknown antigen are then added in a buffer that will minimize attachment to the 
solid phase (96 well plate) while facilitating formation of antibody antigen binding.  
The lysate is discarded and the captured antigens are detected with a second antibody 
(enzyme  labelled)  raised  against  the  same  antigen.    The  Sandwich  ELISA  is  the 
method  which  gives  the  most  specific  and  sensitive  results  for  cytokine  antigens 
found in very low concentrations. 
 
2.4.3  Protocol: Quantikine™ human sVEGFR1 ELISA  
Levels  of  plasma  s.flt 1  (soluble  VEGFR1)  were  determined  using  a  quantitative 
sandwich enzyme immunoassay kit (Quantikine™ human sVEGFR1; R&D Sytems, 
UK) according to the manufacturer’s instructions.  Briefly, 100  l of Assay Diluent 
was added to each well of the 96 well polystyrene microplate, provided pre coated 
with a mouse monoclonal antibody against VEGFR1.  100  l of either recombinant 
human s.flt 1standard (doubling dilutions 31.25 – 2000 pg/ml), or plasma sample was 120 
added to each well in duplicate.  The plates were covered with the adhesive strip 
provided and incubated on a horizontal orbital shaker at 500rpm for 2 hours at room 
temperature.  Following incubation, plates were aspirated and washed (x4) using 400 
 l wash buffer per well.  200  l of detection antibody (polyclonal antibody against 
VEGFR1 conjugated to horseradish peroxidase) were added to each well.  The plates 
were covered (as above) and incubated on the orbital shaker for 2 hours at room 
temperate.  Following washing (x 4) 200  l of Substrate Solution was added to each 
well.  The plates were wrapped in aluminium foil to protect from light and incubated 
for 30 minutes at room temperature.  50  l of Stop Solution was added to each well 
and the optical density (OD) at 450nm (correction at 540nm) was recorded (Dynex 
microplate  reader).    For  analysis,  the  mean  of  duplicate  experiments  (each  with 
duplicate  wells/sample)  was  calculated  and  the  quantity  of  s.flt 1  in  each  sample 
determined by extrapolation from the standard curve.  
 
2.4.4  Polyacrylamide gel electrophoresis 
In solution proteins are amphoteric and have a net charge at any pH other than their 
isoelectric point.  As discussed previously (chapter 2.3.5) electrophoresis describes 
the situation in which a charged molecule in solution is separated in an electric field 
at constant viscosity and applied voltage.  Electrophoretic mobility therefore can be 
used to resolve proteins in two fundamentally different ways, either by using their 
intrinsic charge differences (isoelectric focusing) or by imparting a large extrinsic 
charge  on  the  protein  (SDS PAGE).    Before  gel  systems  were  developed  protein 
electrophoresis was performed in the Tiselius free boundary system (Scopes 1993).  
Dissolved  protein  mixtures  were  placed  in  a  U  shaped  buffer  filled  channel  and 
exposed to an electrical field.  Resolution was poor however and any disturbance of 121 
the apparatus compromised the separation.  Gel matrices were developed to serve as 
solid  supports  during  electrophoresis  to  stabilise  the  separated  components  by 
minimising  movement  through  diffusion  and  facilitating  easy  handling  of  the 
separated  protein.    Although  starch  was  the  first  matrix  used  successfully  the 
development  of  the  synthetic  gel  medium  polyacrylamide,  improved  resolution 
dramatically  (Ornstein  et  al.,  1964).    Further  developments  which  improved  the 
resolving power of polyacrylamide gel electrophoresis included the use of a stacking 
gel with discontinuous buffer systems (Ornstein et al., 1964) and the incorporation of 
the detergent, sodium dodecyl sulphate (SDS) into the buffers (Laemmli 1970).  
 
In the Laemmli system, the strong anionic detergent SDS is used in combination with 
reducing agents and heat, to totally denature the protein before the sample is loaded 
on the gel.  SDS binds strongly to proteins reaching saturation at approximately 0.1% 
SDS (1 detergent molecule per 2 amino acid residues, Reynolds et al., 1970).  The 
hydrophobic  tail  of  SDS  interacts  with  the  hydrophobic  domain  of  the  denatured 
polypeptide which confers a strong extrinsic negative charge to the polypeptide.  As 
SDS  binds  protein  in  the  constant  ratio  (1.4g  detergent  per  gram  of  polypeptide) 
polypeptides of different size will bind an amount of SDS that is in proportion to their 
size.    The  amount  of  SDS  bound  by  the  polypeptide  is  therefore,  almost  always 
directly proportional to the molecular weight of the polypeptide irrespective of its 
specific amino acid sequence.  Consequently the charge to mass ratio (Q/r) for all 
polypeptides in solution with saturating SDS is virtually identical and the separation 
of  the  SDS polypeptide  complexes  occurs  according  to  size  as  a  result  of  the 
molecular sieving capability of the gel.   122 
In  most  cases,  SDS PAGE  is  performed  using  the  discontinuous  buffer  system 
described  by  Ornstein  and  Davies.    Here  the  sample  and  running  buffer  have  a 
different pH and ionic strength to the buffer used to cast the gel.  The sample and 
stacking gel contain Tris HCl at pH 6.8 the resolving gel contains Tris HCl at pH 8.8, 
while the running buffer is comprised of Tris Glycine at pH 8.3.  All the components 
contain  SDS  at  a  minimum  0.1%  (Laemmli  1970).    During  electrophoresis,  the 
chloride ions in the sample and stacking gel buffer form the leading edge of the 
moving boundary, while the slower moving glycine forms the trailing edge.  Between 
the leading and trailing edge is a zone of low conductivity and steep voltage gradient.  
This sweeps the SDS polypeptide complexes through a stacking gel of high porosity 
and deposits the complexes in a thin zone on the surface of the resolving gel.  The 
higher pH of the resolving gel initiates the ionisation of glycine which increases the 
rate  of  migration  of  the  anion.    The  glycine  anions  quickly  migrate  through  the 
stacked polypeptides catching up with and migrating immediately behind the chloride 
ions in the resolving gel.  Expelled from the moving boundary, the SDS polypeptide 
complexes migrate through the resolving gel in a zone of uniform voltage and pH and 
are separated according to size by the molecular sieving effect of the gel matrix.   
 
The molecular sieving properties (effective range of separation) of a SDS PAGE gel 
are determined by the size of the pores in the gel.  Polyacrylamide gels are composed 
of chains of polymerised acrylamide crosslinked with N,N’ methylenebisacrylamide 
to  form  a  gel  of  uniform  pore  size.    The  pore  size  is  dependant  on  both  the 
concentration of acrylamide used and the degree of  crosslinking in the gel.  The 
porosity of the gel decreases as the bisacrylamide:acrylamide ratio increases reaching 
a  minimum  at  a  molar  ratio  of  approximately  1:20.    For  consistency,  a  standard 123 
bisacrylamide:acrylamide molar ratio of 1:29 is commonly used in SDS PAGE and 
pore size is changed simply by varying the concentration of acrylamide.   
 
Today almost all analytical electrophoresis of protein is undertaken with SDS PAGE.  
The advantages of SDS PAGE are the ease of operation, the method is relatively 
quick, has a high level of sensitivity and yields sharp resolution of complex protein 
mixtures  into  their  individual  components.  SDS PAGE  enjoys  wide  spread 
application in protein isolation and characterisation protocols including the separation 
of protein mixtures and measurement of the relative abundance of a protein in a 
sample, determination of approximate molecular weight of a polypeptide and analysis 
of purity of protein isolation. 
 
Here  we  have  used  the  NuPAGE
®  Novex  Bis Tris  Electrophoresis  System  from 
Invitrogen.    NuPAGE
®  Bis Tris  is  a  discontinuous  SDS PAGE,  pre cast 
polyacrylamide mini gel system which unlike the Laemmli system is maintained at a 
neutral pH (pH 7.0).  Similar to Ornstein and Davies system, chloride supplied by the 
gel buffer (Bis Tris
+ and Cl
 , pH 6.4) is the leading ion.  MOPS SDS running buffer, 
however has a trailing ion in neutral pH (running buffer Tris
+, MOPS
  and dodecyl 
sulphate
 , pH 7.3 7.7).  The combination of a lower gel buffer and running buffer pH 
results in a significantly lower operating pH during electrophoresis contributing to 
increased stability of both the polyacrylamide gel matrix and protein sample (reduced 
deamination and alkylation reactions) which results in better protein band resolution. 124 
2.4.5  Protocol:  Denaturing NuPAGE® Bis Tris electrophoresis 
For each sample, 20  g total protein was added to NuPAGE
® LDS sample buffer and 
NuPAGE reducing agent (500mM dithiothreitol, DTT)  as indicated in (Table 2.6).  
Samples were heated at 70°C for 10 minutes and transferred to and stored on ice.  
Prestained and biotinylated broad range protein markers (NEB Ltd, UK) and control 
protein  (ECV304,  microvascular  endothelial  cell  lysate)  were  similarly  prepared.  
One litre of NuPAGE
® MOPS SDS running buffer (1x) was prepared from stock 
(20x) and mixed thoroughly (Appendix 4).  A NuPAGE
® Novex gradient gel (4 12% 
acrylamide) was removed from its pouch, rinsed with distilled water (x3) and the 
well comb carefully removed.  The wells were rinsed with 200  l of running buffer 
(x3) and after removal of the tape from the bottom of the cassette, the gel was placed 
in the Mini Cell module (wells facing inwards toward the Buffer Core).  Finally the 
gel cassette was locked in place with the Gel Tension Wedge.  The upper buffer 
chamber (cathode) was filled with 200 ml MOPS SDS running buffer containing 500 
 l NuPAGE
® Antioxidant (proprietary reagent) and checked for leaks.  NuPAGE
® 
Antioxidant  co migrates  with  protein  during  electrophoresis  which  maintains  the 
proteins in a reduced state and protecting sensitive amino acids such as methionine 
and tryptophan from oxidation (NuPAGE
® Technical Guide).  After the loading of  
protein samples, marker and control the lower buffer chamber (anode) was filled with 
600 ml MOPS SDS running buffer and the proteins were separated  at a constant 
voltage of 200 volts (current: start 100 115mA, end 60 70mA) for 50 minutes.  On 
completion the gel cassette was removed from the Mini Cell module, cracked opened 
with a gel knife and the NuPAGE
® gel prepared for western blot transfer. 125 
2.4.6  Western blot 
Western blotting is a sensitive technique that exploits the specific recognition of an 
antibody for its antigen.  In western blotting, protein is transferred from acrylamide 
gel and immobilised on a membrane support in such a manner that the pattern of the 
protein’s electrophoretic separation is maintained.  The membrane is probed with 
antibodies raised against the specific protein of interest and bound antibody/antigen 
complex is detected with labelled secondary antibody following the addition of a 
detection  substrate.    Protein  was  transferred  from  NuPAGE
®  Novex  gel  with  the 
XCell II™ Blot Module (Invitrogen Ltd, UK) and protein antibody complexes were 
detected  by  chemiluminesence  with  Phototype
®   HRP  western  blotting  detection 
system (New England Biolabs Ltd, UK).  The Phototype
®  HRP western blotting 
detection system is an extremely sensitive (10
 12g) non radioactive method to detect 
immobilised antigens using antibodies labelled with horseradish peroxidase (HRP) 
and the chemiluminescent substrate Luminol
®.  In the presence of hydrogen peroxide 
HRP converts Luminal
® to an excited intermediate dianion. The dianion emits light 
on return to its ground state which is captured on X ray film for analysis. 
 
2.4.7  Protocol: XCell II™ Blot Module protein transfer 
One litre of NuPAGE
® Transfer Buffer (1x) was prepared from stock (20x) mixed 
thoroughly  and  NuPAGE
®  Antioxidant  and  methanol  was  added  (Table  2.7).  
[Methanol  increases  the  hydrophobic  interaction  between  protein  and  membrane 
required for binding.  The volume of methanol added therefore is determined by the 
number of gels transferred (10% per gel)].  Gloves were worn for all manipulations of 
polyvinylidene fluoride (PDVF) membranes.  A pre cut NuPAGE
® PDVF membrane 
was  wet  with  methanol  for  30  seconds,  rinsed  in  water  for  1  minute  (x3)  and 126 
incubated together with blotting pads and filter paper for at least 20 minutes before 
use.  The blot module was assembled by first placing two blotting pads on the bottom 
(cathode) as shown.  The NuPAGE
® gel removed from the cassette was carefully 
overlaid with a piece of saturated  filter paper,  all air bubbles were  excluded and 
rapidly inverted to capture the gel on the filter paper.  The filter paper NuPAGE
® gel 
was  then  placed  on  top  of  the  blotting  pads  (filter  paper  down).    The  pre cut 
membrane was carefully aligned on top of the gel followed by the last piece of filter 
paper and two blotting pads ensuring that no air bubbles were trapped between the 
layers.  The assembly was checked to ensure there was no contact between the paper 
layers, the top (anode) was attached and the XCell II™ Blot Module placed in the 
Mini Cell unit.  The blot module was filled with NuPAGE
® Transfer Buffer just 
covering the gel membrane assembly, while the outer chamber was filled with 650 ml 
cold water.  Protein was transferred at a constant voltage of 30 volts (current: start 




Reagent  Volume ( l) 
sample  x 
NuPAGE
® LDS sample buffer (4x)  2.5 
NuPage
® reducing agent (10x)  1 
deionised water  to 6.5 
Total volume  10 
 
 
Table 2.6  Sample preparation for NuPAGE




Reagent  1 gel (ml)  2 gels (ml) 
NuPAGE
® Transfer Buffer (20x)  50  50 
NuPAGE
® Antioxidant  1  1 
Methanol  100  200 
water  849  749 
Total volume  1000  1000 
 
 
Table 2.7  Preparation of NuPAGE
® Transfer Buffer (Appendix 4) 
 128 
2.4.8  Protocol: Phototype
® HRP chemiluminescence detection 
The electroblotter was dismantled, the membrane washed with Tris buffered saline 
(TBS, 20 mM Tris base pH 7.4, 137 mM NaCl) and transferred to a rocking platform.  
Blots were first stained for total protein with Ponceau S (Sigma Aldrich Ltd, UK) to 
confirm  equal  protein  loading  before  proceeding  with  antibody  detection.  Non 
specific binding sites on the membrane were blocked with Block buffer (TBS, 10% 
Marvel,  0.1%  Tween  20)  for  one  hour  at  room  temperature.    Block  buffer  was 
discarded and the membrane washed twice with wash buffer (TBS, 01% Tween 20).  
The membrane was incubated with a rabbit anti human β catenin polyclonal antibody 
diluted as per the manufacturers recommendation (1:2000, # 9562, Cell signalling 
Technology™,  UK)  in  diluent  (TBS,  5%  Marvel,  0.1%  Tween  20)  with  gentle 
agitation  overnight  at  4°C.    Primary  antibody  diluent  was  discarded  and  the 
membrane washed three times with wash buffer.  Bound antibody was detected with a 
goat  anti rabbit  antibody  conjugated  to  HRP  (1:5000  fold  dilution)  with  gentle 
agitation for one hour at room temperature.  The detection antibody was discarded, 
the membrane washed five times with wash buffer and transferred to Sarafan film on 
the bench for processing. The LumiGLO chemiluminesence substrate and hydrogen 
peroxide (both 20x) were diluted in 10ml and incubated with the membrane for 1 
minute in the darkroom.  Excess solution was  discarded, the membrane enclosed 
completely  in  Sarafan  film  and  exposed  to  Hyperfilm
TM  ECL  (Amersham 
Biosciences  Ltd) for 5  minutes.  The film was developed manually  with Kodack 
BioMax reagents (Sigma Aldrich UK).  The integrated optical density (IOD) of each 
band was measured by scanning densitometry (LabWorks Imaging and Acquisition 
software,  UVP,  Cambridge  UK),  and  normalised  for  protein  loading  against  IOD 
values from the Ponceau S membrane stain. 129 
2.5  SCANNING DENSITOMETRY  
2.5.1  Background 
Scanning densitometry is a software package used for the quantitative measurement 
of the signal intensity from digitalised images.  The shade of each pixel in the area of 
interest  (AOI)  on  the  gel  image  is  characterised  according  to  a  greyscale  range 
comprising  256  different  shades.    Discrimination  of  the  differences  between  the 
intensity of different pixel shade facilitates the quantification of signal intensity of 
each pixel used to construct the band in the AOI.  This data is converted to a lane 
profile  graph  which  displays  either  the  optical  density  (X ray  and  gel  image)  or 
intensity (fluorescent light image) for each band under investigation.  The band is 
represented by a peak in the profile graph which represents the molecular weight 
value for that particular band, relative to the molecular weight marker used.  The area 
under the peak is used to calculate the volume (amount) of signal in each band and is 
termed the Integrated Optical Density (IOD).  With IOD the relative abundance of a 
PCR product (agarose gel) or protein (Western Blot) can therefore be determined 
from the band intensity due to the captured fluorescence or chemiluminescence in the 
original image  
 
2.5.2  Analysis of DNA agarose gels  
For  reproducibility,  all  agarose  gels  were  photographed  with  a  Kodak  Polaroid 
camera using the default settings (exposure1/2 second, F stop 5.6 8).  The photograph 
was digitalised with an Epson GT 9500 scanner at a pixel depth of 800 with a 150% 
enlargement.    All  digital  gel  images  were  analysed  at  a  single  sitting  with 
Labworks™  Image  Aquisition  and  Analysis  software  (Ultra Violet  Products  Ltd).  
Analysis of the image was performed with the 1D Gels tool palette using the same 130 
parameters for all gels analysed.  The gel was imported into Labworks™ and the 1D 
Gel tool palette was activated.  Lanes of 200 pixels wide were assigned to each lane 
investigated and the bands (AOI) marked automatically.  Analysis of the lane profile 
graph was examined for each lane and spurious banding was deleted.  No background 
correction was used and the default was the greyscale range as determined from the 
image under investigation.  The relative abundance of each DNA band in the image, 
as  determined  from  band  fluorescence  was  used  to  calculate  the  IOD.    Semi 
quantitative analysis was performed by comparing the IOD of the band of interest to 
the IOD of the standard, here GAP3DH (Figure 2.5). 
 
2.5.3  Analysis of western blots 
The  developed  film  of  the  western  blot  was  digitalised  with  an  Epson  GT 9500 
scanner at a pixel depth of 800 with a 150% enlargement.  All digital western blot 
images  were  analysed  at  a  single  sitting  with  Labworks™  Image  Aquisition  and 
Analysis software as described.   The integrated optical density (IOD) of each band 
was  measured  reported  normalised  for  protein  loading  against  IOD  values  from 
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GAP3DH (100ng cDNA)
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C. Integrated optical density   
A.  agarose gels     B.  lane profile graph  
Lanes: 20 30 35 40 positive
βcat 7 (200ng) 3.40E+04 1.20E+06 3.00E+06 3.80E+06 2.49E+06
Sum 3.40E+04 1.20E+06 3.16E+06 3.80E+06 2.49E+06
In Lane 1.16E+06 2.74E+06 6.06E+06 7.23E+06 7.74E+06
Lanes: 20 30 35 40 positive
βcat 7 (100ng) 4.E+04 2.E+05 7.E+05 2.E+06 4.E+05
Sum 4.E+04 2.E+05 7.E+05 2.E+06 4.E+05
In Lane 2.E+06 2.E+06 2.E+06 3.E+06 2.E+06
Lanes: 20 30 35 40 positive
GAP406  1.31E+06 4.00E+06 5.20E+06 5.97E+06 3.44E+06
Sum 1.31E+06 4.32E+06 4.77E+06 5.97E+06 3.44E+06
In Lane 2.74E+06 6.57E+06 8.19E+06 8.50E+06 6.14E+06
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Figure 2.5  Scanning densitometry analysis of PCR products. 
Here the kinetics of the PCR reaction for the primer sets (BCAT 7 and GAP406) were 
investigated to determine optimal cycle number. All reactions contained 2 mM MgCl2 
but had differing amounts of cDNA template (200ng or 100ng for BCAT 7 and 100ng 
for  GAP406).    PCR  products,  separated  by  DNA  agarose  gel  electrophoresis  are 
capture  on  film  and  digitalised  (A).    For  each  product  band,  ethidium  bromide 
fluorescence is captured as a lane profile by scanning densitometry (B), and recorded 
as  an  Intergrated  Optical  Density  (IOD)  (C).  Plot  of  IOD  versus  cycle  number 
indicates the linearity of the reaction per starting quantity cDNA, for each primer pair 
investigated (D).   132 
C. integrated optical density   
A.  membranes     B.  lane profile graph  
D. plot of ratio   
western blot: β catenin
Ponceau S: total protein
western blot
Lanes: 1 2 3 4 5 6 7 8 9
Bands (IOD) (IOD) (IOD) (IOD) (IOD) (IOD) (IOD) (IOD) (IOD)
1 605 99 228 183 561 20 72 141 312
Sum 605 99 228 183 561 20 72 141 312
In Lane 829 265 428 391 775 192 219 293 446
Ponceau
Lanes: 1 2 3 4 5 6 7 8 9
Bands (IOD) (IOD) (IOD) (IOD) (IOD) (IOD) (IOD) (IOD)
1 2.37 5.31 6.40 3.86 4.39 1.41 1.16 2.98
Sum 2.37 5.31 6.40 3.86 4.39 1.41 1.16 2.98
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Figure 2.6  Scanning densitometry analysis of western blot.   
Total protein, separated by SDS PAGE was transferred to membranes, stained with 
Ponceau  S  and  probed  with  anti  β catenin  antibody  (A).    Each  product  band  is 
captured  as  a  lane  profile  by  scanning  densitometry  (B),  and  recorded  as  an 
Intergrated Optical Density (IOD) (C).  Values reported are IOD ratio of β catenin 
divided by total protein Ponceau S (D).   133 
2.6  STATISTICS 
The age of individuals within each group are presented as a median value with range 
in parenthesis, and significance between groups evaluated by Mann Whitney U test.  
The  distribution  of  experiment  results  obtained  for  gene  transcription  and  protein 
expression were tested for normality with Kolmogorov Smirnov test and descriptive 
statistics examining skewness and kurtosis.  Comparisons between the experimental 
groups  were  investigated  with  Students  T test  (paired  or  unpaired),  analysis  of 
variance (ANOVA) or Kruskal Wallis analysis of variance (ANOVA) and presented 
as mean (± s.e.m.) or median (with interquartile range) as appropriate.  Comparisons 
of differences in gene transcription in vein sections per position, from proximal to 
distal  were  made  by  one way  ANOVA  with  Bonferroni’s  correction  to  identify 
differences  between  individual  group  means.  Also,  to  examine  for  possible 
correlations between position and levels of gene transcription or protein expression, 
results were analysed by Kendall’s bivariate correlation.  All tests (where appropriate) 
were two tailed; statistical significance was accepted  at p<0.05;  analyses  yielding 
non statistically significant results are cited as p>0.1; actual p values are reported to 
three decimal places to p<0.001.  All statistical analysis reported in this study was 
investigated with the software package SPSS version 11.5 (IBM).   
 
2.6.1  Transcription of VEGF A and its receptors 
Ages  of  individuals,  per  group,  are  presented  as  median  values  with  range  in 
parenthesis, and comparisons between groups were made by Mann & Whitney U test, 
two tailed.  Experimentally obtained results for levels of gene transcription were of a 
similar  and  normal shaped  distribution,  as  determined  by  a  Kolmogorov Smirnov 
one sample test of normality, and descriptive exploration and analysis of Skewness, 134 
and  are  presented  as  mean  (s.e.m.)  values.    Comparisons  of  the  levels  of  gene 
transcription between experimental groups were made by one way or Kruskal Wallis 
analysis of variance (ANOVA).  Comparisons of differences in gene transcription in 
vein sections per position, from proximal to distal (see Figure 2.1), were made by 
one way  ANOVA  with  Bonferroni’s  correction  to  identify  differences  between 
individual group means.  Also, to examine for possible correlations between position 
(proximal  –  distal;  sections  1  –  5)  and  levels  of  gene  transcription,  results  were 
analysed by Kendall’s bivariate correlation analysis.  All tests (where appropriate) 
were two tailed; p<0.05 was considered to be statistically significant; actual p values 
are reported to three decimal places to p<0.001. 
 
2.6.2  Release of s.flt 1  
The overall ages of individuals within each subject group are presented as a median, 
with range in parenthesis and comparisons of experimental groups made by Mann & 
Whitney ‘U’ test.  Experimentally obtained results for the levels of plasma s.flt 1 
were of a uniform, but not normal, distribution as determined by descriptive statistics 
examining skewness and kurtosis, and have been presented as (median values; range).  
Graphical presentation of results is by box plot (median, inter quartile  range, and 
range).  Comparison of the levels of plasma s.flt 1 between controls and subjects, and 
changes in plasma s.flt 1 before and after cuff application (per group) were analysed 
by Kruskal Wallis analysis of variance.  Percentage changes in plasma s.flt 1 after 
cuff application were determined by ‘(after cuff – before cuff) / (before cuff) x 100’ 
and are presented as a mean (± s.e.m.) percentage change.  Statistical significance 
was accepted at p<0.05 and reported significant to p<0.001 level, while non statistical 
significance was reported as p>0.1. 135 
2.6.3  β catenin, c myc and cyclin D1 transcription and expression 
Age of individuals are presented as a median value with range in parenthesis, and 
significance between groups evaluated by Mann & Whitney ‘U’ test.  Experimentally 
obtained  results  for  β catenin,  c myc  and  cyclin  D1  transcription  and  β catenin 
protein  expression  are  presented  as  median  values  with  interquartile  range  in 
parenthesis following analysis by Kolmogorov Smirnov one sample test of normality 
and  analysis  of  Skewness.    Comparisons  between  levels  of  β catenin,  c myc  and 
cyclin D1 transcription and β catenin protein expression between groups were made 
by Kruskal Wallis analysis of variance.  Possible correlations between factors were 
examined using Kendall’s bivariate correlation analysis.  All tests (where appropriate) 
were two tailed.  Statistical significance was accepted at p<0.05, with actual p values 



























3.1  TRANSCRIPTION OF VEGF A AND ITS RECEPTORS 
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3.1.1   Background 
The homeostatic response of the vein wall to environmental stimuli like a change of 
luminal  pressure,  disturbed  blood  flow,  venous  stasis  and  hypoxia  should  be  the 
production and release of agents that mediate vessel wall reactivity (Luscher 1991; 
Micheils  et  al.,  1997;  Browse  et  al.,  1999).    In  normal  vein,  venous  stasis  and 
disturbances in blood flow induce a rapid change in the level of detectable VEGF A 
(Hollingsworth et al., 2001A), the generation of which is regulated at a number of 
levels to modulate VEGF A protein availability and activity (see chapter 1.2.2).  As 
the control of transcription of VEGF A (and its receptors) involved in maintaining 
vascular reactivity might become altered, either as a causative mechanism, or simply 
as a result of the pathological process itself, examination of such genes may help to 
elucidate the mechanism(s) underlying the development of VVs.      
 
3.1.2  Aim 
To examine the pattern of transcription of genes for VEGF A (the soluble isoforms 
VEGF A121 and VEGF A165) and its receptors VEGFR1 (and s.flt 1) and VEGFR2 in 
the  wall  of  the  GSV,  and  in  relation  to  the  underlying  venous  incompetence  in 
primary VVs. 
 
3.1.3  Methods 
This study was conducted with approval of the Joint UCL/UCLH Committees on the 
Ethics of Human Research as described in chapter 2.1.1.  With informed consent, 
samples of varicose GSV were obtained from patients undergoing sapheno femoral 
ligation  and  stripping  of  the  long  saphenous  for  the  treatment  of  primary  VVs.  
Control GSV was obtained from patients undergoing cardiac bypass, and who had no 139 
clinical  evident  symptoms  of  varicose  disease  in  either  limb  (see  chapter  2.1.2).  
Samples of varicose or control GSV collected on ice at operation were processed as 
described  in  chapter  2.1.2.    Total  RNA  was  extracted  with  TRI  Reagent™  (see 
chapter 2.2.2) and then reverse transcribed to cDNA as described in chapter 2.3.1.   
 
The gene activity of the soluble VEGF isoforms (VEGF A121 and VEGF A165) and the 
VEGF receptors (VEGFR1, s.flt 1 and VEGFR2) were examined by semi quantitative 
PCR  (see  chapter  2.3.4).    Gene  products  were  fractionated  by  agarose  gel 
electrophoresis (see chapter 2.3.6 and representative gel pictures Figure 3.1 3) and 
analysed by scanning densitometry as described in chapter 2.5.2.  The author thanks 
Mr Cooper for the initial round of RT PCR investigations used in this study. 
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Figure 3.1  RT PCR gel analysis of VEGF A and its receptors in control vein. 
For each individual segment analysed, the competency of the SFJ and vessel wall was 
determined from duplex scan and classified as being competent with no reflux (c) or 
incompetent with reflux evident (i) (A).  Gene transcription was examined by semi 
quantitative RT PCR.  Products were visualised by agarose electrophoresis and the 
IOD of each band measured by scanning densitometry.  Levels of gene transcription 
were reported as IOD ratio of gene PCR product normalised against control house 
keeping gene GAP 3 (GAPDH) (B).  141 
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Figure 3.2  RT PCR gel analysis of VVs segments with a competent SFJ.  
For each individual segment analysed, the competency of the SFJ and vessel wall was 
determined from duplex scan and classified as being competent with no reflux (c) or 
incompetent with reflux evident (i) (A).  Gene transcription was examined by semi 
quantitative RT PCR.  Products were visualised by agarose electrophoresis and the 
IOD of each band measured by scanning densitometry.  Levels of gene transcription 
were reported as IOD ratio of gene PCR product normalised against control house 
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Figure 3.3  RT PCR gel analysis in VVs with an incompetent SFJ.  
For each individual segment analysed, the competency of the SFJ and vessel wall was 
determined from duplex scan and classified as being competent with no reflux (c) or 
incompetent with reflux evident (i) (A).  Gene transcription was examined by semi 
quantitative RT PCR.  Products were visualised by agarose electrophoresis and the 
IOD of each band measured by scanning densitometry.  Levels of gene transcription 
were reported as IOD ratio of gene PCR product normalised against control house 
keeping gene GAP 3 (GAPDH) (B). 143 
 
3.1.4  Results 
Patient demographics:  GSV was obtained from 23 individuals resulting in a total of 
97 samples overall available for gene analysis (Table 3.1).  Of the 23 individuals 
examined, 18 had primary VVs as confirmed by venous duplex scan resulting in a 
total  of  83  samples  available  for  gene  analysis.    Of  these,  7  individuals  had  a 
functionally intact and competent SFJ (29 samples; 4 male, 3 female) while for the 
remaining 11, the SFJ was incompetent (54 samples; 3 male, 8 female).  Control GSV 
was obtained from 5 individuals (3 male, 2 female) resulting in a total of 14 control 
samples available for analysis.   
 
Overall, patients with VVs were younger than those from whom control veins were 
taken  (p<0.030,  Mann Whitney  U,  Table  3.1).  [This  age  difference  was  mainly 
accountable by the larger subgroup of female individuals with an incompetent SFJ, 
whose median age was less than those with VVs with a competent SFJ].   Individuals 
with an intact and functional SFJ had a greater, although not statistically significant 
median age than those individuals who presented with an incompetent SFJ with blood 
reflux. 
 
RNA of suitable quality was isolated from all vein sections analysed as illustrated in 
representative gels for individuals from control (Figure 3.1), competent SFJ (Figure 







Description  Varicose  Control 
  competent 
SFJ 
incompetent 
SFJ  total   
         
Individuals, n =  7  11  18  5 
median age (range)           62 (28 69)    43 (27 58)         48 (27 69)
*  63 (50 72) 
male, n =  4  3  7          3 
female, n=  3  8  11          2 
         
mRNA samples, n =  29  54  83  14 
male, n =  15  15  30  7 




Table 3.1  Patient demographics and samples for analysis of gene transcription.  
Vein samples were obtained from 23 individuals. 18 patients had primary VVs (7 
male, 11 female) resulting in 83 samples for analysis. Control GSV was obtained 
from  5  individuals  (3  male,  2  female)  resulting  in  a  total  of  14  control  samples 
available  for  analysis.  Overall,  patients  with  VVs  were  younger  than  those  from 
whom control veins were taken (p<0.030, Mann Whitney U).  SFJ, sapheno femoral 
junction, *p<0.03 versus control vein, Mann & Whitney U 
 145 
Varicose and control veins overall:  For VVs overall, the transcription of all genes 
except s.flt 1 were elevated in sections of VVs compared to those from control veins 
(Figure  3.4);  VEGF A121,  VEGF A165  and  VEGFR2  (all,  p<0.001),  VEGFR1 
(p<0.002); s.flt 1 (p=0.743); all Kruskal Wallis. 
 
Competence  of  the  SFJ:    Results  from  VVs  were  sub divided  and  analysed 
specifically in conjunction with competence at the SFJ.  Individuals in whom the SFJ 
was intact and functional (as determined from duplex scan) had a greater, but not 
statistically significant, median age than those in whom the SFJ was incompetent and 
showing reflux (Table 3.1).  In VVs with a functional SFJ, transcription of VEGF 
A165, VEGFR2, VEGFR1 and s.flt 1 was similar to that of control veins (Figure 3.5).  
However, transcription of the VEGF A121 isoform was elevated (p<0.02; see Figure 
3.5), although not to the levels seen when the SFJ was incompetent.  
 
In contrast, when the SFJ was incompetent the levels of transcription of VEGF A121, 
VEGF A165, VEGFR2, and VEGFR1 were elevated compared to either those where 
the SFJ was functional (all p<0.001), or to control veins (all p<0.001, see Figure 3.5).   
 
Competence of the vein wall:  To examine levels of gene transcription in conjunction 
with vein competence, results were now grouped and analysed as follows.  For each 
individual  VVs  sample  analysed,  the  original  position  of  the  segment  was  cross 
referenced  to  the  duplex  scan,  and  the  vessel  wall  was  classified  as  being  (i) 
competent  with  no  reflux,  or  (ii)  incompetent  with  evident  reflux.    Pre operative 
duplex scans on control individuals used in this study indicated that the vessel wall of 
all control vein samples used were indeed competent.   146 
 
In  VVs,  competent  sections  had  elevated  levels  of  transcription  of  VEGF A121 
(p<0.02), VEGF A165 (p<0.006), and VEGFR2 (p<0.007) when compared to control 
vein  (Figure  3.6).    VEGFR1  transcription  was  also  elevated,  although  not 
significantly  compared  to  control  and  as  previously  there  was  no  change  in  the 
transcription of s.flt 1.    In incompetent sections the levels of transcription for all 
genes except s.flt 1 were elevated compared to sections from control veins (VEGF 
A121, VEGF A165, VEGFR2 and VEGFR1, all p<0.001, Figure 3.6).   
 
Interestingly transcription of VEGF A165 and the receptors VEGFR2, VEGFR1 and 
s.flt 1  were  similarly  elevated  in  competent  and  incompetent  VVs  sections.  
Furthermore, there was a trend for greater transcription of VEGF A121 in incompetent 




















































































Figure 3.4  Transcription of VEGF A and its receptors in VVs overall. 
Control  (open  bars)  and  VVs  (grey  bars).    IOD  gene:GAP 3  is  the  ratio  of  the 
integrated optical density (IOD) of the specific gene product to its’ corresponding 
product for GAP 3 as determined by scanning densitometry.  Bars represent means 
values, and error bars are s.e.m. (n=83 sections analysed from VVs; n=14 sections 
analysed from control vein sections; all with two PCR analyses per section for each 
gene examined).  *p<0.001 and 






















































































Figure 3.5  Transcription of VEGF A and its receptors by SFJ status. 
 Control veins (open bars), VVs from individuals with a competent and functional 
SFJ (dark grey bars), or incompetent and dysfunctional SFJ (light grey bars).  IOD 
gene:GAP 3  is  the  ratio  of  the  integrated  optical  density  (IOD),  determined  by 
scanning densitometry, of the specific gene product to its’ corresponding product for 
GAP 3.  Bars represent means values, and error bars are s.e.m. (n=14 sections from 
control veins; n=29 sections analysed from VVs with a competent SFJ; n=54 sections 
analysed from VVs with an incompetent SFJ; all with two PCR analyses per section 
for each gene examined).  *p<0.001 versus competent SFJ, and versus control vein; 










































































Figure 3.6  Transcription of VEGF A and its receptors by segmental status. 
Control veins (open bars) and VVs where the section of vein was competent and 
functional (dark grey bars), or incompetent and showing reflux (light grey bars).  IOD 
gene:GAP 3 is the ratio of the integrated optical density (IOD) of the specific gene 
product  to  its’  corresponding  product  for  GAP 3,  as  determined  by  scanning 
densitometry.  Bars represent means values, and error bars are s.e.m. (n=14 sections 
from control veins; n=16 competent sections from VVs; n=67 incompetent sections 
from  VVs;  all  with  two  PCR  analyses  per  section  for  each  gene  examined).  
*p<0.001, 
†p<0.02, 
‡p<0.006  and 
§p<0.007  versus  sections  from  control  vein;  all 
Kruskal Wallis test. 150 
Position and SFJ or segmental competence:  Gene transcription was now examined 
according to position from where derived; as proximal, proximal mid, mid, mid distal 
and distal from the SFJ (see chapter 2.1.2. and Figure 2.1).  Overall, including all 
sections  of  vein  analysed,  there  was  little  or  no  difference  in  the  levels  of 
transcription of VEGF A121, VEGF A165, VEGFR2 or VEGFR1 dependent on position.  
However,  there  was  a  direct  correlation  for  increased  transcription  of  s.flt 1  with 
descending  position  from  the  SFJ  for  VVs  overall  (p<0.04,  Kendall’s  bivariate 
correlation; Figure 3.7).   
 
To investigate further, results were subdivided by i) competence at the SFJ, and ii). 
segmental competence.  With descending position, the competency of the SFJ had no 
effect on levels of transcription of VEGF A121 (Figure 3.8) VEGF A165 (Figure 3.9), 
VEGFR2  (Figure  3.10)  or  VEGFR1  (Figure  3.11)  and  no  correlation  was  seen.  
However, when the SFJ was incompetent and dysfunctional, there was a correlation 
between  descending  position  from  the  SFJ  and  increased  transcription  of  s.flt 1 
(p<0.05; Figure 3.12). 
 
When this analysis was repeated but this time examining competence of the segment, 
a  similar  pattern  was  observed.    For  competent  segments,  gene  transcription  was 
unaffected by position and no correlation was seen.  When however, the segment was 
incompetent  and  showing  reflux,  there  was  again  increased  s.flt 1  transcription 
correlated to descending position from the SFJ (p<0.03; Figure 3.13).  In addition, 
there was a similar correlation in these segments of increasing transcription of VEGF 







































































































Figure 3.7  Transcription of s.flt 1 in VVs overall by segmental position.   
s.flt 1  transcription  increased  with  descending  position  from  the  SFJ,  p<0.04 
(Kendall’s  bivariate  correlation).    IOD  Gene:GAP 3  is  the  ratio  of  the  integrated 
optical density (IOD), determined by scanning densitometry, of s.flt 1 gene product to 
its’ corresponding product for GAP 3.  Bars represent means values, and error bars 
are s.e.m.  Position from the SFJ, (Px) proximal, (PM) proximal mid, (Mid) mid, 






























































































































































































































Figure 3.8  Transcription of VEGF A121 in sections of VVs by position.  
Sections of VVs descending below a competent (A) or incompetent (B) SFJ.  IOD 
gene:GAP 3  is  the  ratio  of  the  integrated  optical  density  (IOD),  determined  by 
scanning densitometry, of VEGF A121 gene product to its’ corresponding product for 
GAP 3.  Bars represent means values, and error bars are s.e.m.  Position from the 
SFJ, (Px) proximal, (PM) proximal mid, (Mid) mid, (MD) mid distal and (Dis) distal; 













































































































































































Figure 3.9  Transcription of VEGF A165 in sections of VVs by position. 
Sections of VVs descending below a competent (A) or incompetent (B) SFJ.  IOD 
gene:GAP 3  is  the  ratio  of  the  integrated  optical  density  (IOD),  determined  by 
scanning densitometry, of VEGF A165 gene product to its’ corresponding product for 
GAP 3.  Bars represent means values, and error bars are s.e.m.  Position from the 
SFJ, (Px) proximal, (PM) proximal mid, (Mid) mid, (MD) mid distal and (Dis) distal; 

































































































































































































Figure 3.10  Transcription of VEGFR2 in sections of VVs by position. 
Sections of VVs descending below a competent (A) or incompetent (B) SFJ.  IOD 
gene:GAP 3  is  the  ratio  of  the  integrated  optical  density  (IOD),  determined  by 
scanning densitometry, of VEGFR2 gene product to its’ corresponding product for 
GAP 3.  Bars represent means values, and error bars are s.e.m.  Position from the 
SFJ, (Px) proximal, (PM) proximal mid, (Mid) mid, (MD) mid distal and (Dis) distal; 































































































































































































Figure 3.11  Transcription of VEGFR1 in sections of VVs by position. 
Sections of VVs descending below a competent (A) or incompetent (B) SFJ.  IOD 
gene:GAP 3  is  the  ratio  of  the  integrated  optical  density  (IOD),  determined  by 
scanning densitometry, of VEGFR1 gene product to its’ corresponding product for 
GAP 3.  Bars represent means values, and error bars are s.e.m.  Position from the 
SFJ, (Px) proximal, (PM) proximal mid, (Mid) mid, (MD) mid distal and (Dis) distal; 
























































































































































































































Figure 3.12  Transcription of s.flt 1 in sections of VVs by position. 
Sections of VVs descending below a competent (A) or incompetent (B) SFJ.  Bars 
represent  means  values,  and  error bars  are  s.e.m.    Position  from  the  SFJ,  (Px) 
proximal, (PM) proximal mid, (Mid) mid, (MD) mid distal and (Dis) distal; all with 
two  PCR  analyses  per  section  examined.    s.flt 1  transcription  increased  with 





























































































































































Figure 3.13  s.flt 1 (A) and VEGF A121 (B) transcription in incompetent sections. 
Transcription of s.flt 1 (p<0.03) and VEGF A121 (p<0.02) increased with descending 
position from the SFJ (both, Kendall’s bivariate correlation).  Bars represent means 
values,  and  error bars  are  s.e.m.    Position  from  the  SFJ,  (Px)  proximal,  (PM) 
proximal mid,  (Mid)  mid,  (MD)  mid distal  and  (Dis)  distal;  all  with  two  PCR 
analyses per section examined. 158 
3.1.5  Discussion 
Primary  VVs  are  a  chronic  disease  (Allan  et  al.,  2000),  the  prevalence  of  which 
increases with age (Evans et al., 1998; Ruckley et al., 2002), is higher in females 
(Evans et al., 1999) and associated with a number of risk factors (see chapter 1.1.2).  
Incompetence of the GSV is the most common manifestation of VVs (Labropoulos et 
al., 1999; Ruckley et al., 2002) and is characterised functionally by disturbed blood 
flow (reflux/stasis), venous hypertension and abnormal vessel dilation (Browse et al., 
1999;  Labropoulos  et  al.,  1999;  Badier Commander  et  al.,  2000;  Ruckley  et  al., 
2002).  Their pattern of appearance might suggest a progressive disease (Jones et al., 
1999; Brunner et al., 2000) with the underlying process(es) potentially overcoming 
homeostatic repair mechanisms over time (Rose 1986; Venturi et al., 1996) resulting 
in the dilated, elongated or tortuous vein observed with varicosity (Travers et al., 
1996;  Woodside  et  al.,  2003).    At  the  cellular  level,  VVs  are  associated  with  a 
number of structural abnormalities (see chapter 1.1.6) considered to be the result of 
aberrant vessel wall remodelling (Gandhi et al., 1993; Venturi et al., 1996; Badier 
Commader et al., 2000), with the processors involved influenced by the same growth 
factors implicated in the regulation of normal vascular homeostasis (Gale et al., 1999; 
Yancopoulos  et  al.,  2000;  Badier Commader  et  al.,  2001).    As  the  control  of 
transcription of genes involved in maintaining vascular reactivity is fundamental in 
the regulation of homeostasis, examination of their transcriptional activity may help 
to elucidate the mechanism(s) underlying varicogenesis.  This study is the first to 
examine  changes  in  the  pattern  of  gene  transcription  (VEGF A  subtypes  and  its 
receptors) in segments of VVs, matched anatomically in descending position from the 
SFJ, in relation to SFJ status and the underlying venous incompetence. 159 
For  VVs  overall,  transcription  of  VEGF A121/165,  VEGFR1  and  VEGFR2  were 
elevated compared to control veins (Figure 3.4) suggesting a potential for greater 
plasma  VEGF A  and  EC  VEGF  receptor  expression.    While  transcription  was 
elevated here, previously plasma VEGF A was not increased in VVs (Hollingsworth 
et al., 2001A, Howlader et al., 2004), although raised plasma VEGF A was reported 
in conjunction with skin changes in CVD (Shoab et al., 1998; Howlader et al., 2004).  
Protein  levels  were  not  measured  here  however,  due  in  part  to  the  difficulty  in 
determining levels of secreted VEGF A isoforms in the vessel wall, and as this study 
was  undertaken  specifically  to  investigate  possible  alterations  in  transcriptional 
activity of VEGF A and its receptors produced by the varicose vessel wall.   
 
In VVs, reduced contractile responses to endothelin 1 (ET 1) in vitro were associated 
with decreased ET 1 receptors, an effect regulated at the level of transcription (Barber 
et  al.,  1997).    The  generation  of  VEGF A  mRNA  is  regulated  at  the  level  of 
transcription  by  binding  of  transcription  factors  to  the  VEGF A  gene  promoter 
(Tischer  et  al.,  1989;  Houck  et  al.,  1992;  Pages  et  al.,  2005)  and  at  the  post 
transcriptional level by mechanisms that increase VEGF A mRNA half life (Levy et 
al., 1996; Levy et al., 1998; see chapter 1.2.4).  Consistently, an increase in VEGF A 
expression in EC models affects VEGF receptor transcription, suggesting that VEGF 
A may modulate the expression of its own receptors (Shen et al., 1998; Wang et al., 
2000).  Enhanced VEGF A transcription but (potentially) without increased protein 
production (Hollingsworth et al., 2001A) might suggest a problem with translation to 
protein.  Alternatively, if the elevated levels of message (mRNA) detected here were 
not of full length, the resultant protein (if produced) might potentially be truncated 
and so unable to bind the antibodies used for detection (Hollingsworth et al., 2001A).  160 
Further studies should address, therefore the rates of translation of VEGF A and its 
receptors to protein, and the production of full length mRNA transcripts. 
 
The presence of VVs with levels of transcription similar to control veins (see Figures 
3.1, 3.2 and 3.5), i.e. those VVs were the SFJ was competent and functional, provides 
several  explanations.    Firstly,  aberrations  in  VEGF A/receptor  transcription  may 
simply not be a causative mechanism in VVs development.  In contrast however, a 
fault in the control of VEGF A/receptor transcription might be involved (see chapter 
1.2.2).  For example, in vitro EC pre incubated with VEGF A165 down regulate cell 
surface  expression  of  VEGFR1  and  2,  which  initiates  elevated  VEGF  receptor 
transcription (Wang et al., 2000).  Notably, receptor down regulation desensitised 
cells to VEGF A165 activation of intracellular  cell signalling pathways, associated 
with  EC  proliferation  and  survival  (Wang  et  al.,  2000).    Removal  of  exogenous 
VEGF A165 allowed rapid recovery of both cell surface VEGF receptor expression as 
well as cellular responsiveness to VEGF A165 (Wang et al., 2000).  In VVs, continued 
stimulation  (from  enhanced  VEGF  expression)  in  response  to  hypoxia,  elevated 
pressure  or  disturbed  blood  flow  may  similarly  induce  VEGF  receptor  down 
regulation (or induced redundancy).  Furthermore, this could result ultimately in a 
compromised  ability  of  the  vessel  wall  to  respond  appropriately,  as  with  ET 1 
receptors  in  VVs  in  vitro  (Barber  et  al.,  1997),  an  effect  which  may  have  been 
initiated due to elevated ET 1 production/exposure (Barber et al., 1997; Mangiafico 
et al., 1997).  
 
A  possible  further  explanation  could  be  that  VEGF A/receptor  transcription  is 
proportional to intra luminal pressure, so with SFJ incompetence pressure increases 161 
and transcription becomes proportionally elevated.  For this however, intra luminal 
pressure in VVs with an incompetent SFJ should be greater than in those where the 
SFJ is functional, for which currently there is no reported evidence and should be 
considered for future investigations.  Although unclear, the altered pattern of VEGF 
A/receptor transcription seen suggests that incompetence of the SFJ may represent 
disease of a differing stage of development (i.e. later than when the SFJ is functional).   
 
Besides intra luminal pressure, functional characteristics like disturbed blood flow 
(stasis or reflux) are associated with VVs and suggested to play a role in vessel wall 
remodelling (Browse et al., 1999; Badier Commader et al., 2001; Wali et al., 2002B). 
Comparisons of patterns of incompetence with the distribution of varicosities using 
colour flow duplex ultrasound examination suggests that the development of VVs 
may occur by a process of ‘spreading incompetence’ (Cooper et al., 2003) potentially 
originating  from  an  initial  focal  point(s)  (Labropoulos  et  al.,  1999).    This  is 
substantiated by observations that the presentation of varicosity is often patchy and 
irregular  (Badier Commader  et  al.,  2001),  with  varicose  segments  of  vessel  wall 
interspersed  with  apparently  normal  segments  (see  chapter  1.1.6).    To  further 
investigate this, the pattern of  gene transcription was examined in relation to the 
competency (reflux or no reflux) of the vessel wall segment along the vein.  When 
examining  segmental  competence  (in  contrast  to  SFJ  competency),  the  pattern  of 
transcription  seen  was  different.    Transcription  of  VEGF A121/165,  VEGFR2  and 
VEGFR1 was similar in both competent and incompetent segments of VVs, but was 
elevated  in  all  segments  (competent  or  incompetent)  compared  to  control  (Figure 
3.6).  Activation of VEGF A/receptor transcription as a homeostatic response might 162 
therefore, reflect an earlier event occurring prior to the development of incompetence 
within the vein wall.   
 
VEGF A, produced from the vSMC in response to hypoxia, disturbed blood flow or 
pressure, stimulates production of NO from the vascular endothelium (Dulak et al., 
2003;  Kimura  et  al.,  2003).    NO,  itself  released  from  the  endothelium  due  to 
mechanical stimuli like shear stress associated with disturbed flow (Luscher 1991; 
Bundy et al., 2000) and hypoxia (Pearson et al., 1998; Kimura et al., 2000), in turn 
acts  on  vSMC  to  produce  VEGF A,  generating  a  ‘loop’  mechanism  to  mediate 
vascular reactivity (Servos et al., 1999, Bundy et al., 2000; Kimura et al., 2003).  
Again, as with ET 1, (Barber et al., 1997; Mangiafico et al., 1997) enhanced VEGF 
A/receptor transcription in response to ‘stimulus’ like hypoxia, disturbed blood flow 
or  pressure,  if  not  relieved  or  controlled  appropriately,  might  lead  ultimately  to 
altered VEGF A/receptor activity and vein wall to responses.  Furthermore, continued 
and elevated VEGF A/receptor expression (via the mechanism described above) may 
lead  to  elevated  production  of  nitric  oxide  (Servos  et  al.,  1999)  resulting  in  the 
generation  of  other  reactive  oxygen  species,  and  so  contributing  to  the  further 
development  of  pathology.    Therefore,  in  trying  to  maintain  homeostasis,  the 
activation of VEGF A/receptor transcription may itself become a central part of the 
subsequent pathological process.   
 
A  surprising  result  was  that  transcription  of  s.flt 1  was  similar  in  all 
samples/segments and unaffected by varicosity or competence (Figure 3.5 and 3.6).  
The importance of control of VEGF A in the pathogenesis of vascular disorders has 
been  realised  through  isolation  of  a  soluble  truncated  extra cellular  isoform  of 163 
VEGFR1, s.flt 1 (Kendall et al., 1993; Kondo et al., 1998).  Soluble flt 1 modulates 
the action of VEGF by sequestering free VEGF A and so preventing binding to trans 
membrane receptors (Kendall et al., 1993; Kendall et al., 1996A; Siemester et al., 
1998; Barleon et al., 2001) and by reducing the activation status (phosphorylation) of 
VEGFR2 (Graubert et al., 2001), possibly by forming stable inactive heterodimers 
(Kendall et al., 1996A; see chapter 1.2.3).  Hypoxia can both stimulate the production 
of VEGF A (Shima et al., 1995; Levy  et al., 1996) and up regulate s.flt 1 protein 
production  (Liu  et  al.,  1995;  Gerber  et  al.,  1997),
  whilst  down regulating  auto 
phosphorylation (hence, activation) of VEGFR1  (Ahmed et al., 2000; Graubert et al., 
2001).    Potentially  therefore,  hypoxia  may  stimulate  in  conjunction  with  the 
production/release of VEGF A, an associated down regulation of VEGFR1 in favour 
of s.flt 1 to control the action of the VEGF A produced (Kendall et al., 1993; Kondo 
et al., 1998).   
 
Transcription of s.flt 1 increased in VVs overall with descending position from the 
SFJ (Figure 3.7), and with SFJ incompetence (Figure 3.12).  Similarly, this pattern of 
increased s.flt 1 transcription was observed descending from the SFJ in incompetent 
segments  (Figure  3.13A).    Therefore,  if  intra luminal  pressure  increases  with 
descending position from the SFJ, enhanced VEGF A transcription might be expected 
and accordingly, enhanced s.flt 1 transcription to mediate VEGF A action (Kendall et 
al., 1993; Kondo et al., 1998).  However, elevated VEGF A transcription was not 
observed with descending position from the SFJ (Figure 3.8 and 3.9), although this 
may be masked by the overall elevated levels of VEGF A transcription seen in VVs 
(Figure 3.4).  Alternatively, enhanced s.flt 1 transcription may simply reflect an on 
going pathological process.  Previously, we have observed that varicosities tend to 164 
appear  more  distally,  and  at  a  position  at,  or  below,  the  underlying  venous 
incompetence  (Labropoulos  et  al.,  1999;  Cooper  et  al.,  2003).    Collectively,  the 
pattern of disease, in conjunction with alterations in gene transcription, might reflect 
a process of increasing pressure from proximal to distal, but with disease and the 
appearance of varicosities developing in a distal to proximal manner.  Descending 
position from the SFJ correlated in incompetent segments with increased transcription 
also,  of  VEGF A121  (Figure  3.13B);  notably  the  only  gene  to  be  elevated 
transcriptionally in VVs with a competent SFJ (Figure 3.5).  The function of VEGF 
A121 is currently unclear however, although structurally it is less effective at inducing 
EC proliferation than VEGF A165 (see chapter 1.2.3) enhanced transcription has been 
observed associated with inflammatory disease.  
 
Although  the  results  reported  here,  may  suggest  a  potential  problem  with  VEGF 
responses in VVs they should be interpreted with caution.  Firstly, the results are 
based on small patient numbers and it would be more informative to extend these 
studies  to  more  individuals,  specifically  those  with  an  “earlier”  stage  of  varicose 
disease i.e. VVs with competent SFJ and/or vessel wall segments.  In addition, the 
use  of  control  samples  from  individuals  undergoing  surgery  for  cardiovascular 
disease,  while  not  the  most  appropriate  were  the  most  suitable  control  available.  
Although  great  care  was  taken  when  correlating  harvested  GSV  to  duplex  scan 
reports, the inherent variability of the diseased vessel together with the difficulties in 
marking  sites  of  reflux,  suggests  that  certain  alignments  may  not  be  completely 
accurate.    Finally,  investigation  of  the  possible  mechanism(s)  of  transcriptional 
induction (transcriptional activators)  would help clarify  whether VEGF A/receptor 
transcription  is  indeed  causative  or  merely  a  reflection  on  the  on going  disease 
process(es).   165 
Summary points 
The results of this study can be summarised as follows:  
 
1. The transcription of all genes examined except s.flt 1 were elevated in sections of 
VVs compared to those from control veins.   
 
2. Transcription of the secreted VEGF A isoforms (VEGF A121 and VEGF A165) and 
receptors  (VEGFR2  and  VEGFR1)  were  elevated  in  VVs  when  the  SFJ  was 
incompetent.  
 
3. Transcription was similarly elevated in VVs irrespective of segmental competence. 
 
4. There  was  no  change  in  transcription  of  s.flt 1  with  SFJ  or  segmental 
incompetence although transcription increased with descending position from SFJ. 
 
5. Altered transcription of VEGF A and its receptors (notably VEGF A121 and s.flt 1) 
maybe associated in some part, with the process(es) of varicogenesis and represent 
an earlier event, before the development of vessel wall incompetence. 
 
6.  In contrast, SFJ incompetence may represent a later stage of disease development, 












3.2  RELEASE OF S.FLT 1 WITH AN INDUCED STASIS 
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3.2.1   Background 
Although an imbalance between the mediators of vascular tone has been proposed as 
a causative mechanism in primary VVs (Schuller Petrovic et al., 1997; Brunner et al., 
2001), it is unclear where the fault lies, i.e. with the production of these mediators, 
the  vessels  ability  to  respond  appropriately  to  them  when  produced  or  indeed  an 
inability to switch off activating VEGF A signals.  Previously, an increase in luminal 
pressure (application of a cuff) resulted in a rapid elevation of plasma VEGF A in 
control  subjects,  but  not  in  patients  with  VVs  (Hollingsworth  et  al.,  2001A).  
However, both elevated transcription (see chapter 3.1.4) and VEGF A protein (Shoab 
et al., 1998; Howlader et al., 2004) are associated with VVs, suggesting potentially 
either a loss of response to increased pressure in these veins or rapid clearance of the 
released VEGF A.  Notably, the transcription of s.flt 1 (soluble isoform of VEGFR1 
membrane  receptor)  was  similar  elevated  in  VVs,  with  increased  transcription 
associated with decreasing position below an incompetent SFJ (see chapter 3.1.4).  
VEGF A mediates its dilatory and mitogenic effects through activation of VEGFR2 
(Millauer et al., 1993) the action of which potentially is modulated by s.flt 1, which 
binds VEGF A with high affinity and modulates VEGF A signalling (Kendall et al., 
1993; Belgore et al., 2000).    
 
3.2.2  Aim 
To examine baseline levels of plasma s.flt 1 in the GSV and its release following a 
mild experimentally induced venous hypertension and whether release is affected by 
varicosity.  
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3.2.3  Methods 
This study was conducted with approval of the Joint UCL/UCLH Committees on the 
Ethics of Human Research.  Patients attending The Vascular Unit, The Middlesex 
Hospital, London for assessment for primary VVs and control subjects (selected from 
staff within the Department of Surgery) were asked to participate and if agreeable, 
written consent obtained (see Chapter 2.1.1).   
 
A mild, venous stasis was experimentally induced as described in chapter 2.1.2.  This 
method was used for a number of experimental reasons.  Ideally, to induce venous 
stasis, patients and subjects would have stood upright for 20 25 minutes before blood 
samples were obtained.  However, this was not practical as patients were reluctant to 
stand  for  prolonged  periods  on  a  voluntary  basis.  Furthermore,  the  intent 
experimentally was to induce a mild and localised change in the venous blood flow, 
rather  than  a  more  severe  venous  stasis  as  might  be  expected  from  prolonged 
standing.    The  ‘cuffing’  time  of  10  minutes  was  chosen  to  observe  how  quickly 
changes  in  plasma  factors  might  be  brought  about  under  such  conditions  and 
therefore, a closer approximation of how the vein might react to minor changes in 
localised  blood  flow.    Before  and  following  venous  stasis,  blood  samples  were 
collected and processed as described in chapter 2.1.2. 
 
From plasma, levels of s.flt 1 were determined using a quantitative sandwich enzyme 
immunoassay kit (Quantikine™ human sVEGF R1; R&D Sytems, UK) according to 
the manufacturer’s instructions as described in chapter 2.4.3.   
 
Statistical analysis of results was undertaken as described in chapter 2.6.2. 169 
3.2.4  Results 
Patient demographics: 32 subjects were recruited, of which 13 (of 21) patients with 
primary VVs and 7 (of 11) control subjects yielded analysable results (Table 3.2.); 
samples  and  results  were  not  obtained  for  all  subjects  recruited  due  to  either 
difficulties in obtaining blood from the foot, or coagulation of samples due to limited 
volumes obtained.  Samples from individuals were only included for analysis if they 
produced  on  repeated  and  separate  assays,  results  with  less  than  a  10%  inter 
experimental variation.   
 
Before cuff:  Baseline levels of plasma s.flt 1 in samples obtained from the arm were 
similar in both control subjects (median, range: 35.4, 30.1 – 41.0 pg/ml) and patients 
with primary VVs (33.1, 24.3 – 48.5 pg/ml; p>0.1).  In control subjects, baseline s.flt 
1 in samples obtained from the foot before application of the below knee cuff vein 
(33.2, 25.0 – 37.0 pg/ml) were similar to those obtained from the arm (35.4, 30.1 – 
41.0 pg/ml; p>0.1; Figure 3.14.).  In contrast however, levels of s.flt 1 in plasma 
samples obtained from the foot of patients with primary VVs before cuff application 
(51.1, 39.7 – 89.4 pg/ml) were markedly elevated compared to those from the arm 
(33.1, 24.3 – 48.5 pg/ml; foot before versus arm, p<0.001) and baseline samples from 
control subjects (foot before control versus varicose, p<0.001; see Figure 3.14. and 
Figure 3.15.). 
 
After cuff  Application of the below knee cuff for 10 minutes resulted in an overall 
mean (± s.e.m) increase of 54.2 (± 22.5) % in the levels of plasma s.flt 1 in control 
subjects from 33.2 (25.0 – 37.0) pg/ml to 44.3 (32.5 – 87.4) pg/ml (before versus 







  Description  Varicose   Control 
  patients, n =  13   7 
  median age  





  male, n =  4  5 





Table 3.2  Patient demographics and samples for analysis of plasma s.flt 1.  
32 subjects were recruited, of which 13 (of 21) patients with primary VVs and 7 (of 
11)  control  subjects  yielded  analysable  results.    *p<0.1  versus  control,  Mann  & 











































































Figure 3.14  Levels of plasma s.flt 1 detected in blood of control subjects. 
Blood  taken  from  arm  (open  bars)  or  the  foot  veins  (grey  bars)  before  and  after 
application of a below knee cuff.  For each subject, duplicate assays were performed, 
each  with  at  least  two  replicates  per  assay,  and  the  mean  value  used  for  further 
analysis.  Box plots represent thick line (median), boxes (inter quartile range) and 
error bars (range), 










































































































































Figure 3.15  Plasma levels of s.flt 1 in blood from patients with VVs. 
Bloods taken from arm (open bars) or the foot veins (grey bars) before and after 
application of a below knee cuff.  For each subject, duplicate assays were performed, 
each  with  at  least  two  replicates  per  assay,  and  the  mean  value  used  for  further 
analysis.  Box plots represent thick line (median), boxes (inter quartile range) and 
error bars (range). *p<0.001 versus VVs ‘before cuff’, and control subjects ‘before 
cuff’ Kruskal Wallis test. 173 
However, in patient’s with primary VVs there was little or no change in plasma s.flt 1 
following  application  of  the  cuff,  these  being  only  marginally  elevated;  with  an 
overall mean increase of 5.5 (± 5.8) % from 51.1 (39.6 – 89.4) pg/ml to 59.2 (34.7 – 
126.4) pg/ml (see Figure 3.15). 
 
3.2.5  Discussion 
Application  of  a  cuff  and  the  resulting  venous  stasis  should  induce  a  change  in 
luminal  pressure  and  local  blood  chemistry  in  the  vein,  the  normal  homeostatic 
response to which should be vessel wall dilation and/or increased vessel permeability 
(Micheils  et  al.,  1997;  Browse  et  al.,  1999).    For  dilation,  the  production  of 
vasodilators like VEGF A and NO would be expected (Servos et al., 1999).  The 
production of VEGF A by the vessel wall would induce a concomitant increase in the 
expression of the VEGF receptors in the vascular endothelium (Wang et al., 2000) 
including the production of s.flt 1 (Barleon et al., 1997A; Chen et al., 2000B) as a 
possible mechanism to attenuate the action of VEGF A (Kendall et al., 1993).   
 
Soluble flt 1, the truncated extra cellular isoform of VEGFR1 (Kendall et al., 1993; 
Kondo  et  al.,  1998)  can  modulate  the  action  of  VEGF  via  at  least  two  known 
mechanisms: i) by binding to, and thus sequestering free VEGF A and so preventing 
its ligation to the trans membrane receptors (Kendall et al., 1993; Barleon et al., 
1997B; Ferrara et al., 1998; Siemester et al., 1998B; Barleon et al., 2001), ii) by 
reducing the activation status (phosphorylation) of VEGFR2 (Siemester et al., 1998B; 
Graubert et al., 2001), possibly by forming stable inactive heterodimers (Kendall et 
al., 1996A; see chapter 1.2.3).  Evidence for the modulation of VEGF A by s.flt 1 
was  observed  during  endometrial  regeneration  during  menstruation  (Clarke  et  al., 174 
1998) where complexes of s.flt 1 bound to VEGF are detected in plasma during the 
early  menstrual  phase  of  the  cycle  (Graubert  et  al.,  2001).    Furthermore,  with 
progression to the late menstrual and early proliferative phase, a reduction in plasma 
s.flt 1 was associated with elevated levels of plasma VEGF A (Graubert et al., 2001).  
Similarly,  in  patients  with  peripheral  arterial  disease,  a  significant  reduction  in 
baseline  levels  of  plasma  s.flt 1  was  associated  with  elevated  plasma  VEGF A 
(Belgore et al., 2001A; Blann et al., 2002).  Furthermore, in hypertensive patients 
elevated  VEGF A  with  reduced  s.flt 1  was  associated  with  increased  endothelial 
damage  and  cardiovascular  risk  (Felmeden  et  al.,  2003);  the  decrease  of  which 
following intensive management was associated with an increase in plasma s.flt 1 and 
a concomitant lowering of plasma VEGF A levels (Felmeden et al., 2003).   
 
In contrast, elevated VEGF A was not associated with a reduction in plasma s.flt 1 in 
patients with coronary arterial disease (Blann et al., 2002) and plasma VEGF A and 
s.flt 1 were both elevated in patients with (uncomplicated) essential hypertension, and 
both  decreased  following  treatment  (Belgore  et  al.,  2001A).    Although  levels  of 
plasma  VEGF A  and  s.flt 1  increase  with  the  progression  of  normal  pregnancy 
(McKeenan  et  al.,  2004),  a  marked  elevation  in  s.flt 1  occurs  earlier  and  in  the 
absence of any change in circulating VEGF A, during early gestation in preeclampsia 
(McKeenan et al., 2004).  However, in patients with preeclampsia, systemic plasma 
s.flt 1 is further increased with progression of pregnancy (Maynard et al., 2003) and 
elevated levels of sflt 1 are associated with a marked reduction in circulating free 
VEGF  (Maynard  et  al.,  2003).    Interestingly,  during  vascular  repair  after 
menstruation, the activation of VEGFR2 (phosphorylation) was inversely correlated 175 
with the presence of s.flt 1 suggesting a more direct role in attenuating VEGFR2 
mediated signalling by s.flt 1 (Graubert et al., 2001).    
 
In control subjects, as for VEGF A previously (Hollingsworth et al., 2001A), a mild 
venous stasis induced an increase in the levels of plasma s.flt 1 within 10 minutes 
(see Figure 3.14.).  VEGFR1 and s.flt 1, like VEGF A contain a hypoxia response 
element in their promoter region and are potently up regulated by hypoxia (Liu et al., 
1995;  Gerber  et  al.,  1997).    Hypoxia  also  down regulates  the  activation 
(phosphorylation)  of  membrane  bound  VEGFR1  which  is  thought  to  elevate  the 
production of s.flt 1 (Ahmed et al., 2000).  However, s.flt 1 is produced de novo as an 
alternative splice variant (Kendall et al., 1993; Kondo et al., 1998) and even though 
post  transcriptional  modulation  of  polyadenylation  sites  by  the  spliceosome  is 
suggested to elevate s.flt 1 mRNA expression (Huckle et al., 2004), the rapid increase 
in s.flt 1 protein seen her after 10 minutes is unlikely to have been produced by this 
route. 
 
Alternatively, the increased level of s.flt1 protein detected in control subjects might 
have been derived by release from bound VEGF:s.flt 1 complexes present within the 
plasma  (Belgore et al., 2001B).  The dissociation of these complexes under increased 
oxygen  tension  could  liberate  both  VEGF  and  s.flt 1,  and  help  to  explain  the 
elevation of VEGF and s.flt 1 in the plasma of patients with VVs.  However, the 
stochiometry does not support this as a mechanism, as levels of s.flt 1 (picograms) 
are an order of magnitude less than that detected for VEGF A (nanograms) in VVs.  
So,  as  for  hypoxia  induced  transcriptional  activation,  s.flt 1  release  from  bound 
VEGF:s.flt 1 complexes are unlikely to account for our results here after 10 minutes 176 
and further examination is required to interpret the results obtained.  To clarify the 
possible mechanism(s) underlying the rapid elevation in s.flt 1 protein observed in 
VVs,  further  investigations  including  analysis  post translational  modifications  and 
protease activity would be of benefit.  
 
In patients with primary VVs, the baseline level of s.flt 1 were markedly elevated in 
the foot vein before application of the cuff compared to those from the arm (p<0.001) 
and baseline levels in control subjects (p<0.001, see Figure 3.14.).  This suggests that 
elevated s.flt 1 probably reflects a more localised situation associated with the site of 
disease in VVs instead of a systemic problem (Goldman et al., 1998; Belgore et al., 
2001B; Hoar et al., 2004).  We did not observe elevated levels of VEGF in VVs 
(Hollingsworth  et  al.,  2001A),  but  elevated  VEGF A  was  reported  in  peripheral 
venous  disease,  primarily  in  the  presence  of  skin  changes  (Shoab  et  al.,  1998; 
Howlader et al., 2004) and with chronic critical limb ischaemia (Choksy et al., 2004).  
Although  plasma  s.flt 1  was  not  determined  in  these  studies,  another  potential 
explanation for elevated s.flt 1 in VVs could be simply a reflection of an ongoing 
inflammatory process in the vein.  If so the elevated s.flt 1 observed in patients with 
VVs would be due to factors including pro inflammatory cytokines, alterations to pH 
or reactive oxygen species localised more to the site of disease.    
 
With application of the below knee cuff to patients with VVs, a slight non significant 
increase in s.flt 1 was observed, similar to that observed previously for VEGF A in 
these subjects (Hollingsworth et al., 2001A).  A lack of increase in s.flt 1 might 
reflect a position whereby as the baseline levels are already significantly elevated, 
there is a reduced ability to elevate these further; for example, responses are already 177 
near  maximal,  or  that  control  of  the  mechanism  enhancing  s.flt 1  production  is 
compromised. 
 
The  results  reported  here,  extend  the  earlier  observations  suggesting  a  potential 
problem with VEGF responses in VVs.  There are however, several caveats to this 
study.  Firstly, the results are based on small samples numbers and it would be more 
informative to extend these studies to more individuals.  Further, investigation of the 
relationships between VEGF A and s.flt 1 with reference to C.E.A.P. grading would 
help to clarify if the effects seen are causative rather than simply a reflection of on 
going disease processes.  Finally, a more detailed examination of s.flt 1 mRNA half 
life, rates of protein translation, and potential post translation modifications would 
aid  our  understanding  of  the  role  of  s.flt 1  and  its’  control  of  VEGF  in  the 
development and progression of VVs.   
 
Summary points 
The results of the studies performed here can be summarised as follows:  
 
1. Plasma  levels  of  s.flt 1  are  rapidly  increased  in  control  subjects  following  an 
induced stasis, but not in patients with primary VVs.   
 
2. Baseline levels of plasma s.flt 1 are elevated in patients with primary VVs before 












3.3  Β CATENIN TRANSCRIPTION AND PROTEIN EXPRESSION 
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3.3.1   Background 
Normal  VEGF A  signalling  (via  VEGFR2)  dismantles  the  endothelial  adherens 
junction (Esser et al 1998; Kevil et al., 1998) resulting in a loss of cadherin mediated 
cell cell adhesion (Cohen et al., 1999) and increased endothelial permeability (Kevil 
et al., 1998) with the release β catenin into the cytoplasm (Moon et al., 2004; Nelson 
et al., 2004; see chapter 1.3.2.).  In the absence of a stabilisation signal, cytoplasmic 
β catenin is rapidly degraded (Aberle et al., 1997; Moon et al., 2004) and as such is 
rarely  detected  in  the  adult  vasculature  (Goodwin  et  al.,  2002).    However  in  the 
presence of a stabilisation signal, β catenin translocates to the nucleus and acts as a 
potent transcriptional activator of various genes implicated with cellular proliferation 
including c myc and cyclin D1 (He et al., 1998; Beherens et al., 1996; see chapter 
1.3.1.).  The cadherin/catenin complex therefore, is suggested to regulate the activity 
of β catenin signalling  by retaining bound β catenin in the AJ and preventing its 
translocation  to  the  nucleus  for  targeted  gene  expression  (Gottardi  et  al.,  2004; 
Dejana  et  al.,  2004).    If  as  suggested,  VEGF A  signalling  is  disturbed  with  the 
initiation of VVs, alterations in the normal functioning of the protein in the regulation 
of vascular homeostasis should be observed in VVs, i.e. EC proliferation survival and 
permeability (see chapter 1.2.6.2).  Dysfunction in VEGF A signalling may therefore 
predispose  to  elevated  β catenin,  and  so  the  potential  for  altered  gene  expression 
associated with vascular remodelling in primary VVs. 
 
3.3.2  Aim 
To  examine  the  pattern  of  activity  of  β catenin  in  primary  VVs,  specifically  in 
relation to the underlying venous incompetence using samples previously assessed for 
VEGF A and the VEGF receptors. 180 
3.3.3  Methods 
This study was conducted with approval of the Joint UCL/UCLH Committees on the 
Ethics of Human Research as described in chapter 2.1.1.  Samples of varicose GSV 
were obtained from patients undergoing sapheno femoral ligation and stripping of the 
long saphenous vein for the treatment of primary VVs.  Control GSV was obtained 
from patients undergoing cardiac bypass, and who had no clinical evident symptoms 
of varicose disease in either limb (see chapter 2.1.2).   
 
Samples of varicose or control GSV collected on ice at operation were processed as 
described  in  chapter  2.1.2.    Total  RNA  was  extracted  with  TRI  Reagent™  (see 
chapter 2.2.2) and then reverse transcribed to cDNA as described in chapter 2.3.1.  
Total protein was extracted as described in chapter 2.2.3 and separated by reducing 
and denaturing SDS PAGE (see chapter 2.4.5). 
 
Transcription of β catenin, c myc and cyclin D1 was examined by semi quantitative 
PCR (see chapter 2.3.4 and representative gel pictures Figures 3.16 18) and analysed 
by scanning densitometry as described in chapter 2.5.2.  The expression of β catenin 
protein was examined by semi quantitative Western Blot (see chapter 2.4.7 & 2.4.8 
and  representative  western  blots  Figures  3.16 18)  and  analysed  by  scanning 
densitometry as described in chapter 2.5.3. 
 
Statistical analysis of results was undertaken as described in chapter 2.6.3. 181 







































Figure 3.16  β catenin gel and western blot of VVs sections in control vein segments.   
For each individual segment analysed, the competency of the SFJ and vessel wall was 
determined from duplex scan and classified as being competent with no reflux (c) or 
incompetent with reflux evident (i) (A).  β catenin gene (CTNNB1) transcription was 
examined  by  semi quantitative  RT PCR.    Products  were  visualised  by  agarose 
electrophoresis and the IOD of each band measured by scanning densitometry.  Gene 
transcription was reported as IOD ratio of β catenin PCR product normalised against 
control house keeping gene GAP 3 (GAPDH) (B).  β catenin protein was detected 
with antibody and determined by western blot (C).  β catenin protein was measured 
by scanning densitometry and reported as IOD ratio of β catenin protein normalised 
to total protein loaded (Ponceau S) (D).  182 
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Figure 3.17  β catenin gel and western blot of VVs sections with a competent SFJ.   
For each individual segment analysed, the competency of the SFJ and vessel wall was 
determined from duplex scan and classified as being competent with no reflux (c) or 
incompetent with reflux evident (i) (A).  β catenin gene (CTNNB1) transcription was 
examined  by  semi quantitative  RT PCR.    Products  were  visualised  by  agarose 
electrophoresis and the IOD of each band measured by scanning densitometry.  Gene 
transcription was reported as IOD ratio of β catenin PCR product normalised against 
control house keeping gene GAP 3 (GAPDH) (B).  β catenin protein was detected 
with antibody and determined by western blot (C).  β catenin protein was measured 
by scanning densitometry and reported as IOD ratio of β catenin protein normalised 
to total protein loaded (Ponceau S) (D).  183 
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Figure 3.18  β catenin gel and western blot of VVs sections with an incompetent SFJ.   
For each individual segment analysed, the competency of the SFJ and vessel wall was 
determined from duplex scan and classified as being competent with no reflux (c) or 
incompetent with reflux evident (i) (A).  β catenin gene (CTNNB1) transcription was 
examined  by  semi quantitative  RT PCR.    Products  were  visualised  by  agarose 
electrophoresis and the IOD of each band measured by scanning densitometry.  Gene 
transcription was reported as IOD ratio of β catenin PCR product normalised against 
control house keeping gene GAP 3 (GAPDH) (B).  β catenin protein was detected 
with antibody and determined by western blot (C).  β catenin protein was measured 
by scanning densitometry and reported as IOD ratio of β catenin protein normalised 
to total protein loaded (Ponceau S) (D).  184 
3.3.4  Results 
Patient demographics:  GSV was obtained from 21 individuals resulting in a total of 
99 and 87 samples available for gene and protein analysis respectively (Table 3.3).  
Of the 21 individuals examined, 16 had primary VVs as confirmed by venous duplex 
scan.  Of these, 7 individuals presented with a functionally intact and competent SFJ 
(4 male, 3 female) resulting in 29 samples available for gene analysis and 30 samples 
for protein analysis respectively.  The remaining 9 individuals with VVs presented 
with an incompetent SFJ (3 male, 6 female) resulting in 56 and 43 samples for gene 
and protein analysis respectively.  Control GSV was obtained from 5 individuals (3 
male, 2 female) making a total of 14 control samples available for both gene and 
protein analysis.  RNA and protein of suitable quality was isolated from all vein 
sections analysed as illustrated in representative gels and western blot for individuals 
from  control  (Figure  3.16),  competent  SFJ  (Figure  3.17)  and  those  with  an 
incompetent SFJ (Figure 3.18). 
 
Varicose and control veins overall:  For VVs overall, transcription of β catenin was 
elevated  compared  to  control  vein  (Figure  3.19).  Similarly,  the  expression  of  β 
catenin protein was elevated in VVs compared to control vein (Figure 3.19).  
 
Competence at the sapheno femoral junction:  To examine the relevance of SFJ 
competency, the results were analysed specifically in conjunction with status of the 
SFJ (see Table 3.3).  Transcription of β catenin in VVs with competent SFJ was 
similar to that detected in control samples (Figure 3.20).  However, when the SFJ was 
incompetent transcription of β catenin was elevated compared to either control veins  
 185 
Description  Varicose  Control 
  competent 
SFJ 
incompetent 
SFJ  total   
         
Individuals, n =  7  9  16  5 
median age (range)  62 (28 69)  43 (27 58)  48 (27 56)
*  63 (50 72) 
male, n =  4  3  7  3 
female, n =  3  6  9  2 
         
mRNA samples, n =  29  43  72  14 
male, n =  15  15  30  7 
female, n =  14  28  42  7 
         
Protein samples, n =  30  39  69  14 
male, n =  15  15  30  7 
female, n =  15  24  39  7 
         
 
 
Table 3.3  Patient demographics and description of samples used in study. 
Vein samples were obtained from 21 individuals. 16 patients had primary VVs (7 
male, 9 female) resulting in a total of 72 and 69 samples available for gene and 
protein analysis respectively. Control GSV was obtained from 5 individuals (3 male, 
2 female) resulting in a total of 14 control samples available for analysis.  Overall, 
patients with VVs were younger than those from whom control veins were taken 
















































































































































Figure 3.19  β catenin transcription (A) and protein expression (B) in VVs overall. 
Control (open bars) and VVs overall (grey bars).  Gene transcription is reported as a 
ratio  of  the  IOD  of  β catenin  PCR  product  to corresponding  product  for  GAP 3, 
determined by scanning densitometry.  Expression of β catenin protein reported as 
IOD ratio of β catenin protein (western blot) to total protein (Ponceau S) determined 
by  scanning  densitometry.    Box  plots  represent  median  values  with  interquartile 









































































































































































































































Figure 3.20  β catenin transcription (A) and protein expression (B) by SFJ.  
Sections of control veins (open bars), VVs from individuals with a competent (dark 
gray bars), or incompetent SFJ (light gray bars).  Box plots represent median values 
with interquartile range, error bars the range, *p<0.001 incompetent versus competent 







































































































































































































































Figure 3.21  β catenin transcription (A) and protein expression (B) by segment. 
Sections of control veins (open bars), and VVs where the section of vein wall was 
determined  from  duplex  scan  as  competent  (dark  gray  bars),  or  incompetent  and 
showing reflux (light gray bars).  Box plots represent median values with interquartile 
range, error bars the range, 
† p<0.020 versus control (Kruskal Wallis).  189 
 (p<0.002) or VVs with a competent SFJ (p<0.001).  The pattern of expression of β 
catenin protein was different. Now, VVs with a competent SFJ, β catenin protein was 
elevated compared to either control or VVs when the SFJ was incompetent (Figure 
3.20).    Interestingly,  there  was  a  negative  (although  not  significant)  correlation 
between β catenin transcription and protein expression with SFJ incompetence.   
 
Competence of the vein wall:  To examine levels of gene transcription in conjunction 
with vein wall competence, results were now grouped and analysed as described in 
chapter 3.1.4.  As with the SFJ, β catenin transcription was elevated in sections of 
VVs that were incompetent compared to sections from either control (p<0.020) or 
competent sections of VVs (Figure 3.21).  β catenin protein expression was elevated 
in sections of VVs with competent vein wall segments compared to either control or 
segments that were incompetent (Figure 3.21).  An inverse correlation, although not 
significant was observed between β catenin transcription and protein expression in 
competent vein segments. 
 
Position  and  competence  of  the  sapheno femoral  junction:    The  transcription  and 
expression  of  β catenin  was  examined  according  to  position  from  where  derived; 
proximal, proximal mid, mid, mid distal and distal from the SFJ.  For VVs overall, 
increased transcription of β catenin correlated with descending position from the SFJ 
(p<0.050,  Kendall’s  bivariate  correlation;  Figure  3.22).    A  similar  (although  not 
significant) correlation was seen for elevated expression of β catenin protein (Figure 
3.22).  When considering both position and competency of the SFJ, transcription of β 
catenin was unaffected by descending position in veins with a competent SFJ.  Indeed 
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Figure 3.22  β catenin transcription (A) and protein expression (B) by position. 
Box  plots  represent  median  values  with  interquartile  range,  error  bars  the  range, 
position descending from the SFJ as (Px) proximal, (PM) proximal mid, (Mid) mid, 



























































































































Figure 3.23  β catenin transcription (A) and expression (B) by position & SFJ.  
Box  plots  represent  median  values  with  interquartile  range,  error  bars  the  range, 
position descending from a competent (dark grey bars) or incompetent (light grey 
bar) the SFJ as (Px) proximal, (PM) proximal mid, (Mid) mid, (MD) mid distal and 
(Dis)  distal.    Gene  transcription,  incompetent  SFJ  p<0.050,  protein  expression, 
competent SFJ p< 0.010, (both Kendall’s bivariate correlation). 192 
 In contrast when the SFJ was incompetent, β catenin transcription was elevated for 
all segments along the vein length.  Furthermore, there was a positive correlation for 
increased transcription of β catenin with descending position from the SFJ (p<0.050, 
Kendall’s bivariate correlation).  The converse was detected for β catenin protein, 
which was elevated when the SFJ was competent for all positions except proximal 
(Figure 3.23).  In contrast β catenin protein was similar for all anatomical positions in 
VVs  samples  with  an  incompetent  SFJ.    Notably,  the  elevated  β catenin  protein 
correlated  to  descending  position,  away  from  the  SFJ  in  VVs  samples  with  a 
competent SFJ (p< 0.010, Kendall’s bivariate correlation). 
 
Transcription  of  c myc  and  cyclin  D1:    To  examine  the  relevance  of  elevated  β 
catenin here, the transcription of two nuclear target genes of β catenin, c myc and 
cyclin D1 were similarly investigated (He et al., 1998; Beherens et al., 1996).  In 
sections from VVs with an incompetent SFJ, transcription of both c myc and cyclin 
D1 were elevated compared to either control (p<0.001), or VVs with a competent SFJ 
(p<0.001,  Figure  3.24).    When  considering  segmental  competency  however, 
transcription of c myc and cyclin D1 were elevated in all VVs segments compared to 
control, i.e. when the segment was competent (cyclin D1, p<0.050) or incompetent 
(both p<0.001, Figure 3.25).  Transcription of β catenin correlated to that of c myc 
and  cyclin  D1  when  the  SFJ  or  segment  was  incompetent  (p>0.050,  Kendall’s 
bivariate correlation).  In contrast, an inverse relationship between β catenin protein 
and c myc cyclin D1 transcription was observed with SFJ incompetence (p>0.050, 
Kendall’s  bivariate  correlation).    Elevated  transcription  of  c myc  and  cyclin  D1 
correlated with decreasing position below an incompetent SFJ (c myc p<0.050, cyclin 





























































































































































Figure 3.24  Transcription of c myc (A) and cyclin D1 (B) with SFJ status.   
Sections of vein from control (open bars) and VVs from GSV with a competent (dark 
grey bars) or incompetent (light grey bars) SFJ.  Box plots represent median values 
with interquartile range, error bars the range, *p<0.001 incompetent versus control 























































































































































































Figure 3.25  Transcription of c myc (A) and cyclin D1 (B) by segment status.   
Sections of vein from control (open bars) and VVs from GSV with a competent (dark 
grey bars) or incompetent (light grey bars) SFJ.  Box plots represent median values 
with interquartile range, error bars the range, *p<0.001 incompetent versus control, 























































































































































































Figure 3.26  Transcription of c myc (A) and cyclin D1 (B) by position & SFJ.  
Box  plots  represent  median  values  with  interquartile  range,  error  bars  the  range, 
position descending from a competent (dark gray bars) or incompetent (light gray 
bar) the SFJ as (Px) proximal, (PM) proximal mid, (Mid) mid, (MD) mid distal and 
(Dis)  distal.    Gene  transcription;  c myc  incompetent  SFJ  p<0.050,  cyclin  D1 
incompetent p<0.010 (Kendall’s bivariate correlation). 
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3.3.5  Discussion 
Binding of VEGF to its receptor, VEGFR2 tyrosine phosphorylates VE cadherin and 
β catenin (Esser et al., 1998; Cohen et al., 1999) disrupting the endothelial AJ (Kevil 
et  al.,  1998).    Dismantling  the  AJ  results  in  loss  of  cadherin  mediated  cell cell 
adhesion and increased vessel wall permeability (Kevil et al., 1998) with the release 
of β catenin into the cytoplasm (Moon et al., 2004; Nelson et al., 2004).  Under 
normal conditions cytoplasmic β catenin is rapidly degraded (Aberle et al., 1997; 
Moon  et  al.,  2004),  however,  several  signalling  pathways  modulate  β catenin 
turnover rates and regulate β catenin availability (Moon et al., 2004; Vincent et al., 
2004).  If stabilised, cytoplasmic β catenin translocates to the nucleus and initiates the 
transcription of genes implicated in cellular proliferation and differentiation (He et 
al., 1998; Beherens et al., 1996; see chapter 1.3.1).  VVs demonstrate loss of release 
of VEGF A (Hollingsworth et al., 2001A) and aberrant VEGF A gene transcription at 
a stage prior to vessel wall incompetence (see chapter 3.1.4).  VEGF dysfunction in 
VVs therefore, may affect the release of β catenin predisposing to elevated protein, 
and  so  the  potential  for  inappropriate  gene  expression  involved  with  vessel  wall 
remodelling. 
 
In  VVs  overall,  both  β catenin  gene  transcription  and  protein  expression  were 
elevated  (Figure  3.19)  suggesting  β catenin  protein  was  accumulated  (or  not 
degraded) in VVs.  Transcription (as for VEGF A and its receptors previously, see 
chapter 3.1.5) was elevated with SFJ incompetence (Figure 3.20A) and segmental 
incompetence  (Figure  3.21A).    In  contrast,  accumulated  β catenin  protein  was 
observed in VVs sections prior to SFJ incompetence (Figure 3.20B) (i.e. when the 
SFJ was functional and without reflux) suggesting perhaps that incompetence of the 197 
SFJ may represent a later stage of disease development to when the SFJ is functional.  
Interestingly, alterations to β catenin expression may not be due to transcriptional 
activation of the β catenin gene.  For SFJ competency, when comparing β catenin 
transcription  to  quantity  of  protein  detected,  minimal  β catenin  transcription  was 
proportional to a small quantity of detectable protein in control vein (Figure 3.27A).  
In  contrast,  a  similar  quantity  of  β catenin  transcription  (to  control)  produced 
proportionally  a  larger  quantity  of  protein  in  VVs  with  a  competent  SFJ  (Figure 
3.27B).    However,  with  SFJ  incompetence  the  proportions  between  β catenin 
transcription and protein expression returned to that observed previously for control 
segments (Figure 3.27C).  This suggests that alterations to the accumulation of β 
catenin protein in VVs, occurs before disturbances to the flow of blood in the vessel 
becomes apparent, substantiating earlier observations (for VEGF A, see chapter 3.1.5) 
that SFJ incompetence may represent a later stage of disease progression.  Similarly, 
when considering segmental competence, elevated β catenin protein was observed 
before vessel wall incompetence (Figure 3.21B), suggesting perhaps that changes in 
the  availability  of  β catenin  protein  (potentially  due  to  VEGF A  signalling)  may 
occur as an earlier event i.e. before disturbances to blood flow.  Furthermore, the 
accumulation of β catenin protein detected here, without a concomitant up regulation 
of the β catenin gene transcription, suggests perhaps that the increased availability of 
β catenin protein may be regulated at the post transcriptional level. 
 
According to the canonical Wnt pathway, cytoplasmic β catenin protein is targeted 
for degradation by a complex of serine/threonine kinases consisting of GSK 3β and 
CK1 in a scaffold complex of axin and APC (Aberle et al., 1997; Moon et al., 2004, 
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Figure 3.27  Proportional relationship between β catenin transcription and protein. 
Influence  of  SFJ  status  on  the  relationship  between  β catenin  gene  transcription 
(mRNA) and protein expression (protein).  In control, low levels of mRNA produce 
minimal detectable β catenin protein (A).  However in VV, segments from veins with 
a competent SFJ, a higher proportion of protein per quantity of mRNA is produced 
(B). In VV with SFJ incompetence, elevated β catenin transcription did not yield an 
associated elevated protein availability (C) suggesting perhaps that altered β catenin 
activity may reflect an earlier event in varicogenesis, before disturbances to blood 
flow are observed. 199 
Conventionally, β catenin degradation is inhibited by Wnt signalling (Akiyama 2000) 
or mutation (Morin et al., 1997), both of which prevent GSK 3β phosphorylation of 
β catenin  required  for  proteosome  mediated  degradation  (Aberle  et  al.,  1997; 
Akiyama  2000;  Moon  et  al.,  2004).    In  the  canonical  pathway,  activation  of  the 
Frizzled family of receptors by Wnt ligands activates Dishevelled (Dsh) (Akiyama 
2000;  Goodwin  et  al.,  2002).    Dsh  inhibits  GSK 3β  which  promotes  β catenin 
accumulation in the cytoplasm (Ikeda et al., 1998; Sakanaka et al., 1999; (see chapter 
1.3.1).  Alternatively, growth factor activation of PI3K Akt or Wnt/Ca 
2+ pathway 
(Wnt activation of PKC) both inhibit GSK 3β resulting in elevated β catenin (Chen et 
al., 2000A; Kuhl et al., 2000; Fukumoto et al., 2001).   
 
Although  constitutively  expressed  in  the  vasculature  (Cattelino  et  al.,  2003),  β 
catenin is rarely detected in normal adult vessels (Goodwin et al., 2002; van Gijn et 
al.,  2002),  but  has  been  observed  in  the  vascular  endothelium  in  response  to 
ischaemic  injury  (Blankesteijn  et  al.,  2001)  and  during  vessel  wall  remodelling 
associated with angiogenesis (Eberhart et al., 2001, Goodwin et al., 2002; Wright et 
al., 2002).  However, in varicose GSV, vessel wall remodelling is predominately 
associated with proliferation and migration of SMC, not the endothelium (see chapter 
1.1.6).    Consequently,  β catenin  has  been  implicated  in  the  stabilisation  of  SMC 
cellular junctions (associated with N cadherin in SMC), and regulation of vascular 
SMC proliferation, migration and survival (Uglow et al., 2003; Wang et al., 2002; 
Slater et al., 2004).  Although the cellular origin of the β catenin detected here is not 
known, the accumulation of β catenin protein in VVs suggests an increased potential 
for nuclear translocation and β catenin mediated gene transcription in the varicose 
vessel wall.  Further studies investigating the cellular location of the β catenin here 200 
would be informative and may associate β catenin expression with both cell type and 
remodelled area(s) of the VVs wall.  Furthermore, as elevated β catenin is normally 
associated with Wnt signalling and several studies demonstrate the presence of Wnt 
ligands and Fz receptors in vascular cells (Wright et al., 1999;  Goodwin et al., 2002; 
van  Gijn  et  al.,  2002)  additional  studies  investigating  the  presence  of  Wnt 
ligands/receptors, and mutational status of β catenin might help explain the elevated 
β catenin protein observed here.  
 
A further explanation for elevated β catenin protein may be due to the dismantling of 
the AJ in response to growth factor activation like VEGF A (Cohen et al., 1999; 
Rahimi et al., 1999; Lampugnani et al., 1997; Dejana et al., 2001).  In addition to 
regulating endothelial barrier function (Cohen et al., 1999), the AJ is suggested to 
regulate the activity of β catenin by maintaining bound β catenin in the AJ and thus 
preventing both its degradation (Aberle et al., 1997) and translocation to the nucleus 
for gene transcription (Gottardi et al., 2001; Dejana 2004).  The accumulation of β 
catenin  protein  in  competent  VV  wall  segments  (i.e  before  disturbances  to  blood 
flow) may perhaps suggest the dismantling of the AJ in these segments (Wright et al., 
2002).  In addition to releasing β catenin however, dismantling of the AJ increases 
responsiveness of the vascular endothelium to growth factor signalling due to the loss 
of contact inhibition (Rahimi et al., 1999; Lampugnani et al., 1997A; see chapter 
1.3.2).    Notably,  as  a  loss  of  contact  inhibition  is  required  for  endothelial  cell 
proliferation and migration associated with vessel remodelling (in response to both 
growth factor activation and disturbed blood flow) elevated β catenin may indicate 
the initiation of the remodelling process (Rahimi et al., 1999; Lampugnani et al., 
1997A; Dejana et al 2000; Dejana et al., 2001).   201 
With dismantling of the AJ following VEGF A activation, VEGFR2 forms a complex 
with VE cadherin (Rahimi et al., 1999; Wright et al., 2002; Zanetti et al., 2002) that 
localises to the intracellular junction (Carmeliet et al., 1999; Rahimi et al., 1999; 
Lampugnani  et  al.,  2003;  see  chapter  1.3.2).    The  formation  of  the  VE  cadherin 
VEGFR2 complex is dependant on the release of β catenin (Carmeliet et al., 1999) 
and furthermore modulates VEGFR2 signalling (Rahimi et al., 1999; Zanetti et al., 
2002).  Recruitment of adapter proteins (see chapter 1.2.5) to phosphorylated tyrosine 
residues on the intracellular VEGFR2 domain, determines the signalling pathway(s) 
activated (Carmeliet et al., 1999; Lampugnani et al., 2003).  VEGF A (via VEGFR2) 
induces activation of PI3K Akt (Carmeliet et al., 1999; Gerber et al., 1998a) while 
simultaneously inhibiting PLCγ mediated proliferation in confluent EC (Lampugnani 
et al., 2003).  Conversely, when the AJ is dismantled, VEGF A stimulates both PI3K 
Akt  and  EC  proliferation  via  PLCγ  mediated  MAPK  activity  (Gliki  et  al,  2002; 
Lampugnani  et  al.,  2003).    Consequently,  VEGF A  activation  of  PI3K Akt  via 
VEGFR2 not only inhibits EC apoptosis (Gerber et al., 1998A; Shiojima et al., 2002; 
see chapter 1.2.5) but potentially inhibits GSK 3β in a PI3K Akt dependant manner 
(Chen et al., 2000A; Fukumoto et al., 2001).  In terms of β catenin therefore, VEGF 
A binding to VEGFR2, in addition to releasing β catenin from the AJ (Cohen et al., 
1999), may also regulate its stabilisation through PIK3 Akt mediated inhibition of 
GSK 3β (Chen et al., 2000A; Fukumoto et al., 2001; Gliki et al, 2002) resulting in 
the accumulated β catenin observed here.  
 
Besides regulating endothelial barrier function (Corada et al,. 1999), the endothelial 
AJ has been proposed as a mechanotransducer responsible for vessel wall responses 
to haemodynamic forces such as shear stress and disturbed blood flow (Noria et al., 202 
1999;  Ukropec  et  al.,  2002;  Shay Salit  et  al., 2002).    In  the  arterial  system  it  is 
generally accepted that the causative effect of haemodynamic forces like shear stress 
acting  through  the  endothelium  is  chronic  restructuring  of  blood  vessels  and  the 
initiation  of  angiogenesis  (Sho  et  al.,  2003).    Although  less  is  known  of  similar 
mechanisms in the venous system, in saphenous veins used as conduits in bypass 
grafting, the increased pressure and disturbed blood flow of the arterial system is 
associated with acute remodelling of the venous wall (Shay Salit et al., 2002; Sho et 
al., 2003).  Local disturbances in the flow of blood at sites along the length of the 
vein should stimulate the release of VEGF A and VEGFR2 mediated disruption of 
the AJ, releasing of β catenin (Shay Salit et al., 2002; Sho et al., 2003).  As venous 
incompetence tends to appear more distally in the leg, and at a position at, or below 
the underlying venous incompetence in the vein (Labropoulos et al., 1999; Cooper et 
al., 2003); investigations of the pattern of β catenin expression in relation to position 
along  the  length  of  the  vein,  may  show  potential  associations  between  disease 
presentation and β catenin expression.   
 
The position of the segment below the SFJ had a significant effect on the pattern of 
activity of β catenin (Figure 3.22 and 3.23) with elevated β catenin protein observed 
with descending position below a competent and functional SFJ (see Figure 3.23B).  
Again in VVs, elevated β catenin protein was observed before disturbances to blood 
flow in vein with a competent and functional SFJ, suggesting perhaps that altered β 
catenin activity may reflect an earlier event in varicogenesis.  Notably, there was no 
change in the transcription of VEGF A and its receptors with descending position, 
although  the  activation  status  of  the  VEGF  receptors  were  not  investigated.  
Additional  studies  should  investigate  the  phosphorylation  status  of  the  VEGFR2 203 
receptor as well as downstream mediators of VEGFR2 signalling (notably PI3K Akt) 
which  may  help  to  clarify  the  potential  role  of  VEGF A  signalling  in  the 
production/stabilisation of β catenin seen here (Gliki et al, 2002).  
 
Cytoplasmic β catenin, if not degraded translocates to the nucleus (Huber et al., 1996; 
Blankesteijn et al., 2001), and initiates TCF/LEF transcription of numerous genes 
involved implicated in vessel wall remodelling including c myc, cyclin D1 and matrix 
metalloproteinases (Gumbiner 1995; Behrens et al., 1996; He et al., 1998; Shtutman 
et al., 1999; see chapter 1.3.1).  Consequently, to determine whether the elevated β 
catenin  detected  here  was  functional  and  active,  the  transcription  of  the  nuclear 
targets  c myc  and  cyclin  D1  were  investigated  (He  et  al.,  1998;  Shtutman  et  al., 
1999).  In VVs, transcription of both c myc and cyclin D1 were elevated with SFJ 
incompetence  (Figure  3.24).    However,  when  considering  segmental  competency, 
transcription of c myc and cyclin D1 were elevated in all VVs segments, i.e. when the 
segment was competent or incompetent (Figure 3.25), again, as for VEGFR2 (see 
chapter 3.1.4) and β catenin protein previously, suggesting perhaps an earlier altered 
molecular event, before disturbances to blood flow become apparent.  
 
Besides initiating the transcription of c myc and cyclin D1 in these samples, what role 
may β catenin play in VVs before the onset of venous incompetence i.e may elevated 
β catenin  simply  reflect  a  differing  gene  expression  associated  with  an  on going 
pathological process.  More recently, the model of a single molecular form of β 
catenin that participates in cell adhesion and gene expression was suggested to be an 
over  simplification  of  the  mechanisms(s)  involved  (Gottardi  et  al.,  2004).  
Observations of multiple forms of β catenin co existing in the cell have introduced a 204 
new  layer  of  regulation,  with  differing  conformations  of  β catenin  protein  itself 
preferentially determining either adhesion or nuclear signalling roles (Gottardi et al., 
2004).  As Wnt signalling was suggested to determine the β catenin conformational 
change and binding specificity, further studies into the types of β catenin molecular 
variations  here  maybe  useful  in  explaining  the  elevated  β catenin  observed.  
Alternatively, elevated β catenin may simply be inducing expression of a different 
molecule  (Akiyama  2000;  Goodwin  et  al.,  2002).    Indeed,  besides  inducing 
transcription of genes for proliferation, more recently β catenin was demonstrated to 
elevate both the transcription and protein expression of VEGF A in vitro, giving rise 
potentially to the possibility of another positive feedback loop involving VEGF A (as 
for NO see chapter 1.2.6.2) in the vessel wall (Easwaran et al., 2003; Skurk et al., 
2005).   
 
As discussed previously, the results reported here should be interpreted with caution 
as they are based on small patient numbers.  It would be more informative to extend 
these studies to more individuals, specifically those with an “earlier” stage of varicose 
disease (i.e. VVs with competent SFJ and/or vessel wall segments).  Other problems 
with this sample set have been discussed (see chapter 3.1.5). A clearer understanding 
of the mechanisms underlying the development and progression of varicosity would 
help with the treatment of this disease, as disturbed β catenin activity (possible due to 
VEGF) may precede vessel wall compromise in VVs, with elevated β catenin protein 
potentially providing a mechanism for vessel wall remodelling. 205 
 
Summary points 
The results of this study can be summarised as follows:  
 
1. The transcription and protein expression of β catenin was elevated in sections of 
VVs compared to control.   
 
2. The  transcription  of  β catenin  was  elevated  in  VVs  when  the  SFJ  was 
incompetent.  
 
3. β catenin  protein  was  accumulated  in  competent  segments  of  VVs  i.e.  before 
disturbances to the flow of blood. 
 
4. β catenin protein increased with descending position below a competent SFJ. 
 
5. Altered activity of β catenin may be associated in some part, with the process(es) 
of varicogenesis, representing an early event before development of vessel wall 
incompetence.  In contrast SFJ incompetence may represent a later stage of disease 
development. 
 
6. Elevated  β catenin  protein  availability  may  potentially  drive  vessel  wall 
remodelling through the transcriptional activation of TCF/LEF targets, c myc and 
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4.1  SUMMARY AND CONCLUSIONS 
In summary, how do the results presented here affect the hypothesis of a potential 
molecular abnormality in the VEGF A system being involved in the initiation and 
development  of  primary  VVs?    If  altered  VEGF A  signalling  is  a  driving  force 
underlying  the  initiation  and  progression  of  venous  incompetence  and  vessel 
remodelling in the vein, it may be expected that disturbances in the expression of 
VEGF A and/or its receptors would associate with the pattern of disease presentation 
in the vein wall.  Furthermore, the progressive nature of varicose disease (Jones et al., 
1999;  Cooper  et  al.,  2003;  Labropoulos  et  al.,  2005)  together  with  the  irregular 
distribution of the disease along the length of the vessel (Badier Commader et al., 
2001;  Wali  et  al.,  2001B),  potentially  may  help  to  discriminate  a  differing  gene 
activity between these sites; as determined by local disease severity and functional 
characteristics of varicose disease like disturbed blood flow (reflux/stasis) (Browse et 
al., 1999; Nicolaides 2000).   
 
Do varicose vessels have the capability to produce VEGF A (and its receptors) and if 
so is altered transcription of VEGF A and/or its receptors, a causative mechanism in 
VVs?  The first study demonstrated that VVs have the capability to transcribe both 
VEGF A and its receptors, and that gene activity of VEGF A (and its receptors) was 
disturbed in VVs.  Notably, transcription of VEGF A and its membrane receptors 
were elevated before development of vessel wall incompetence, which may suggest 
an  association  in  some  part,  with  the  process(es)  of  varicogenesis,  potentially 
representing an altered early molecular event.  In contrast however, incompetence of 
the SFJ may represent a later stage of disease development. 208 
The second part of the hypothesis attempted to address whether the vessel wall could 
respond to, or control the VEGF A produced appropriately.  As VEGF A mediates 
most of its dilatory and mitogenic effects through activation of VEGFR2 (Vaisman et 
al., 1990; Millauer et al., 1993; Waltenberger et al., 1994), disordered functioning of 
VEGFR2 may play a role in the initiation and development of VVs.  Two lines of 
investigation were examined.  With VEGFR2 signal activation, the receptor may be 
redundant  and  not  function  correctly,  or  a  continued  signal  may  arise  due  to  the 
inability to switch off, or deactivate the activated receptor.   
 
In the vascular endothelium, the action of VEGFR2 is modulated by s.flt 1 (Kendall 
et al., 1993; Barleon et al., 1997B; Barleon et al., 2001), which binds VEGF A with 
high affinity and potentially modulates VEGF A signalling (Siemester et al., 1998B; 
Graubert et al., 2001).  The second study demonstrated that s.flt 1 was significantly 
elevated in plasma of patients with VVs.  Notably, although baseline levels of s.flt 1 
were elevated, there was a loss of response to venous hypertension in VVs, extending 
earlier observations suggesting a potential problem with VEGF A responses in VVs.  
 
If indeed signalling via VEGF A (or receptors) is disturbed with the initiation of 
varicose  disease,  then  alterations  to  VEGF A’s  normal  functions  in  regulating 
vascular  permeability  and  dilation  would  similarly  be  affected.    Although  the 
mechanism(s) by which VEGF A mediates permeability are not clearly understood, 
VEGF A signalling dismantles the AJ resulting in a loss of endothelial cell adhesion, 
with increased paracellular permeability and the release of β catenin to the cytoplasm 
(see chapters 1.2.6 and 1.3.2).  If VEGF A signalling is disturbed with the onset of 
varicose disease, which does indeed occur by a process of progressive “spreading 209 
incompetence” (Jones et al., 1999; Cooper et al., 2003), then alterations to the pattern 
of  expression  of  β catenin  may  similarly  associate  to  the  patterns  of  disease 
presentation observed.   
 
Study  three  demonstrated  that  β catenin  activity  (as  for  VEGF A  and  receptors 
previously) was disturbed in VVs.  Furthermore, the pattern of activity of β catenin 
expression was associated with the pattern of disease presentation, as determined by 
SFJ or vessel segment competency.  This extends earlier observations that changes in 
the  availability  of  β catenin  protein  (potentially  due  to  VEGF A  signalling)  may 
represent an early event in the development of VVs, and be associated in some part, 
with the initiation of varicose disease.  Furthermore, accumulated β catenin protein 
potentially, may drive vessel wall remodelling through the transcriptional activation 
of TCF/LEF targets, c myc and cyclin D1.  However, as a large number of growth 
factors, including activation of the Wnt signalling pathway are known to stabilise β 
catenin, the relevance of the association here between VEGF A and β catenin should 
be interpreted with caution, until additional studies can clarify their interactions.   
 
The relationships described here are complex and due consideration needs to be given 
to  a  number  of  limitations  with  this  study.    Overall,  all  genes  investigated  were 
transcriptionally activated in VVs, and except for s.flt 1 had a significant positive 
correlation to each other overall (see Table 4.1).  Furthermore, the status of the SFJ 
had a significant effect on the transcriptional activation of all genes investigated, as 
illustrated by elevated transcription of all genes with SFJ incompetence.  The strong 
association between venous incompetence and transcriptional activation was further 
illustrated by the significant partial correlations between genes when controlling for 210 
both SFJ status (Table 4.2) and segmental competency (Table 4.3).  The concern here 
therefore,  may  be  that  the  transcriptional  activation  observed  with  venous 
incompetence may not be necessarily be associated with the pathological process of 
varicogenesis  (blood  reflux/stasis),  but  merely  represent  the  results  of  a  pan 
transcriptional response  by the  components of the vessel wall to, for example an 
underlying chronic inflammation in the diseased vein.  This seems unlikely however, 
as all gene transcripts were normalised against an internal cellular control GAP 3, 
which would also be elevated by a cellular pan transcriptional response.  In addition, 
the  positive  correlations  observed  are  not  associated  with  the  transcription  of  all 
genes investigated (see Table 4.2 and 4.3, see for example s.flt 1).  However, due to 
the mechanisms involved in the regulation of s.flt 1 transcription (alternative splice 
variant, see Figure 2.4) it would be informative to investigate the transcription of 
other gene(s) in the vessel wall not necessarily associated with varicose disease or 
inflammation, for clarification. 
 
In  addition,  the  relationship  between  gene  transcription  and  quantities  of  actual 
protein produced, need to be carefully investigated (as illustrated by the negative 
relationship between β catenin gene transcription and protein expression, see Table 
4.2).    A  clearer  appreciation  of  the  relationships  between  VEGF A/VEGFR  gene 
transcription and protein expression, together with a better understanding of the post 
transcriptional mechanisms controlling VEGF A/VEGFR protein production in the 
vessel wall would be informative in determining the effects of disturbed VEGF A 
function in the development of VVs.   Finally, the analyses undertaken represent 
merely a “molecular snapshot” in time and may not fully appreciate the genetic and 
molecular nuances required to control VEGF A activity.  As such, additional studies 211 
investigating the differing patterns of disease association to other molecules affected 
by and potentially affecting VEGF A action in sections of vein at different stages of 
disease  progression  (varicose  but  competent  to grossly  varicose  and  incompetent) 
may further help our understanding of the potential role of VEGF A in the initiation 
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Table 4.1  Bivariate correlations between all genes investigated in this study. 
Excluding sflt 1 and β catenin protein there was a positive correlation between the 
transcription of all genes in the study (+  positive correlation, p<0.010, Kendall’s 
bivariate correlation). 213 
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Table 4.2  Partial correlations between all genes controlling for SFJ status. 
A positive partial correlation between transcription of VEGF A, the VEGF receptors, 
β catenin, c myc and  cyclin D1 (all p<0.001, Kendall’s bivariate correlation) was 
demonstrated, when controlling for SFJ.  Similiarly, there was a positive correlation 
between the transcription of β catenin and that of c myc and cyclin D1 (all p<0.001, 
Kendall’s bivariate correlation). In contrast, a negative correlation was found when 
examining  β catenin  transcription  and  the  amount  of  β catenin  protein  detected 
(p<0.010,  Kendall’s  bivariate  correlation).  (+  positive  correlation,  p<0.010;  ++ 
positive correlation, p<0.001;   negative correlation, p<0.050;  * negative correlation, 
p<0.010, all Kendall’s bivariate correlation). 214 
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Table 4.3  Partial correlations between all genes controlling for segment. 
A positive partial correlation between transcription of VEGF A, the VEGF receptors, 
β catenin, c myc and  cyclin D1 (all p<0.001, Kendall’s bivariate correlation) was 
found, when controlling for segment.  Similiarly increased transcription of β catenin 
correlated to increased transcription of c myc and cyclin D1 (all p<0.001, Kendall’s 
bivariate  correlation).  (++  positive  correlation,  p<0.001;     negative  correlation, 
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7.1  APPENDIX 1: ETHICS APPROVAL 










7.2  APPENDIX 2: RESULTS DATA TABLES 
7.2.1  Sample characteristics 
SampleID sample position gender age leg location SFJ segment
Control
1 PN1a M 60       C
2      1b C
3 PN2a F 71       C
4      2b C
5      2c C
6 PN3a M 50       C
7      3b C
8 PN4a M 72       C
9      4b C
10      4c C
11 PN5a F 63       C
12      5b C
13      5c C
14      5d C
Competent SFJ









24 PC6 Px M 67 right calf C I
25 PM I
26 M I





32 PC8 Px M 62 right thigh+calf C I
33 PM I
34 M I












SampleID sample position gender age leg location SFJ segment
Incompetent SFJ






























































107 Pi 19 Px         I
108 PM
109 M
110 Pi 20 Px         I
111 PM
112 M  250 
7.2.2  VEGF A and VEGF receptor transcription 
SampleID sample position segment VEGF 121 VEGF 165 KDR flt 1 s.flt 1
Control ratio  ratio  ratio  ratio  ratio 
1 PN1a C 0.030 0.000 0.011 0.006 0.622
2      1b C 0.023 0.000 0.010 0.007 0.656
3 PN2a C 0.017 0.000 0.101 0.016 0.737
4      2b C 0.029 0.000 0.153 0.117 0.753
5      2c C 0.055 0.000 0.236 0.216 0.798
6 PN3a C 0.000 0.000 0.000 0.043 0.590
7      3b C 0.000 0.000 0.000 0.020 0.509
8 PN4a C 0.014 0.000 0.000 0.000 0.611
9      4b C 0.005 0.000 0.000 0.000 0.555
10      4c C 0.033 0.000 0.000 0.000 0.561
11 PN5a C 0.000 0.000 0.000 0.026 0.460
12      5b C 0.000 0.000 0.000 0.012 0.564
13      5c C 0.000 0.000 0.000 0.077 0.494
14      5d C 0.000 0.000 0.000 0.007 0.528
n = 14 14 14 14 14
Competent SFJ ratio  ratio  ratio  ratio  ratio 
15 PC3 Px C 0.066 0.000 0.098 0.034 0.640
16 PM C 0.021 0.000 0.057 0.120 0.663
17 M I 0.152 0.000 0.056 0.026 0.560
18 MD I 0.073 0.000 0.088 0.064 0.444
19 PC5 Px I 0.000 0.000 0.000 0.000 0.502
20 PM I 0.000 0.000 0.000 0.000 0.644
21 M C 0.000 0.000 0.000 0.000 0.683
22 MD C 0.000 0.000 0.000 0.000 0.656
23 Dis C 0.000 0.000 0.000 0.000 0.592
24 PC6 Px I 0.000 0.000 0.000 0.000 0.596
25 PM I 0.000 0.000 0.000 0.000 0.710
26 M I 0.000 0.000 0.000 0.000 0.633
27 PC7 Px I 0.060 0.029 0.188 0.016 0.229
28 PM I 0.054 0.005 0.052 0.034 0.052
29 M I 0.300 0.061 0.186 0.568 0.516
30 MD I          
31 Dis I 0.248 0.039 0.369 0.225 0.782
32 PC8 Px I 0.066 0.000 0.056 0.069 0.635
33 PM I 0.036 0.000 0.002 0.010 0.640
34 M I 0.144 0.000 0.005 0.015 0.663
35 PC9 Px I 0.069 0.000 0.000 0.000 0.755
36 PM I 0.057 0.000 0.026 0.003 0.696
37 M I 0.013 0.000 0.000 0.000 0.883
38 MD I 0.063 0.000 0.000 0.000 0.938
39 Dis I 0.011 0.000 0.058 0.348 0.610
40 PC10 Px I 0.041 0.000 0.045 0.047 0.516
41 PM I 0.036 0.000 0.090 0.004 0.472
42 M C 0.044 0.000 0.032 0.003 0.556
43 MD C 0.070 0.000 0.060 0.001 0.588
44 Dis C 0.087 0.000 0.081 0.005 0.578





SampleID sample position segment VEGF 121 VEGF 165 KDR flt 1 s.flt 1
Incompetent SFJ ratio  ratio  ratio  ratio  ratio 
45 Pi 1 Px I 0.073 0.025 0.972 0.677 0.322
46 PM C 0.081 0.040 1.016 0.433 0.249
47 M C 0.142 0.069 1.179 0.729 0.472
48 MD C 0.047 0.006 1.010 0.505 0.420
49 Pi 4 Px I 0.057 0.000 0.359 0.311 0.699
50 PM I 0.048 0.000 0.262 0.331 0.617
51 M I 0.130 0.000 0.863 0.526 0.782
52 MD I 0.142 0.000 0.533 0.413 0.753
53 Dis I 0.029 0.000 0.331 0.360 0.711
54 Pi 6 Px I 0.123 0.000 0.075 0.038 0.734
55 PM I 0.130 0.000 0.297 0.173 0.797
56 M I 0.285 0.047 0.132 0.118 0.659
57 MD I 0.229 0.043 0.277 0.102 0.706
58 Dis I 0.199 0.027 0.291 0.183 0.649
59 Pi 7 Px I 0.219 0.078 0.061 0.486 0.563
60 PM I 0.076 0.020 0.016 0.186 0.688
61 M I 0.318 0.086 0.188 0.535 0.668
62 MD I 0.204 0.037 0.031 0.264 0.835
63 Dis I 0.303 0.068 0.081 0.403 0.670
64 Pi 8 Px I 0.434 0.142 0.334 0.482 0.600
65 PM I 0.302 0.068 0.085 0.100 0.669
66 M I 0.177 0.028 0.271 0.147 0.593
67 MD I 0.260 0.042 0.061 0.053 0.550
68 Dis C 0.222 0.065 0.216 0.264 0.640
69 Pi 10 Px I 0.246 0.086 0.711 0.393 0.583
70 PM I 0.203 0.083 0.646 0.182 0.680
71 M I 0.284 0.086 0.595 0.605 0.440
72 MD I 0.301 0.065 0.497 0.533 0.482
73 Dis C 0.311 0.138 0.554 0.427 0.757
74 Pi 12 Px I 0.234 0.032 0.238 0.290 0.444
75 PM I 0.285 0.029 0.176 0.256 0.548
76 M I 0.229 0.064 0.276 0.112 0.565
77 MD I 0.303 0.034 0.341 0.113 0.476
78 Dis I 0.292 0.070 0.503 0.201 0.500
79 Pi 13 Px I 0.291 0.106 0.802 0.627 0.601
80 PM I 0.160 0.024 0.346 0.441 0.560
81 M I 0.295 0.041 0.717 0.663 0.767
82 MD I 0.182 0.020 0.552 0.286 0.663
83 Dis I 0.256 0.041 0.753 0.319 0.608
84 Pi 15 Px I 0.044 0.026 0.489 0.617 0.091
85 PM I 0.110 0.105 0.387 0.419 0.466
86 M I 0.195 0.079 0.329 0.553 0.607
87 MD I 0.110 0.035 0.421 0.331 0.437
88 Dis C 0.209 0.113 0.800 0.482 0.677
89 Pi 16 Px I 0.035 0.022 0.115 0.299 0.066
90 PM I 0.034 0.023 0.446 0.509 0.634
91 M I 0.060 0.018 0.141 0.292 0.415
92 MD I 0.203 0.019 0.231 0.936 0.670
93 Dis C 0.026 0.013 0.111 0.201 0.299
102 Pi 18 Px C 0.000 0.000 0.046 0.011 0.339
103 PM I 0.000 0.000 0.207 0.012 0.668
104 M I 0.000 0.000 0.082 0.101 0.645
105 M-D I 0.000 0.000 0.006 0.008 0.750
106 Dis C 0.000 0.000 0.026 0.136 0.850
n= 54 54 54 54 54
 252 
7.2.3  s.flt 1 ELISA 
SampleID Normal Assay 1 Assay 2 Mean
Arm OD1 OD2 mean s.flt 1 OD1 OD2 mean s.flt 1 s.flt 1
1 A002 0.059 0.060 0.060 37.45 0.059 0.060 0.060 37.45 37.45
2 A003 0.083 0.075 0.079 50.45 0.082 0.070 0.076 31.38 40.92
3 A005 0.090 0.065 0.078 49.45 0.070 0.064 0.067 24.46 36.95
4 A007 0.069 0.063 0.066 41.78 0.076 0.070 0.073 29.08 35.43
5 A009 0.059 0.064 0.062 38.78 0.062 0.064 0.063 21.38 30.08
6 A010 0.077 0.066 0.072 45.45 0.063 0.066 0.065 22.54 33.99
7 A011 0.064 0.065 0.065 40.78 0.062 0.066 0.064 22.15 31.47
n =  7
Leg before OD1 OD2 mean s.flt 1 OD1 OD2 mean s.flt 1 s.flt 1
8 A002 0.033 0.068 0.051 41.33 0.067 0.080 0.074 29.46 35.40
9 A003 0.040 0.046 0.043 33.00 0.075 0.082 0.079 33.31 33.15
10 A005 0.044 0.056 0.050 40.78 0.080 0.077 0.079 33.31 37.04
11 A007 0.031 0.027 0.029 17.44 0.102 0.053 0.078 32.54 24.99
12 A009 0.046 0.047 0.047 36.89 0.074 0.070 0.072 28.31 32.60
13 A010 0.048 0.041 0.045 34.67 0.089 0.083 0.086 39.08 36.87
14 A011 0.042 0.052 0.047 37.44 0.065 0.068 0.067 24.08 30.76
n =  7
Leg after OD1 OD2 mean s.flt 1 OD1 OD2 mean s.flt 1 s.flt 1
15 A002 0.064 0.051 0.058 49.11 0.080 0.081 0.081 34.85 41.98
16 A003 0.082 0.099 0.091 85.78 0.160 0.142 0.151 89.08 87.43
17 A005 0.042 0.038 0.040 29.67 0.083 0.079 0.081 35.23 32.45
18 A007 0.050 0.063 0.057 48.00 0.091 0.090 0.091 42.54 45.27
19 A009 0.055 0.050 0.053 43.56 0.079 0.082 0.081 34.85 39.20
20 A010 0.064 0.057 0.061 52.44 0.098 0.104 0.101 50.62 51.53
21 A011 0.062 0.062 0.062 54.11 0.081 0.079 0.080 34.46 44.29
n =  7
 253 
 
SampleID Varicose Assay 1 Assay 2 Mean
Arm OD1 OD2 mean s.flt 1 OD1 OD2 mean s.flt 1 s.flt 1
22 B007 0.075 0.131 0.103 46.47 0.063 0.063 0.063 19.80 33.13
23 B008 0.071 0.070 0.071 24.80 0.068 0.070 0.069 23.80 24.30
24 B009 0.074 0.080 0.077 29.13 0.087 0.075 0.081 31.80 30.47
25 B010 0.080 0.078 0.079 30.47 0.198 0.068 0.133 66.47 48.47
26 B011 0.097 0.084 0.091 38.13 0.075 0.080 0.078 29.47 33.80
27 B013 0.086 0.091 0.089 36.80 0.083 0.082 0.083 32.80 34.80
28 B014 0.086 0.082 0.084 33.80 0.087 0.085 0.086 35.13 34.47
29 B015 0.121 0.109 0.115 54.47 0.086 0.101 0.094 40.13 47.30
30 B016 0.073 0.075 0.074 27.13 0.068 0.075 0.072 25.47 26.30
31 B017 0.077 0.084 0.081 31.47 0.077 0.087 0.082 32.47 31.97
32 B018 0.094 0.105 0.100 44.13 0.101 0.103 0.102 45.80 44.97
33 B019 0.118 0.126 0.122 59.13 29.57
34 B020 0.077 0.088 0.083 32.80 0.077 0.089 0.083 33.13 32.97
n =  13
Leg before OD1 OD2 mean s.flt 1 OD1 OD2 mean s.flt 1 s.flt 1
35 B007 0.048 0.080 0.064 56.33 0.065 0.065 0.065 22.92 39.63
36 B008 0.063 0.067 0.065 57.44 0.089 0.092 0.091 42.54 49.99
37 B009 0.074 0.074 67.44 0.094 0.090 0.092 43.69 55.57
38 B010 0.063 0.080 0.072 64.67 0.082 0.086 0.084 37.54 51.10
39 B011 0.060 0.074 0.067 59.67 0.081 0.089 0.085 38.31 48.99
40 B013 0.069 0.046 0.058 49.11 0.074 0.075 0.075 30.23 39.67
41 B014 0.079 0.091 0.085 79.67 0.130 0.133 0.132 74.08 76.87
42 B015 0.069 0.078 0.074 66.89 0.105 0.096 0.101 50.23 58.56
43 B016 0.060 0.073 0.067 59.11 0.087 0.087 0.087 39.85 49.48
44 B017 0.095 0.094 0.095 90.22 0.117 0.133 0.125 69.08 79.65
45 B018 0.084 0.083 0.084 78.00 0.113 0.112 0.113 59.46 68.73
46 B019 0.107 0.115 0.111 108.56 0.119 0.134 0.127 70.23 89.39
47 B020 0.066 0.070 0.068 60.78 0.086 0.090 0.088 40.62 50.70
n  =  13
Leg after OD1 OD2 mean s.flt 1 OD1 OD2 mean s.flt 1 s.flt 1
48 B007 0.068 0.047 0.058 49.11 0.062 0.061 0.062 20.23 34.67
49 B008 0.057 0.071 0.064 56.33 0.083 0.090 0.087 39.46 47.90
50 B009 0.062 0.067 0.065 56.89 0.108 0.118 0.113 59.85 58.37
51 B010 0.077 0.088 0.083 76.89 0.084 0.089 0.087 39.46 58.18
52 B011 0.066 0.062 0.064 56.33 0.075 0.082 0.079 33.31 44.82
53 B013 0.073 0.067 0.070 63.00 0.088 0.088 0.088 40.62 51.81
54 B014 0.086 0.082 0.084 78.56 0.157 0.149 0.153 90.62 84.59
55 B015 0.082 0.108 0.095 90.78 0.131 0.126 0.129 71.77 81.27
56 B016 0.080 0.074 0.077 70.78 0.099 0.101 0.100 49.85 60.31
57 B017 0.073 0.087 0.080 74.11 0.104 0.110 0.107 55.23 64.67
58 B018 0.084 0.093 0.089 83.56 0.114 0.125 0.120 64.85 74.20
59 B019 0.139 0.178 0.159 161.33 0.156 0.152 0.154 91.38 126.36
60 B020 0.076 0.076 0.076 69.67 0.096 0.101 0.099 48.69 59.18
n  =  13
 254 
7.2.4  β catenin transcription 
SampleID sample position segment β cat 7 β cat 7 β catenin 7 β cat 11 mean
Control ratio 1 ratio 2 mean ratio 1 ratio 
1 PN1a C 0.302 0.192 0.247 0.035 0.141
2      1b C 0.087 0.136 0.111   0.111
3 PN2a C 0.378 0.111 0.245 0.041 0.143
4      2b C 0.253 0.233 0.243 0.111 0.177
5      2c C 0.157 0.128 0.142   0.142
6 PN3a C 0.326 0.175 0.251 0.025 0.138
7      3b C 0.163 0.143 0.153   0.153
8 PN4a C 0.621 0.414 0.518 0.069 0.293
9      4b C 0.323 0.276 0.300   0.300
10      4c C 0.935 0.650 0.793 0.129 0.461
11 PN5a C 0.450 0.364 0.407 0.036 0.222
12      5b C 0.632 0.443 0.538   0.538
13      5c C 0.583 0.627 0.605   0.605
14      5d C 0.117 0.120 0.118   0.118
n = 14 14
Competent SFJ ratio 1 ratio 2 mean ratio 1 ratio 
15 PC3 Px C 0.055 0.035 0.045   0.045
16 PM C 0.163 0.032 0.097   0.097
17 M I 0.116 0.034 0.075   0.075
18 MD I 0.353 0.060 0.207   0.207
19 PC5 Px I 0.813 0.135 0.474   0.474
20 PM I 0.151 0.076 0.113 0.501 0.307
21 M C 0.276 0.081 0.178   0.178
22 MD C 0.137 0.074 0.105   0.105
23 Dis C 0.209 0.060 0.134 0.220 0.177
24 PC6 Px I 0.215   0.215   0.215
25 PM I 0.114   0.114 0.728 0.421
26 M I 0.323   0.323 1.197 0.760
27 PC7 Px I 0.034 0.074 0.054   0.054
28 PM I 0.086 0.193 0.140 0.006 0.073
29 M I 0.351 0.074 0.213   0.213
30 MD I     -    
31 Dis I 0.713 0.945 0.829 0.133 0.481
32 PC8 Px I 0.071 0.251 0.161   0.161
33 PM I 0.065 0.265 0.165   0.165
34 M I 0.073 0.157 0.115   0.115
35 PC9 Px I 0.024 0.040 0.032   0.032
36 PM I 0.035 0.073 0.054   0.054
37 M I 0.064 0.087 0.075   0.075
38 MD I 0.097 0.087 0.092   0.092
39 Dis I 0.151 0.054 0.102   0.102
40 PC10 Px I 0.212 0.221 0.216   0.216
41 PM I 0.084 0.174 0.129   0.129
42 M C 0.100 0.128 0.114   0.114
43 MD C 0.085 0.160 0.123   0.123
44 Dis C 0.079 0.119 0.099 0.349 0.224
n = 29 29
 255 
 
SampleID sample position segment β cat 7 β cat 7 β catenin 7 β cat 11 mean
Incompetent SFJ ratio 1 ratio 2 mean ratio 1 ratio 
45 Pi 1 Px I 0.791 0.677 0.734   0.734
46 PM C 1.044 0.783 0.914 2.060 1.487
47 M C 0.943 0.567 0.755 1.481 1.118
48 MD C     -    
49 Pi 3 Px I 0.191 0.064 0.128   0.128
50 PM I 0.446 0.267 0.356   0.356
51 M I 0.429 0.198 0.314   0.314
52 MD I     -  
53 Pi 4 Px I 0.032 0.582 0.307   0.307
54 PM I 0.040 0.137 0.089 0.875 0.482
55 M I 0.267 0.595 0.431   0.431
56 MD I 0.168 0.744 0.456   0.456
57 Dis I 0.227 0.355 0.291 0.609 0.450
58 Pi 6 Px I 0.126 0.286 0.206   0.206
59 PM I 1.197 0.700 0.949 1.032 0.990
60 M I 1.252 0.868 1.060   1.060
61 MD I 1.243 0.789 1.016   1.016
62 Dis I 1.306 0.550 0.928 3.709 2.318
63 Pi 7 Px I 0.795 0.040 0.417   0.417
64 PM I 0.795 1.245 1.020 0.236 0.628
65 M I 0.735 1.148 0.942   0.942
66 MD I 0.566 1.092 0.829   0.829
67 Dis I 0.686 0.974 0.830 2.202 1.516
68 Pi 8 Px I 1.283 2.974 2.128   2.128
69 PM I 1.211 3.061 2.136 0.616 1.376
70 M I 0.866 0.482 0.674   0.674
71 MD I 1.176 0.403 0.789   0.789
72 Dis C 1.048 0.086 0.567 1.831 1.199
73 Pi 10 Px I 1.577 1.045 1.311   1.311
74 PM I 1.054 1.030 1.042   1.042
75 M I 1.097 1.041 1.069 0.709 0.889
76 MD I 1.206 1.241 1.224   1.224
77 Dis C 1.096 1.207 1.152 1.345 1.248
78 Pi 12 Px I 1.244 1.156 1.200   1.200
79 PM I 1.088 0.498 0.793 0.443 0.618
80 M I 1.154 0.986 1.070   1.070
81 MD I 0.881 0.785 0.833   0.833
82 Dis I 1.161 0.898 1.029 0.486 0.757
93 Pi 16 Px I 0.835 0.573 0.704   0.704
94 PM I 0.760 0.560 0.660 0.256 0.458
95 M I 0.842 0.786 0.814   0.814
96 MD I 2.154 0.919 1.536   1.536
97 Dis C 0.916 0.713 0.814 1.336 1.075
98 Pi 17 Px I 0.175 0.134 0.154   0.154
99 PM I 0.100 0.069 0.085   0.085
100 M I 0.072 0.066 0.069   0.069
101 MD I 0.105 0.031 0.068   0.068
102 Pi 18 Px C 0.394 0.143 0.269   0.269
103 PM I 0.494 0.347 0.420 0.361 0.391
104 M I 0.332 0.449 0.391   0.391
105 M-D I 0.447 0.539 0.493   0.493
106 Dis C 0.175 0.397 0.286 0.140 0.213
107 Pi 19 Px 0.027 0.022 0.024   0.024
108 PM 0.398 0.355 0.377   0.377
109 M 0.557 0.051 0.304   0.304
110 Pi 20 Px 0.056 0.050 0.053   0.053
111 PM 0.054 0.051 0.052   0.052
112 M 0.327 0.481 0.404   0.404
n = 56 56  256 
7.2.5  β catenin protein expression 
SampleID sample position segment β catenin ponceau S β catenin ponceau S mean
Control IOD 1 IOD 1 IOD 2 IOD 2 ratio
1 PN1a C 18.2 1.54     11.84
2      1b C 51.7 6.09     8.49
3 PN2a C 12.1 3.37     3.60
4      2b C 24.9 5.73     4.34
5      2c C 12.9 2.46     5.23
6 PN3a C 44.7 3.28     13.63
7      3b C 22.3 3.81     5.86
8 PN4a C 115.0 4.46     25.78
9      4b C 95.4 2.65     36.01
10      4c C 16.0 3.72     4.30
11 PN5a C 40.3 4.59     8.79
12      5b C 10.9 1.23     8.84
13      5c C 5.8 2.54     2.28
14      5d C 9.0 2.06     4.38
n = 14
Competent SFJ IOD 1 IOD 1 IOD 2 IOD 2 ratio
15 PC3 Px C 15.9 4.67     3.41
16 PM C 215.4 4.57     47.13
17 M I 80.5 3.05     26.39
18 MD I 49.7 2.40     20.69
19 PC5 Px I 8.6 3.53     2.44
20 PM I 322.9 4.22     76.52
21 M C 346.5 3.10     111.77
22 MD C 91.3 1.13     80.79
23 Dis C 18.3 2.84     6.46
24 PC6 Px I 4.5 3.23     1.39
25 PM I 67.4 4.62     14.58
26 M I 48.1 2.35     20.46
27 PC7 Px I 4.7 3.10     1.53
28 PM I 98.7 5.16     19.13
29 M I 280.4 4.07     68.90
30 MD I 193.2 1.14     169.45
31 Dis I 59.8 5.03     11.89
32 PC8 Px I 7.5 2.94     2.57
33 PM I 12.6 4.84     2.59
34 M I 101.9 2.48     41.07
35 PC9 Px I 0.0 3.61     0.00
36 PM I 20.5 3.46     5.92
37 M I 155.7 2.86     54.45
38 MD I 140.0 1.88     74.48
39 Dis I 115.6 4.21     27.46
40 PC10 Px I 16.1 4.81     3.34
41 PM I 368.9 4.36     84.60
42 M C 846.9 3.62     233.94
43 MD C 461.6 2.05     225.18
44 Dis C 251.2 2.53     99.29
n = 30 30
 257 
 
SampleID sample position segment β catenin ponceau S β catenin ponceau S mean
Incompetent SFJ IOD 1 IOD 1 IOD 2 IOD 2 ratio
45 Pi 1 Px I 11.4 2.19     5.19
46 PM C 6.0 2.55 19.0 1.05 10.22
47 M C 0.0 2.90 10.0 3.13 1.60
48 MD C 14.5 2.31     6.27
49 Pi 3 Px I 8.3 1.67     4.97
50 PM I 0.0 3.07 16.0 0.94 8.51
51 M I 0.0 5.96 6.0 3.39 0.88
52 MD I 0.6 2.86     0.23
58 Pi 6 Px I 24.3 2.31     10.53
59 PM I 2.0 4.24 27.0 1.43 9.68
60 M I 9.0 3.09 9.0 2.06 3.64
61 MD I 0.0 2.96     0.00
62 Dis I 0.1 2.60     0.04
63 Pi 7 Px I 459.7 2.36     194.80
64 PM I 0.0 6.09 36.0 0.93 19.35
65 M I 12.0 4.08 22.0 3.29 4.81
66 MD I 229.2 3.86     59.37
67 Dis I 3.6 2.34     1.54
68 Pi 8 Px I 19.1 0.91     20.95
69 PM I 6.0 5.08 57.0 1.56 18.86
70 M I 20.0 5.08 29.0 2.81 7.13
71 MD I 26.1 4.13     6.33
72 Dis C 19.9 2.28     8.74
73 Pi 10 Px I 15.0 1.06     14.16
74 PM I 2.0 3.93 59.0 0.76 39.07
75 M I 29.0 7.10 105.0 2.34 24.48
76 MD I 25.1 3.73     6.73
77 Dis C 7.1 5.86     1.21
78 Pi 12 Px I 69.1 5.72     12.07
79 PM I 446.0 6.67 618.0 0.92 369.30
80 M I 354.0 13.29 429.0 2.84 88.85
81 MD I 938.7 5.93     158.29
82 Dis I 56.0 5.67     9.88
93 Pi 16 Px I 143.4 5.24 27.36
94 PM I 719.0 7.71 775.0 1.82 259.54
95 M I 15.0 5.19 46.0 1.86 13.81
96 MD I 303.5 4.49 67.60
97 Dis C 206.4 4.13 49.97
102 Pi 18 Px C 15.7 3.69 4.26
103 PM I 88.0 4.86 171.0 1.12 85.39
104 M I 28.0 4.48 115.0 2.35 27.59
105 M-D I 284.7 4.16 68.44
106 Dis C 232.3 4.24 54.80
n = 43 43
 
 258 
7.2.6  c myc and cyclin D1 transcription 
SampleID sample position segment c myc 1 cmyc 2 mean cyclin D1 cyclin D1 mean
Control ratio 1 ratio 2 mean ratio 1 ratio 2 mean
1 PN1a C 0.061 0.029 0.045 0.026 0.110 0.068
2      1b C 0.034 0.073 0.053 0.001 0.111 0.056
3 PN2a C 0.049 0.052 0.050 0.018 0.068 0.043
4      2b C 0.085 0.022 0.053 0.021 0.023 0.022
5      2c C 0.103 0.215 0.159 1.083 0.163 0.623
6 PN3a C 0.044 0.082 0.063 0.117 0.149 0.133
7      3b C 0.000 0.000 0.000 0.033 0.000 0.016
8 PN4a C 0.062 0.016 0.039 0.081 0.006 0.044
9      4b C 0.061 0.004 0.032 0.047 0.016 0.031
10      4c C 0.099 0.077 0.088 0.095 0.264 0.179
11 PN5a C 0.006 0.381 0.194 0.144 0.353 0.248
12      5b C 0.552 0.509 0.530 0.539 0.370 0.455
13      5c C 0.088 0.304 0.196 0.172 0.346 0.259
14      5d C 0.070 0.369 0.220 0.061 0.182 0.122
n = 14 14
Competent SFJ ratio 1 ratio 2 mean ratio 1 ratio 2 mean
15 PC3 Px C 0.049 0.009 0.029 0.106 0.018 0.062
16 PM C 0.023 0.021 0.022 0.116 0.022 0.069
17 M I 0.014 0.018 0.016 0.176 0.282 0.229
18 MD I 0.026 0.032 0.029 0.119 0.016 0.067
19 PC5 Px I 0.113 0.481 0.297 0.309 0.441 0.375
20 PM I 0.064 0.314 0.189 0.278 0.414 0.346
21 M C 0.283 0.426 0.355 0.427 0.469 0.448
22 MD C 0.029 0.129 0.079 0.104 0.088 0.096
23 Dis C 0.026 0.185 0.105 0.130 0.118 0.124
24 PC6 Px I 0.403 0.697 0.550 0.395 0.715 0.555
25 PM I 0.281 0.695 0.488 0.272 0.645 0.459
26 M I 0.605 0.782 0.693 0.730 0.945 0.838
27 PC7 Px I 0.449 0.480 0.464 0.668 0.703 0.685
28 PM I 0.125 0.463 0.294 0.576 0.158 0.367
29 M I 0.008 0.113 0.061 0.370 0.245 0.307
30 MD I            
31 Dis I 0.173 0.262 0.217 0.671 0.108 0.389
32 PC8 Px I 0.013 0.003 0.008 0.030 0.303 0.166
33 PM I 0.012 0.011 0.011 0.003 0.072 0.037
34 M I 0.014 0.964 0.489 0.021 0.431 0.226
35 PC9 Px I 0.067 0.005 0.036 0.100 0.000 0.050
36 PM I 0.047 0.014 0.031 0.074 0.001 0.038
37 M I 0.054 0.026 0.040 0.071 0.000 0.035
38 MD I 0.025 0.060 0.043 0.076 0.052 0.064
39 Dis I 0.029 0.076 0.053 0.026 0.005 0.016
40 PC10 Px I 0.067 0.213 0.140 0.093 0.255 0.174
41 PM I 0.065 0.209 0.137 0.084 0.426 0.255
42 M C 0.405 0.511 0.458 0.463 0.525 0.494
43 MD C 0.083 0.130 0.107 0.121 0.258 0.190
44 Dis C 0.070 0.185 0.127 0.231 0.275 0.253




SampleID sample position segment c myc 1 cmyc 2 mean cyclin D1 cyclin D1 mean
Incompetent SFJ ratio 1 ratio 2 mean ratio 1 ratio 2 mean
45 Pi 1 Px I 0.708 1.197 0.953 0.658 0.521 0.589
46 PM C 0.849 1.525 1.187 0.913 0.955 0.934
47 M C 0.704 1.285 0.994 0.789 0.689 0.739
48 MD C 0.919 1.182 1.051 0.680 0.879 0.779
49 Pi 3 Px I 0.034 0.954 0.494 0.036 0.282 0.159
50 PM I 0.106 1.224 0.665 0.500 0.444 0.472
51 M I 0.190 0.946 0.568 0.304 0.334 0.319
52 MD I 1.211 1.121 1.166 0.935 0.894 0.914
53 Pi 4 Px I 0.376 0.629 0.503 0.421 0.430 0.426
54 PM I 0.292 0.852 0.572 0.303 0.318 0.310
55 M I 0.869 0.670 0.769 0.817 0.779 0.798
56 MD I 0.729 1.065 0.897 0.758 1.214 0.986
57 Dis I 1.007 0.730 0.869 0.929 0.594 0.761
58 Pi 6 Px I 0.163 0.875 0.519 0.258 0.174 0.216
59 PM I 0.783 1.243 1.013 0.717 0.626 0.672
60 M I 0.328 0.964 0.646 0.605 0.440 0.523
61 MD I 1.225 1.854 1.540 1.190 1.341 1.266
62 Dis I 1.347 1.364 1.355 1.305 1.091 1.198
63 Pi 7 Px I 1.115 0.990 1.053 0.925 0.807 0.866
64 PM I 0.635 1.449 1.042 0.699 0.866 0.783
65 M I 0.814 1.348 1.081 0.576 0.948 0.762
66 MD I 1.042 1.218 1.130 0.656 0.908 0.782
67 Dis I 1.210 1.579 1.395 0.964 1.129 1.046
68 Pi 8 Px I 1.329 1.515 1.422 1.354 0.789 1.072
69 PM I 0.893 1.384 1.139 1.095 0.708 0.902
70 M I 0.353 1.202 0.777 0.653 0.287 0.470
71 MD I 0.699 1.807 1.253 1.094 0.722 0.908
72 Dis C 1.084 1.175 1.129 1.400 0.892 1.146
73 Pi 10 Px I 1.435 1.110 1.273 1.024 0.508 0.766
74 PM I 1.075 0.556 0.816 0.850 0.842 0.846
75 M I 1.065 1.396 1.231 1.115 1.242 1.179
76 MD I 1.932 1.081 1.507 2.435 0.614 1.525
77 Dis C 1.119 1.394 1.257 1.258 0.446 0.852
78 Pi 12 Px I 0.760 0.823 0.792 1.061 0.553 0.807
79 PM I 0.723 0.829 0.776 1.112 0.444 0.778
80 M I 0.425 0.746 0.585 0.617 0.355 0.486
81 MD I 0.475 0.678 0.577 0.740 0.475 0.608
82 Dis I 0.959 0.739 0.849 0.940 0.512 0.726
93 Pi 16 Px I 0.596 0.498 0.547 0.660 0.493 0.576
94 PM I 0.241 0.655 0.448 0.121 0.378 0.249
95 M I 0.328 0.586 0.457 0.344 0.307 0.326
96 MD I 0.968 1.567 1.268 0.855 1.172 1.013
97 Dis C 0.339 0.496 0.418 0.514 0.420 0.467
98 Pi 17 Px I 0.008 0.000 0.004 0.023 0.002 0.012
99 PM I 0.074 0.000 0.037 0.012 0.064 0.038
100 M I 0.072 0.001 0.036 0.159 0.233 0.196
101 MD I 0.077 0.003 0.040 0.012 0.033 0.023
102 Pi 18 Px C 0.194 0.100 0.147 0.262 0.253 0.258
103 PM I 0.607 0.438 0.523 0.659 0.465 0.562
104 M I 0.790 0.451 0.621 0.696 0.375 0.536
105 M-D I 0.331 0.183 0.257 0.244 0.283 0.264
106 Dis C 0.371 0.219 0.295 0.437 0.322 0.379
107 Pi 19 Px 0.000 0.000 0.000 0.000 0.000 0.000
108 PM 0.495 0.143 0.319 0.372 0.185 0.278
109 M 0.511 0.100 0.305 0.453 0.485 0.469
110 Pi 20 Px 0.121 0.072 0.097 0.201 0.068 0.135
111 PM 0.058 0.047 0.053 0.137 0.006 0.071
112 M 0.099 0.044 0.072 0.147 0.039 0.093
n = 58 58  260 
7.3  APPENDIX 3: GENE SEQUENCES 
 
7.3.1  Glyceraldehyde 3 Phosphate Dehydrogenase (EC 1.2.1.12)  
 
 
Gene  chromosome  12p13 
  exons  9 
  transcript length (bp)  1315 
Protein  amino acids  335 
  MW (kDa)  36 
  Charge  8.00 
  pI  8.73 
     
Sequence  PCR product (bp)         406 
       452 
 
 
7.3.2  Vascular Endothelial Growth Factor  (VEGF A) 
 
 
Gene  chromosome  6p12
  exons  8
  transcript length (bp)  784
Protein  amino acids  232
  MW (kDa)  27
  charge  21.50
  pI  9.08
   
Sequence  PCR product (bp)  vegf165  375 
vegf121  243   
 261 
 
7.3.3  β catenin (CTNNB1) 
 
 
Gene  chromosome  3p22 
  exons  16 
  transcript length (bp)  3357 
Protein  amino acids  781 
  MW (kDa)  85 
  charge   11.5 
  pI  5.71 
     
Sequence  PCR product (bp)   Βcat7  250 
 βcat11 247 
 
7.3.4  c  myc proto oncogene protein (MYC)  
 
 
Gene  chromosome  8 
  exons  3 
  transcript length (bp)  2 168 
Protein  amino acids   439 
  MW (kDa)  48 
  charge   8.50 
  pI  5.16 
     
Sequence  PCR product (bp)             248  
     
 
7.3.5  Cyclin D1 (CNND1) 
 
 
Gene  chromosome  11 
  exons  5 
  transcript length (bp)  4 288 
Protein  amino acids   295 
  MW (kDa)  33 
  charge   11.00 
  pI  4.68 
     
Sequence  PCR product (bp)             354  262 
     
7.3.6  Vascular Endothelial Growth Factor Receptor 1 (flt 1) (EC 
2.7.1.112)  
 
Gene  chromosome  13q12 
  exons  30 
  transcript length (bp)  7 090 
Protein  amino acids  1 338 
  MW (kDa)  150 
  charge  33.00 
  pI  8.48 
     
Sequence  PCR product (bp)  flt 1    248 
s.flt 1  119  
     
 
 




Gene  chromosome  4q12 
  exons  30 
  transcript length (bp)  5 832 
Protein  amino acids  1 356 
  MW (kDa)  151 
  charge   14.00 
  pI  5.64 
     
Sequence  PCR product (bp)             312  




7.4  APPENDIX 4: BUFFERS 
Soltran Kidney perfusate (pH 7.1)  per litre 
Potassium citrate    8.6 g 
Sodium citrate    8.2 g 
Mannitol   33.8 g 
Magnesium Sulphate   10.0g 
 
RT PCR:  5x First Strand Buffer 




NuPAGE® MOPS SDS Running Buffer pH 7.7 (20x)  500ml 
50mM MOPS  104.6 g 
50mM Tris base   60.6 g 
0.1% SDS   10.0 g 
1mM EDTA     3.0 g 
NuPAGE® Transfer Buffer pH7.2 (20x)  125ml 
  25mM Bicine   10.2 g 
  25mM Bis Tris (free base)   13.1 g 
  1mM EDTA   0.75 g 
NuPAGE® LDS Sample Buffer pH 8.5 (4x)   500ml 
106 mM Tris HCl  0.666 g 
141 mM Tris base  0.682 g 
2% LDS  0.800 g 
10% Glycerol  4.000 g 
0.51 mM EDTA  0.006 g 
0.22 mM SERVA® Blue G250 (1% solution)  0.750 ml 
0.175 mM Phenol Red (1% solution)  0.250 ml 
 
 